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ABSTRACT 
 
 
 
 
Biocatalysis has emerged as a powerful tool for the synthesis of high value optically 
pure compounds. With advances in synthetic biology, it is now possible to design de 
novo non-native pathways to perform non-natural chiral bioconversions. However 
these systems are difficult to assemble and operate productively, severely hampering 
their industrial application. 
 
The purpose of this study was to develop a microscale toolbox for the rapid design 
and evaluation of synthetic pathways, in order to increase their operational 
productivities and speed-up their process development.  
 
The first aim of this work was to establish a microscale platform to accelerate the 
evaluation of different variants of transketolase (TK) and transaminase (TAm), in 
order to design and construct a de novo pathway for the one-pot synthesis of chiral 
amino alcohols. The second aim was to develop a microscale methodology to rapidly 
establish the complete kinetic models of the selected TKs and TAms, which would 
allow efficient operation of the one-pot synthesis. The third aim was to scale-up the 
production of the biocatalyst to pilot plant, while controlling and maintaining the 
desired level of expression of each enzyme. Finally the fourth aim of this project was 
to scale-up and simulate the complete one-pot syntheses to preparative scale, while 
predicting and applying the best reaction strategies and reactor configurations.   
 
The experimental microscale toolbox was based on 96 microwell plates with 
automation capacities, where  the one-pot syntheses of the diastereoisomers (2S,3S)-2 
aminopentane-1,3-diol (APD) and (2S,3R)-2-amino-1,3,4-butanetriol (ABT) were 
designed and performed with final product yields of 90%  and 87% mol/mol 
respectively. For the synthesis of ABT and APD, the wild type E. coli TK and the 
engineered D469E TK were identified as the best candidates respectively, and both 
enzymes were paired with the TAm from Chromobacterium violaceum. 
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A microscale methodology for kinetic model establishment was developed based on 
programmable non linear methods. The TAm step was found to be the bottleneck of 
the multi-step syntheses, due to the high a Michaelis constant of intermediate 
substrate erythrulose for the synthesis of ABT, and the low catalytic constants for the 
synthesis of APD. Also the amino donor substrate was discovered to be toxic for the 
TAm, as well as causing side reactions, thus affecting the overall performance of the 
de novo pathway.  
 
The production of the E. coli whole cells containing the de novo pathway were 
successfully scaled-up to pilot plant without losing catalytic activity. By manipulating 
the fermentation temperature and induction time of TAm, it was found the desired 
level of expression of each enzyme could be achieved. 
 
Finally, the complete one-pot syntheses were simulated using the previously 
established microscale kinetic models, which were found to be predictive of 
preparative scale bioconversions. A reactor with fed-batch addition of the amino 
donor was predicted as the best operating strategy in each case. Using this strategy, 
the one-pot syntheses allowed up to a 6-fold increase in product yield (% mol/mol), 
while using concentrations one order of magnitude higher than previously published 
preparative scale data. 
 
As a conclusion, this work is the first of its kind to develop such a microscale 
modelling toolbox, which is designed to exploit the synthetic potential of engineered 
and recombinant enzymes, in order to design, simulate and optimize de novo 
engineered pathways. This makes the results of this work an original contribution for 
the process development of synthetic pathways.  
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NOMENCLATURE AND 
ABBREVIATIONS 
 
 
 
 
  
A260 Absorbance at 260 nm 
ABT (2S,3R)-2-amino-1,3,4-butanetriol 
AP Acetophenone 
APD (2S,3S)-2-aminopentane-1,3-diol 
BRENDA Braunschweig Enzyme Database 
c Protein concentration in mol L-1. 
CO2 Carbon dioxide 
CV20205 Chromacterium Violaceum 20205 
dB Width of baffle (mm) 
di Diameter of impeller (mm) 
DNA Deoxyribonucleic acid 
DOT Dissolved oxygen tension (%) 
dT Diameter of vessel (mm) 
ε Extinction coefficient 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ee Enantiomeric excess 
EiTAm Transaminase concentration 
EiTK Transketolase concentration 
E-PLP Transaminase –PLP complex 
E-PMP Transaminase –PMP complex 
EtOA Ethyl alcohol 
F Feed rate (L hr-1), 
FeedRate Feeding rate of MBA solution (L min-1) 
λ Path length equal to 1 cm 
g Gram 
GA Glycoaldehyde 
gDCW Grams of dry cell weight 
HEPES N−2−hydroxyethylpiperazine−N’−ethanesulphonic acid 
His6-tag 6x histidine- tagged 
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HPA Hydroxypyruvate 
HPLC High pressure liquid chromatography 
IPA Isopropylamine 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
K1 Equilibrium constant of the first half reaction of transaminase 
K2 Equilibrium constant of the second half reaction of transaminase 
KABT Michaelis-Menten constant of ABT 
KABT Michaelis-Menten constant of APT 
KAP Michaelis-Menten constant of  AP 
kDa Kilo Dalton 
Keq Equilibrium constant 
KERY Michaelis-Menten constant of ERY 
kf Catalytic rate constant for the forward reaction 
KGA Michaelis-Menten constant of GA 
KHPA Michaelis-Menten constant of HPA 
KiABT Inhibition constant of ABT 
KiAP Inhibition constant of AP 
KiAPD Inhibition constant of APD 
KiERY Inhibition constant of ERY 
KiGA Inhibition constant of GA 
KiHPA Inhibition constant of HPA 
KiMBA Inhibition constants of MBA 
KiPA Inhibition constant of PA 
KiPKD Inhibition constant of PKD 
KMBA Michaelis-Menten constant of MBA 
KPA Michaelis-Menten constant of PA 
kr Catalytic rate constant for the reverse reaction 
L Litre 
LB Luria Bertrani 
lGM Phosphoglucomutase 
MBA Methybenzylamine 
MBAFeed Concentration of MBA in the feed 
MeOH Methanol 
Mg Magnesium 
mg Milligram 
min Minute 
Nomenclature and Abbreviations 
 
 
 
 
 
     
    25 
 
  
mL Millilitre 
mM Millimolar 
mmol Millimol 
NaOH Sodium Hydroxide 
Ni Nickel 
OD600 Optical density at 600 nm 
PA Propionaldehyde 
PK Pyruvate kinase 
PKD (S)-1,3-dihydroxypentan-2-one 
PLP Pyridoxal 5´phospahte 
pmol Picomol 
PMP Pyridoxamine phosphate 
PP Pyrophsphate-binding domain 
PPG Polypropylene glycol 
Ri kinetic reaction rate of compound i (mM min-1) 
RO Reverse osmosis 
rpm Revolutions per minute 
SA Static surface area 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
t Time 
TAm Transaminase 
TFA Trifluoroacetic acid 
TK Transketolase 
TPP Thiamine pyrophosphate 
TRIS Tris(hydroxymethyl)aminomethane 
U Units of enzyme activity (µmolmin-1) 
µ Specific growth rate (h-1) 
UDP Uridine 5'-diphosphate 
UDPGE UDP-galactose 
µL Microlitre 
µm Micrometer 
µmax Maximum specific growth rate (h-1) 
µmol Micromole 
UTP Uridine 5'-triphosphate 
UV/Vis Ultra violet / visible 
v Reaction rate (mmol/min) 
V Volume (L) 
Nomenclature and Abbreviations 
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V.fluvialis Vibrio Fluvialis 
v/v Volume by volume 
Vol Working reaction volume  (L) 
VW Total well volume 
Wt Wilde type 
x Cell biomass (gDCW L-1), 
Y Yield of cell mass per unit of carbon source of glycerol (g g-1 ) 
ω-TAm ω-transaminase 
  
 
1. INTRODUCTION AND AIMS OF THE 
PROJECT 
 
 
 
 
 
 
The chemist who designs and completes an 
original and aesthetically pleasing multi-step 
synthesis is like the composer, artist or poet 
who, with great individuality, fashions new 
forms of beauty from the interplay of mind and 
spirit (Elias James Corey, Nobel lecture, 1990). 
 
 
 
 
 
1.1.   Introduction to multi-enzyme catalysis 
 
Enzymes have demonstrated their usefulness for chemical organic synthesis due to their 
moderate reaction conditions, reduced environmental impact, and their high chemo-, 
regio- and stereo-selectivity (Whitesides & Wong, 1985; Straathof et al., 2002; Woodley, 
2008). In many cases, enzymes have emerged as the only tool to achieve the direct 
preparation of optically active compounds, resulting in many commercial applications 
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where the key feature is the enzymatic asymmetrical synthesis (Schmid et al., 2001; 
Breuer et al., 2004).  
 
Conventional biocatalytic process development has focused on single reactions and their 
optimization (Murzin, 2008). Nevertheless, Nature did not design enzymes to be used in 
isolation, instead living beings have evolved effective multi-enzymatic strategies to 
synthesize and build complex structures from simple substrates (Roessner & Scott, 
1996b). Enzymes working in cascades lead to important advantages to the cells in terms 
of storage and consumption of energy. It also enables them to minimize metabolic waste, 
make a reversible reaction irreversible, avoid the purification step of intermediates, and 
minimize inhibition or toxic effects of metabolites by keeping their concentration low 
among many other benefits (Bruggink et al., 2003; Schultheisz et al., 2008). 
 
It was not until the late 1980s, with the discovery of the polymerase chain reaction, and 
the further development of metabolic engineering tools, that scientists started to mimic 
the exquisite multi-step efficiency shown by enzymes in Nature (Chotani et al., 2000). 
This has led to the successful investigation of multi-step, metabolically engineered 
pathways towards application as pharmaceutical production platforms (Burkart, 2003).   
 
Nowadays, it is possible to design de novo non-native engineered pathways in 
heterologous hosts, to carry out specific non-natural bioconversions producing chiral 
compounds, difficult to obtain by existing biosynthetic pathways or chemical synthesis 
(Roessner & Scott, 1996; Prather & Martin, 2008; Martin et al.,2009; Dalby et al., 2009) .  
 
This has led to the rapid expansion of molecular pathway construction, creating 
opportunities for the synthesis of a broad range of fine chemicals and pharmaceutical 
intermediates (Wilkinson and Bachmann, 2006). However, those opportunities have been 
rarely applied beyond laboratory scale, because such de novo engineered pathways are 
difficult to assemble, model, scale-up and operate productively (Meyer et al., 2007). In 
order to overcome those complexities, recent advances in protein engineering (Hibbert et 
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al., 2005; Dalby et al., 2009), microscale high-throughput methods (Lye et al., 2003; 
Micheletti & Lye, 2006), and modelling tools for biochemical processes (Chou & Voit, 
2009; Sin et al., 2009) can be applied to facilitate the rational design of such systems. 
This would enable to harvest the potential of de novo pathways, leading to a greater 
integration of such systems in industrial scale synthesis (Lye et al., 2002).  
 
1.2.  Classification of multi-enzymatic processes 
 
A multi-step enzymatic process uses two or more enzymes via  parallel, cascade, or  
network configurations to achieve a desired synthesis (Findrik, 2009). Several 
classifications have been proposed for multi-enzymatic processes, depending on the 
nature of the biocatalyst (living cell, artificial cell, lysate, pure enzymes etc), the number 
of enzymes,  vessels or recovery steps, integration with other type of catalysts 
(enzymatic, chemo-enzymatic etc), the purpose of the extra steps  (equilibrium shift, 
cofactor regeneration, deracemization etc) among many other categories (Schilling et al., 
1999; Bruggink et al., 2003; Hailes et al., 2007; Murzin, 2008). In this work, a simplified 
version of the classification proposed by Santacoloma et al., (2011) has been followed, 
and is represented in Figure 1.2.  
 
 
Figure 1.1. Classification of a multi-enzymatic process. Figure modified from Santacoloma et al., 
(2011). 
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In the first hierarchy, the multi-enzymatic processes have been classified as in vivo when 
the biocatalytic steps are carried out inside a living cell, and ex vivo when the reactions 
take place outside the cell.  
 
Depending on the characteristics of the process and degree of compatibility of each 
enzyme, an in vitro multi-enzymatic synthesis can be operated in multiple or single 
reactors. For an in vivo synthesis, the metabolic pathway inside the cell cannot be 
separated into individual reactions, therefore is not feasible to carry out the process in 
more than one reactor (Findrik, 2009; Santacoloma et al., 2011). Those systems where a 
bioconversion is carried out using two or more enzymes in a single bioreactor are referred 
as “one-pot” synthesis, and the next sections will focus on this type of multi-step 
bioconversions.  
 
1.2.1.  One-pot synthesis 
 
 
The traditional step-by-step approach to convert a starting material A into a final product 
D is using a single reactor for each enzymatic bioconversion step, in which intermediate 
products B and C would be isolated and purified for each conversion step (Figure 1.2a) 
(Bruggink et al., 2003). Such systems present the disadvantages of low overall yields due 
to loses in each separation step, higher capital investment, longer reaction times, 
laborious recycle loops and large amounts of waste produced in each downstream outlet 
(Findrik, 2009).  In contrast, in a multi-enzymatic one-pot synthesis, a starting material A 
is converted by a set of enzymes in a single vessel to produce the final product D without 
separation of intermediates B and C (Figure 1.2b) (Sheldon, 2008).  
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Figure 1.2. Configurations of a multi-step synthesis. (a)  Traditional multiple bioreactors syntheses 
used in industry which involves a recovery step after each bioconversion. (b) One-pot synthesis as it 
is done in the cells which involves coupled reactions without intermediate recovery steps. Figure 
adapted from Bruggink et al., (2003) and from Sheldon, (2008). 
 
In such one-pot processes, all the enzymes working together can be exploited 
simultaneously, leading to a reduction in the global reaction time, a decrease in the 
concentration of toxic intermediates, an improvement in the half life of the enzymes, an 
increase in the overall yield of the reaction, in addition to a considerable reduction in 
downstream processing and operation costs (Ingram et al., 2007; Murzin, 2008; Findrik, 
2009; Kalaitzakis & Smonou, 2010).  
 
However, the one-pot multi-step synthesis offers many challenges, given that each 
enzyme may have disparate optimal conditions; therefore optimum global conditions 
need to be identified, usually at the expenses of the most favourable kinetic steps in order 
to alleviate bottlenecks (Murzin, 2008).  Non-beneficial side reactions between different 
promiscuous enzymes and the intermediates that occur as a result, diminish the final yield 
and severely affect the global economic performance of the process     (Schmid et al., 
2001; Pollard & Woodley, 2007). In addition, the global rate of the steps should be 
harmonized, avoiding the accumulation of toxic intermediates due to a fast reaction step, 
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as well as the substrate “starving” of another step, diminishing the benefits of the 
sequential operation (Roessner & Scott, 1996; Murzin, 2008).   
 
Many different one-pot syntheses have tackled those initial challenges, and have been 
successfully demonstrated at laboratory scale with different objectives like in situ 
cofactor regeneration (Chenault et al., 1998; Schultheisz et al., 2008; Van Hecke et al., 
2009), deracemization (Caligiuri et al., 2006; Koszelewski et al., 2009) and cascade 
biocatalysis (Ingram et al., 2007; Chi et al., 2008). A very complete review has been 
made by Bruggink et al., (2003) covering multi-step one-pot synthesis using pure 
enzymatic, chemoenzymatic, homogeneous and heterogeneous catalytic reactions, 
highlighting the many options and tools available for the synthetic scientist to design one-
pot process. In the following sections, the main advantages about in vivo and ex vivo 
multi-enzymatic one-pot synthesis will discussed and relevant examples will be given; 
special emphasis will be given to the in vivo de novo pathways. 
 
1.2.1.1.  Ex vivo one-pot synthesis  
 
When an enzyme is taken out the cell to perform a specific function, the process is 
considered ex vivo. Therefore, the application of several isolated enzymes in a single 
vessel can be viewed as a multi-step ex vivo synthesis (Roessner &  Scott, 1996). Ex vivo 
processes can make use of catalysts in different forms, such as the trapping or enzymes in 
polymeric microcapsules (artificial cells) (Chang, 1988; Chi et al., 2008), immobilized 
enzymes (Sheldon, 2007; Matosevic et al., 2011) or cellular extracts and purified 
enzymes (Li et al., 1993; Woodley, 2006). 
Using all those different forms of biocatalysts, elegant one-pot syntheses have been 
achieved, including an 8 enzyme one-pot synthesis of N-acetyllactosamine, involving the 
required regeneration of uridine 5'-diphosphate as shown in Figure 1.3 (Wong et al., 
1982). 
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Figure 1.3. Multi-step synthesis of N-acetyllactosamine. Abbreviations: UDP: uridine 5'-
diphosphate; UTP: uridine 5'-triphosphate; UDPGE: UDP-galactose 4'-epimerase; Gal transferase: 
galactosyl transferase; UDPGP: UDP-glucose pyrophosphorylase ; lGM: phosphoglucomutase; PK: 
pyruvate kinase; β-D-Gal(14 )-D-GlcNAc: N-acetyllactosamine. Figure adapted from Wong et al., 
(1982). 
 
A 12 step one-pot synthesis of a precursor of vitamin B12 has been achieved using 
purified cells, reaching an individual yield higher than 90% for each step, leading to an 
overall 20% yield mol/mol (Roessner et al., 1994; Scott, 1994;  Roessner & Scott, 
1996b). Of special interest is the 8 enzyme one-pot synthesis of riboflavin, where 6 
enzymes performed synthetic steps and 2 were involved in cofactor regeneration 
achieving a final yield of 35% mol/mol (Rumisch et al., 2002).  
 
The previous syntheses demonstrated the potential of ex vivo multi step one-pot synthesis. 
While it requires the isolation of the enzymes, ex vivo systems are not hampered by mass 
transfer limitations caused by the cell wall, they can work at conditions toxic for a cell 
such as high substrates or solvent concentrations, and avoid the cellular metabolic 
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pathway interference, which may compete for substrates (Roessner & Scott 1996a; 
Schultheisz et al., 2008; Santacoloma et al., 2011). Apart from its potential in synthesis, 
ex vivo systems are ideal for protein function identification due to the flexibility that they 
offer to the scientist to manipulate the enzymes, substrates and intermediates without any 
cellular background (Kajiwara et al., 2006).  
 
The main drawback for ex vivo one-pot synthesis is that the cost associated to purify the 
enzymes usually does not allow scaling up the process beyond research scale       
(Rozzell, 1999; Meyer et al., 2007). It has been estimated that for a commercial process, a 
metric defined as cost of product/cost of gram of enzyme should be at least 1000 for a 
purified enzyme compared to 15 using a whole cell system, reflecting the difference in 
costs for each biocatalyst form  (Pollard & Woodley, 2007). Immobilization will play an 
important role in lowering the associated costs of purification by recycling the enzyme 
(Sheldon, 2007; Tufvesson et al., 2010).  
 
In vivo biocatalysis is a solution that can reduce the cost of production of the several 
enzymes involved in a multi-step synthesis; this type of system will be studied in more 
detail in Section 1.2.3.  
 
1.2.1.2. In vivo one-pot synthesis 
 
In vivo  biocatalysis is considered the cheaper alternative for multi-step synthesis, 
because it has the potential to synthesize of all the desired enzymes within a single host, 
without any further processing (Woodley, 2006). With the advances in fermentation 
technology, using fed-batch strategies can allow cell cultures to easily reach bacterial 
densities of 50 to 100 g L-1 with up to 40% of the total protein being the desired enzyme 
(Lee, 1996; Shiloach & Fass, 2005). New trends in fermentation for biocatalyst 
production using Pichia Pastoris as the host cells could increase the yield of the cell 
density and the desired enzymes by 1 order of magnitude  (Payne et al., 1997; Macauley-
Patrick et al., 2005). 
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In addition, in vivo biocatalysis has the potential advantages of increasing the stability of 
the enzymes, especially for membrane bounds proteins or enzymes that require accessory 
cellular systems, as well as enabling easy regeneration of expensive cofactors, including 
sources of reducing equivalents and ATP among others  (Wilkinson & Bachmann, 2006; 
Tufvesson et al., 2010).  
 
Nevertheless, optimizing an expression system for in vivo biocatalysis is not 
straightforward, and many variables can have an impact on the production efficiency, like 
the choice of the vector, inducer system, medium composition, and growth conditions 
among others (Thiry & Cingolani, 2002). In vivo systems are generally more complex 
than their ex vivo counterparts, due to the complexity of the cellular metabolic network 
that is still present during the biocatalysis, therefore they present more challenges to be 
assembled and operated efficiently (Tyo et al., 2007). Special care needs to be taken to 
avoid side reactions, and a certain ‘insulation’ of the cellular metabolism can be obtained 
through the overexpression of the target genes relative to the background (Meyer et al., 
2007). New approaches to minimize the harmful interference of the cellular metabolism 
include the use of reduced genomes, like the E. coli minima genome project (Pósfai et al., 
2006).  
 
Advances in metabolic engineering over the past 25 years have resulted in the 
engineering of microorganisms for the production of high value products for industrial 
scale (Burkart, 2003). Successful examples are the production of antibiotics (Li & 
Townsend, 2006; Rokem et al., 2007) or amino acids  (Lee et al., 2007; Sprenger, 2007) 
using native engineered hosts. New tools of metabolic engineering have allowed the 
complete expression of heterologous pathways in new hosts with better growth and 
protein expression characteristics (Pfeifer, 2001; Carter et al., 2003).   
 
Those previously mentioned examples show how in vivo one-pot synthesis using the 
metabolic engineering tools have become a reality (Tyo et al., 2007). Those examples 
focused on the manipulation and optimization of existing natural pathways. However in 
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order to take advantage of the full potential of the in vivo synthesis, it is necessary to shift 
towards the design of new de novo engineered pathways for both natural and unnatural 
compounds (Prather & Martin, 2008). The necessity arises due to the fact that the number 
of compounds of commercial interest greatly outnumbers the available characterized 
natural pathways and enzymes (Martin et al., 2009). From a top 12 list of biochemical 
targets highlighted by the U.S Department of Energy, only half had a known biochemical 
synthetic route (Werpy, 2004).  
 
Prather & Martin (2008) classified synthetic engineered pathways not fully recruited from 
a single source in three categories as described in Figure 1.4. In the first category, 
different pathways can be gathered from different microorganisms and combined in a 
single host. Secondly, pathways can also be modified to produce new non-natural 
compounds. Lastly, by combining the previous two approaches, which are the 
recruitment of biosynthetic components from different sources and the modification of 
those components for new catalytic capabilities, lead to the third approach commonly 
known as de novo pathway design, which will be discussed with more detail in the next 
section 1.2.3.1.  
 
 
Figure 1.4. Strategies for pathway design to perform one-pot in vivo synthesis. (a) The pathway 
from S to I is from one organism while from I to P is from another. (b) New products Pi are produced 
from modifications or extensions of an existing pathway. (c) Each step in the pathway is proposed 
independently. This work will focus especially in this approach. Figure adapted from  Prather & 
Martin (2008). 
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1.2.1.3. De novo pathway design 
 
The essence that distinguishes a de novo pathway from the previously mentioned 
engineered pathways is that its design begins from scratch, without relying upon any 
natural precedent (Tyo et al., 2007; McArthur & Fong, 2010). Its creation involves 
linking unrelated enzymes towards the synthesis of unnatural compounds of high value. 
In theory, this approach offers incredible opportunities to synthesize a wide range of 
compounds, by taking advantage of the natural diversity of enzymes across species 
(Ferrer et al., 2005). Nevertheless, several big challenges and obstacles remain to be 
solved for de novo pathway design, due to the complete unnatural characteristic of the 
pathway, which may result in no natural set of enzymes capable to integrate it (Sprenger, 
2007) . Therefore protein engineering tools emerges as a solution to compensate for the 
lack of natural enzymes to catalyze unnatural substrates (Dalby et al., 2009).  
 
Few successful examples of de novo pathways exist nowadays which have solved this 
challenge, like the synthesis of the energetic material precursor 1,2,4-butanetriol, were 
multiple enzymes from Pseudomonas fragi and putida combined with native E. coli 
enzymes were screened to successfully design the de novo the pathway (Niu et al. 2003). 
Also several biofuels like isobutanol and 2-phenylethanol were successfully synthesized 
using a de novo pathway, by screening and exploiting the promiscuity of several enzymes 
of Lactococcus lactis and E. coli (Lee et al., 2008). An example of a de novo pathway 
used engineered enzymes of Porphyromonas gingivalis combined with E. coli  enzymes, 
allowing the synthesis of 3-hydroxypropionic acid  (Brazeau et al., 2006). A last elegant 
example involved the combination of an engineered pyruvate decarboxylase and 2-
isopropylmalate synthase, which allowed the synthesis of a broad range of unnatural 
alcohols  (Zhang et al., 2008). 
 
In the previous examples, the objective of designing a de novo pathway was to find the 
best combination of enzymes that could work together in vivo to produce a new desired 
compound. Those enzymes could be wild type or engineered, and theoretically many 
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possibilities will exist, therefore tools that would allow the identification and 
characterization of the different enzymes to select the best combination is a central 
challenge of de novo pathway design (McArthur & Fong, 2010). High throughput 
microscale instrumentation combined with protein engineering and mathematical models 
would create a powerful tool to rapidly solve those problems. Those tools will be 
discussed in the Section 1.3.  
 
1.3.  Microscale high-throughput experimentation 
 
Establishing an industrial biocatalytic bioconversion is usually a slow process compared 
with the traditional chemical routes  (Yazbeck et al., 2004). This is due to the necessity to 
screen a large set of biocatalyst libraries in order to identify the appropriate enzymes, 
followed by large amount of data that needs to be collected at each stage of the process 
development (Lye et al., 2003; Fernandes, 2010). New strategies that could handle a large 
quantity of experiments in order to test all the different enzymes are necessary. High-
throughput microscale techniques offer the potential to overcome those problems by 
considerably speeding up the process development with a minimum quantity of materials 
and time (Micheletti & Lye, 2006). The key advantages of such techniques are: (Lye et 
al., 2002, Lye et al., 2003). 
 
• Rapid evaluation of large enzyme libraries. 
• Reduction in the quantity of materials including expensive enzymes and substrates 
required for process development.  
• Rapid generation of early data for process design and models establishment 
predictive of larger scale operations. 
• Early identification of the optimum reaction conditions and reactor configurations. 
• Capacity to automate the complete bioprocess.  
• Promotion of a rapid and efficient translation from discovery to pilot plant scale. 
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The majority of the microscale bioprocesses studies have been performed on microwell 
systems of different geometries and sizes with scales ranging from 20 to 2000 µL  (Doig 
et al., 2002). Figure 1.5 shows the dimensions of 3 standard size microwell bioreactors.   
 
Although the use of microscale techniques has been heavily used since the last 2 decades 
for screening purposes, it is only recently that studies on fundamental engineering aspects 
have been performed, including mass and heat transfer phenomena and scaling up 
techniques (Zhang et al., 2008; Marques et al., 2009; Barrett et al., 2010).   
 
Of special interest is the liquid mixing in such small reactors, which behave different 
from larger scale processes in terms of the importance of diffusion and convection 
(Matosevic et al., 2008). Orbital shaking of microwell plates has been found to be the 
most efficient way to promote mixing, and several studies have been conducted to 
determine the critical speed to assure an uniform mixing (Micheletti et al., 2006). These 
studies have lead to a better understanding of the reaction conditions and engineering 
principles of the microscale tools, allowing the establishment of key parameters for 
efficient scale-up (Islam et al., 2008) .   
 
Recent studies have also focused on the quantification of enzyme kinetics using 
microscale tools (Lye et al., 2002). Of special interest is a study of a whole cell 
cyclohexanone monooxygenase performing the oxidation of bicyclic ketones to 
synthesize chiral lactones ( Doig et al., 2002). In that work, the authors were able to 
characterize the oxygen mass transfer behavior under different reaction conditions and 
microwell geometries, as well as determining accurately substrate inhibition parameters.  
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Figure 1.5.   Diagram representation of individual microwell formats: (a) 96-deep square well 
format; (b) 24-round well format; (c) 96-round well format. VW represents the total well volume; SA 
represents the static surface area available for gas–liquid mass transfer. Figure adapted from Doig et 
al., (2002). 
 
Several other works describe quantitative methods for the determination of    Michaelis -
Menten parameters following spectrophotometrically the change in pH of the reaction 
through the use of pH dependent colorimetric dye. This method could be applied to any 
reaction that produce an acid or a base, but special care must be taken to avoid 
inaccuracies in the kinetic data collected, due to effect of the pH change in the behaviour 
of the enzyme (John & Heinzle, 2001; Truppo et al., 2009) .  
 
The use of microscale techniques combined with analytical tools such as HPLC (high-
performance liquid chromatography) for the reliable determination of kinetic parameters 
has been demonstrated using cellular extracts, pure and immobilized enzymes (Chen et 
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al., 2008; Matosevic et al., 2011). Of special interest is the work from Chen et al., (2009), 
where a full kinetic model was established using automated microscale tools, evaluating 
key parameters such as substrate and product inhibition. 
 
Therefore microscale bioprocessing techniques emerge as an ideal tool that can be used to 
study and evaluate the different components of a complex bioprocess such as a de novo 
pathway, in order to generate quantitative data early on to better inform the process 
design, as will be discussed in the next Section 1.3.1 . 
 
1.3.1.  Microscale processing techniques for de novo pathway design 
 
Microscale high-throughput would allow for the evaluation of each the de novo pathway, 
allowing the determination of the best enzyme candidate of each step under the global 
conditions of the one-pot synthesis.  
 
Therefore, a retro-biosynthetic approach, similar to the one used in organic chemistry to 
design the synthesis target compounds, could be applied to design the de novo pathway 
(Prather & Martin, 2008). The approach would consider the bioconversion of functional 
groups rather than considering entire structures or initial substrates (Yazbeck et al., 
2004). This retro-biosynthetic approach offers the challenge to be able to take advantage 
of the huge diversity of enzymes across species and also the engineered ones.   
 
Nevertheless a methodology is necessary to be able to cope with the expanded 
possibilities of synthesis that de novo pathways offer, and microscale techniques emerge 
as a powerful tool to assist in that aspect. Figure 1.6 shows the proposed retro-
biosynthetic methodology to design a de novo pathway, where microscale 
instrumentation plays a crucial role. 
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Figure 1.6. Methodology proposed in this work to design and optimize a de novo pathway for rapid 
process development. 
 
Starting from a desired compound with specific functional groups, an enzyme recruitment 
step needs to be performed selecting many potential candidates for each individual 
reaction that needs to be performed. The recruitment could be made from databases like 
BRENDA (Schomburg et al., 2004) or SWISE PROT (Wu et al., 2006), or from specific 
previously developed libraries gathered in a particular laboratory. Using the high-
throughput microscale tools, all the candidates could be evaluate under a defined set of 
conditions, and rankings could be given to each set of enzymes depending on their 
performance. Those “rankings” would inform in the identification of the best candidates 
for each reaction step, and also in the early determination of steps where new rounds of 
protein engineering were necessary. 
 
Further characterization of the selected enzymes could be rapidly achieved due to the 
nature of the high-throughput platform, in order to develop mathematical models to 
predict and characterize the kinetic behaviour of each selected enzyme. This would have 
a considerable impact in the assembly of the de novo pathway, where cellular resources 
and physical space limit the overexpression of all the enzymes in a single cell (Tyo et al., 
2007). Therefore the determination of the catalytic steps where strong overexpression 
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needs to be achieved to overcome the slower kinetic rate is necessary, at the expenses of 
the expression of the most kinetically fast enzymes.  
 
The scalable nature of the microscale tools discussed in Section 1.3 would allow 
predicting larger scale operations. Hence the performance of the de novo pathway under 
many scenarios and reactor configurations could be analyzed. This would speed up the 
determination of the best reaction conditions, which would translate in a faster process 
development to manufacturing scale. The development of such models will be review in 
Section 1.4.   
 
1.4.  Modelling of biocatalytic processes. 
 
Mathematical models are tools that contain information of a process in order to describe 
its behaviour under a limited set of physical conditions  (Jimenez-Gonzalez & Woodley, 
2010). For biocatalytic processes, they usually consist on differential and non-linear 
algebraic equations that describe the mass balance of substrates, intermediates and 
products as well and the different reaction rates (Meyer et al. 2007). Apart from 
promoting fundamental process understanding, such models can predict the outcomes 
under different scenarios and reactor configurations, enabling substantial time saving for 
the identification of the optimum reaction conditions (Chou & Voit, 2009; Santacoloma 
et al.,2011). 
 
Sin et al., (2009) classified the models developed in biocatalysis according to their scope 
in the following categories: 
• Enzyme: models aims to understand the molecular structure of the enzyme, 
explaining the interaction of the enzyme-substrate at a molecular level, leading to 
the prediction of the stereo-selectivity of an enzyme catalyzed conversion. 
• Reaction: kinetic models describing reaction mechanism and reaction rate based on 
detectable and controllable inputs like concentration, pH and temperature. 
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• Reactor configuration: kinetic models describing the reaction rates and final 
outcomes in different reactor configurations. Those models include mass balance as 
well as transport phenomena conditions. 
• Process: models allowing the analysis of the global performance of a process, 
including the interaction between different unit operations. 
 
An illustrative representation of the different scopes of each type of model has been 
shown in Figure 1.7.  
 
 
Figure 1.7. Representation of different models applied in biocatalysis categorized in the order of 
increasing scope: (1) intrinsic properties of the enzyme, (2) reaction kinetics, (3) reactor kinetics, and 
(4) process dynamics. Figure adapted from Sin et al., (2009).  
 
Each model scope and the combinations of them can have their own increasing 
complexities. Nevertheless the more complex the model is, the more time and resources it 
will consume to be established(Sin et al., 2009). This can hamper the overall objective of 
establishing the models which is to speed up process development (Law et al., 2008). 
Therefore simplifications of the models need to be done, in order to speed up the design 
of a de novo pathway. For example, in the early screening procedure of the individual 
enzymes using the microscale techniques described in Figure 1.6; simple models 
describing the specific activity of the different enzymes could be used as the rankings for 
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decision making tools. Also, those simplified models could quickly permit the selection 
of appropriate reaction conditions for the overall one-pot synthesis.  
 
When a potential candidate has been selected, the model complexity should be increased 
to establish the reaction kinetic model. The objective of the model would be to 
understand possible bottlenecks of the step (in order to inform subsequent protein 
engineering rounds), as well as to predict different scenarios to determine the best 
reaction conditions. The kinetic model developed in this step should not necessarily be 
very accurate in the enzyme scope level, as obtaining a complete understanding of the 
interaction of the enzyme-substrate at a molecular level would be time consuming, 
without necessarily bringing much extra information to impact in the decision making.  
 
To finalize, when the kinetic models of the different steps have been established, they 
should be compared in order to identify the major bottleneck of the reaction, which will 
define the overall rate of the one-pot synthesis. Reactor models should be used to 
determine the best reaction configuration that would benefit each individual step. The 
reactor configuration should be selected to overcome the previously major detected 
bottleneck step of the reaction.  
 
Therefore a global reaction model should be constructed which should integrate all the 
kinetic models and the selected reactor configuration. This model should enable to predict 
the global performance of the one-pot synthesis as well as the different simultaneous 
interactions between the different catalytic steps. In a one-pot synthesis, there is still 
room to modify different reaction conditions and configurations over the time of the 
bioconversion. For example, switching from a batch mode to a fed-batch transformation 
or changing the pH to switch on and off different enzymes could bring benefits 
(Schoevaart et al., 2000). The possibility to manipulate those conditions with perfect 
timing in order to optimize the overall one-pot synthesis only becomes a possibility due 
to the establishment of the different kinetic models. 
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1.4.1.  Strategies to establish biocatalytic kinetic models 
 
Figure 1.8 describes the general steps followed to establish kinetic mathematical models 
for bioprocesses (Sin et al., 2009).  
 
 
Figure 1.8. General common steps involved in the establishment of biocatalytic mathematical 
models, arrows indicate feedback loops between steps. Figure adapted from Sin et al., (2007). 
 
This procedure should be applied to the “model generation” section represented in Figure 
1.6.  After establishing the objective of the model which will define the scope of 
mathematical model (reaction level scope for selected enzyme candidates) (Figure 1.7), 
experimental work should be planned and performed in order to establish the model 
structure and its corresponding parameters. 
Traditional approaches were based on simplification of the kinetic models to linear plots, 
like the Lineweaver-Burk method, where the kinetic parameters could be successively 
determined using experimental initial rates (Lineweaver &  Burk, 1934; Eisenthal & 
Crosnish-Bowden, 1974). Those methods have been found to be theoretically 
undesirable, because they distort the error weight after linearization of the equations, as 
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well as presenting large errors in the initial rate determination (Dowd & Rigss, 1965; 
Ranaldi et al., 1999). In addition, those methods require a large amount of experiments to 
establish all the kinetic parameters including inhibition constants, making them time 
consuming and unsuitable for the purpose of speeding up process development (Chen et 
al., 2008).  
 
In order to overcome this problem, non-linear regression methods provide an alternative. 
In order to determine the kinetic parameters, those methods use optimization algorithms 
to fit a defined set of concentrations of substrates and products as a function of time, 
minimizing an objective function that punishes deviation between experimental and 
predicted data (Blackmond, 2005; Meyer et al., 2007). 
 
The advantages of such techniques are that they consider the data of the full progress 
curves, in comparison to the initial rates used in the linear methods, therefore requiring 
much less experimentation. Also, they do not distort the error, are programmable and 
consequently faster and more reliable (Morbiducci et al., 2005; Chou & Voit, 2009).  
 
However, the large number of parameters that needs to be estimated, and the highly non -
linear nature of the equations can be difficult for the parameters  determination (Gernaey 
et al., 2010). Initial estimates have been found to play a major role in the quality of the 
results using non-linear methods (Moros et al., 1996). Hybrid methods combining 
traditional initial rates experiments to identify a solution in the vicinity of the global 
minimum, with non-linear regression methods to determine the exact location of the 
global minimum have been successful  (Katare et al., 2004; Chen et al., 2009).  
  
Establishing a systematic model development methodology will be beneficial and 
necessary to design de novo engineered pathways for several reasons (Sin et al., 2009): 
 
• Model development is more efficient, requiring less time and resources. 
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• Model development becomes a systematic routine, which can be easily applied to 
all the different enzymes of the de novo pathway. 
• Following the same methodology, the comparison of the kinetic results of the 
different enzymes is more transparent. 
• Communication and knowledge transfer among the members of a multidisciplinary 
team is facilitated.  
 
Nowadays, there are practically no studies where full kinetic analysis and modelling of de 
novo engineered pathways have been performed. This is because such multi-step 
synthesis are usually focused on non natural substrates with several engineered enzymes 
in a same one-pot synthesis, which  makes the process complex and requires large 
amount of experimentation to characterize (Murzin et al., 2008). By combining the 
advantages of high-throughput microscale instrumentation described in Section 1.3, with 
a systematic procedure for the establishment of kinetic models, and protein engineering, 
powerful toolboxes can be created to rapidly design and optimize de novo pathways as 
described in Figure 1.6.  
 
In this work, the de novo synthesis of optically pure amino alcohols using a transaminase 
(TAm) and a transketolase (TK) was chosen as an example to demonstrate the 
applicability of the toolbox described in Section 1.3.1. In the next Section a state of the 
art of the de novo synthesis of amino alcohols will be given, as well as key information 
about the enzymes TK and TAm which integrate the pathway.  
 
1.5.  De novo pathway for the synthesis of amino alcohols 
 
1.5.1.  Relevance of amino alcohols 
 
Due to the fact that the human body functions using chiral metabolites,  the trend for new 
chiral pharmaceutical compounds  is continuing to increase (Breuer et al., 2004). In 2000, 
35% of intermediates were chiral and this number is expected to increase to 70% by 2010 
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(Pollard & Woodley, 2007). Therefore, it is not surprising that the main reasons for using 
biocatalysis is to perform synthetic steps with regio- and stereoselective properties 
(Schmid et al., 2001). Molecules with more than one chiral centre are compounds 
difficult to synthesize with organic chemistry, like the case of amino alcohols which are 
an ideal target for multi-step synthesis (Hailes, 2009).  
 
Chiral amino alcohols are of great interest to the pharmaceutical and fine-chemical 
industries, since they are used as building blocks for several commercial optically pure 
compounds. For example they are necessary in the synthesis of protease inhibitors (Kwon 
& Ko, 2002), in particular the protein kinase inhibitor sphingosine (Smal & De Meyts, 
1989), or the glycosidase inhibitor deoxymannojirimycin (Fuhrmann et al., 1984) and the 
HIV protease inhibitor Saquinavir (Kaldor et al., 1997). Optically pure amino alcohols 
are also used in the synthesis of detoxifying agents against antibiotics in the treatment for 
rice blast disease (Monache & Zappia, 1999) or serve as chiral starting material in the 
synthesis of various optically active molecules such as (S)-amphetamine (Rozwadoska, 
1993) or broad spectrum antibiotics like chloramphenicol and thiamphenicol (Bhaskar, 
2004; Boruwa et al., 2005).  
 
The standard chemical synthesis route to produce optically pure amino alcohols is usually 
complex, requiring many steps in order to obtain the final product, resulting in low 
overall productivities (Hailes et al., 2009; Smithies et al., 2009). Using the retro-
biosynthetic approach discussed in Section 1.3.1, TAm was selected to perform the amino 
group addition (Ingram et al., 2009), because of its superior features in asymmetric 
synthesis with high stereoselectivity and no need for cofactor recycling (Stewart, 2001). 
For the chiral alcohol, TK was selected because it could enable asymmetric synthesis of 
ketols with high stereoselectivity and no need of cofactors recycling (Ingram et al., 2009), 
in addition that it allowed to perform carbon-carbon bond formation, enabling the 
synthesis of complex molecules from simpler achiral starting substrates (Turner, 2000). 
The principal characteristics of TK and TAm will be summarized in sections 1.5.2 and 
1.5.3.   
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1.5.2. Transketolase 
 
1.5.2.1.  Introduction to transketolase 
 
Transketolase is an enzyme that catalyses a carbon-carbon bond formation by transferring 
a C2 moiety (1,2-dihydroxyethyl group) between a ketose sugar and an aldose sugar 
(Sprenger et al., 1995) (Figure 1.9). The enzyme requires thiamine pyrophosphate (TPP) 
and Mg2+ as cofactors to perform the synthesis (Morris et al., 1996) .  
 
 
 
 
Figure 1.9. General reaction scheme of the carbon-carbon bon formation catalyzed by 
transketolase. A 1,2-dihydroxyethyl group is transferred between a ketose (red carbon skeleton) and 
an aldose (blue carbon skeleton).  X and Y could be variable groups. 
 
In vivo, the enzyme creates a link in conjunction with transaldose between the non-
oxidative branch of the pentose phosphate pathway and glycolysis. The reactions it 
catalyze are the conversion of D-xylulose-5-phosphate and D-ribose-5-phosphate to D-
sedulose-7-phosphate and D-glyceraldehyde-3-phosphate (Figure 1.10a); and the 
conversion of D-xylulose-5-phosphate and D-erythrose-4-phosphate to D-fructose-6-
phosphate and D-glyceraldehyde-3-phosphate as shown in Figure 1.10b ( Sprenger et al., 
1995). In plants and photosynthetic bacteria, transketolase is also found in the Calvin 
cycle where it catalyzes the reverse reaction of the previously mentioned conversions 
(Schenk et al. 1998) 
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Ex vivo, several transketolases have been found to accept a wide range of substrates, 
making it ideal to integrate de novo pathways.  Of particular interest is the use of β-
hydroxypyruvate (HPA) as keto donor so that CO2 is  released as a side product, making 
the reaction irreversible (Figure 1.10c) (Mitra & Woodley, 1996). Using HPA as a 
substrate, the specific activity of the TK of E. coli has been found to be 6 and 30 times 
higher than the yeast or spinach activities (Sprenger & Pohl, 1999),  in addition the TK of 
E. coli can form carbon–carbon bonds between a broader range of substrates including 
hydroxylated and unphosphorylated compounds (Pohl et al., 2004). 
 
The feasibility of the production of the enzyme at larger scale has been demonstrated up 
to 1000 litres (Hobbs et al., 1996). The clarified cell extract these authors obtained 
contained about 230 U/ml of the enzyme, which represented about 40% of the total cell 
protein. Those results make the E. coli TK a very good candidate for industrial catalysis 
(Turner, 2000) and to be part of a de novo pathway for the synthesis of amino alcohols.  
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Figure 1.10. Reactions catalyzed by TK in vivo and ex vivo.  Reactions (a) and (b) are reversible 
reactions that occur in vivo in the pentose phosphate pathway and Calvin cycle. Reaction (c) is used 
ex vivo where β-HPA is used as the keto donor to make the reaction irreversible by releasing CO2.  
 
1.5.2.2.  Structure of transketolase 
 
The E. coli TK is homodimer with a subunit molecular weight of 72 kDA.  The active 
sites of each subunit are located at the interface between the two identical components of 
the homodimer. The thiamine diphosphate cofactor is also situated at the interface 
(a) 
D-Xylulose-5-P 
 
D-Ribose-5-P D-Gyceraldehyde-3-P D-Sedoheptulose-7-P 
(b) 
D-Xylulose-5-P 
 
D-Erythrose-4-P D-Glyceraldehyde-3-P D-Fructose-6-P 
(c) 
β-HPA Aldehyde Ketodiol 
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between these two subunits (Sprenger et al., 1995) . Figure 1.11 shows the ribbon 
structure of the enzyme. 
 
 
Figure 1.11. Ribbon structure of the E. coli transketolase homodimer.  One monomer is coloured 
blue and the other is colored grey.  Figure Created from the PDB structure file 1QGD using PyMOL 
Molecular Graphics System (DeLano, 2002) on World Wide Web http://www.pymol.org 
 
Each subunit of TK is composed by three domains as can be seen in Figure 1.12.  The 
amino-terminal, or PP-domain, consists of a five-stranded parallel β-sheet with α-helices 
on both sides. The second domain, the Pyr-domain, is a six-stranded parallel β-sheet, 
sandwiched between α-helices. Both domains are involved in binding TPP and therefore 
have an important role in catalysis. The carboxy-terminal domain or C-domain contains a 
mixed β-sheet with four parallel and one antiparallel strand, it does not contribute any 
amino acids to the active site and its function remains unclear  (Muller et al., 1993; König 
et al.,1994). 
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Figure 1.12. Ribbon structure of a single subunit of E. coli transketolase. Two TPP molecules, 
which bind to the PP- and Pyr-domains are shown as spherical space-filling models. The divalent 
metal ion Mg2+ binding to TPP required for catalytic activity is highlighted in cyan. Figure created 
from the PDB structure file 1QGD using PyMOL Molecular Graphics System (DeLano, 2002) on 
World Wide Web http://www.pymol.org. 
 
 
1.5.2.3. Kinetic mechanism of transketolase 
 
The kinetic mechanism of TK follows a ping pong bi-bi ordered mechanism, which can 
be described as two half reactions which are represented in a condensed way in Figure 
1.13 (Sayar et al., 2009). Using HPA as the keto donor and any aldehyde (AL) as keto 
acceptor, in the first half reaction, HPA binds the enzyme (E) in the (through the cofactor 
TTP) and is cleaved releasing CO2, while forming a covalently bound active 
intermediate, the 2-α-carbanion of 1,2-dihydroxyethyl-TPP (F). In the second half of the 
reaction, the 2-α-carbanion (F) suffers a nucleophilic attack by the aldehyde (AL), 
PP-domain 
 
Pyr-domain 
C-domain 
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forming the second product, a ketose with an extended 2 carbon skeleton (K) while 
releasing the enzyme in its original form (E). 
 
 
 
Figure 1. 13. Representation of the ping pong bi-bi ordered mechanism followed by TK using HPA 
as keto donor and any aldehyde (AL) as keto acceptor. E represents the enzyme in its original form, 
K is the enzyme in its activated form, HPA is hydroxypyruate, and K is the final ketose product. 
 
The reaction mechanism at a molecular level is shown in figure 1.14 (Wikner et al., 
1997). For modelling purposes, this is a fine example of the different scopes that a model 
can cover as illustrated in Figure 1.7. Using the mechanism in Figure 1.13 would be 
appropriate for developing models at reaction level, while using the mechanism 
represented in Figure 1.14 would be necessary to develop a more complex model at 
enzyme level. Although the model resulting from the Figure 1.14 would give more 
information, due to time limit constrains of process development, all the kinetic models to 
design and optimize the de novo pathway will be done in this work at the reaction level 
scope. 
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Figure 1.14. Molecular scheme of the TK ping pong bi-bi ordered kinetic reaction mechanism. B1-
B3 represents catalytic groups involved in the proton transfer steps during the reaction. Figure 
adapted from Wikner et al., (1997). 
 
1.5.2.4.  Applications of transketolase in multi-step synthesis 
 
Due to the high demand of carbon-carbon bon formation with stereoselective properties, 
TK has been applied in several multi-step syntheses to produce compounds of high value 
(Turner, 2000). For example, TK has been employed in a chemoenzymatic reaction to 
produce 6-deoxy-L-sorbose, which is a precursor of furanol that is used as a fragrance 
component in the food industry (Hecquet, 1996) .  In this bioconversion, HPA was 
prepared from L-serine through the use of serine glyoxylate aminotransferase. The 
aldehyde 4-deoxy-L-threose which would be the keto acceptor of TK was produced 
through the microbial isomerisation of 4-deoxy-L-erythrulose using whole cells of 
Corynebacterium equi or Serratia liquefaciens. TK was finally used to perform a carbon-
carbon bond formation between 4-deoxy-L-threose and HPA, thus yielding 6-deoxy-L-
sorbose (L Hecquet 1996). 
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TK has also been applied for the synthesis of the unnatural sugar 4-deoxy-D-fructose 6-
phosphate through another multi-step chemoenzymatic synthesis shown in Figure 1.15 
(Guérard et al., 1999). (R,S)-1,1-diethoxy-3,4-eqoxybutane (1) was resolved using an 
epoxide hydrolase from Aspergillus niger in order to give (S)-epoxide (2) with a yield of 
30% and >98% enantiomeric excess. This epoxide was converted into the corresponding 
phosphorylated (S)-aldehyde (3) (via a phosphate inorganic treatment followed by acidic 
hydrolysis). The aldehyde was then reacted with (4) L-erythrulose in the presence of the 
S. cerevisiae TK. This generated 4-deoxy-D-fructos 6-phosphate (5) with a yield of 52%. 
The glycolaldehyde (6) that was released was reduced in situ using yeast alcohol 
dehydrogenase and catalytic NADH.    
 
 
 
Figure 1.15. Chemoenzymatic multi-step synthesis of 4-deoxy D-fructose 6-phosphate using an 
epoxide hydrolase and S. cerevisiae TK.  Figure adapted from Hecquet (1996) and Tuner (2000).  
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Another example of using TK in a multi step synthesis involved the synthesis of D-
xylulose 5-phosphate where TK was combined with an aldolase and isomerise to obtain a 
final yield of 82 % mol/mol (Zimmermann et al., 1999). 
 
1.5.3. Transaminase 
 
1.5.3.1.  Introduction to transaminases 
 
A transaminase or an aminotransferase is included in the class of enzymes like the acid 
dehydrogenases  (Brunhuber & Blanchard, 1994) or the amine dehydrogenases ((Hyun & 
Davidson, 1995) that convert a carbonyl group to an amino group as shown in Figure 
1.16. The enzyme needs the cofactor pyridoxal 5´ phosphate (PLP) to catalyze the 
reaction .(John, 1995) 
 
 
Figure 1.16. General reaction scheme of a TAm reaction where an amino group is transferred to a 
carbonyl group.  
 
In vivo, TAms are one of the key enzymes for the formation of desired amino acids at the 
expense of the catabolism of proteins. The main aim of a transaminase reaction within 
amino acid metabolism is to collect the amino groups from several different amino acids 
in the form of mainly L-glutamate (L-alanine in a lesser degree) (Lombardo et al., 1989; 
Davies, 1961) . This L-glutamate then functions as an amino group donor for biosynthetic 
anabolism or for the nitrogen excretion pathway (Urea Cycle) (Stitt et al., 2001).  
Ex vivo, several transaminases with broad range of substrate specificity have been 
identified  (Taylor et al., 1998). This has lead to their increasing industrial application for 
the synthesis of either natural or unnatural D- or L-amino acids (Stewart, 2001) .   
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1.5.3.2.  Classification of transaminases 
 
The classification of the different TAms has been done through sequence homologies, 
this classification corresponded with the structural classification of the substrates utilized 
by the enzymes according to the position of the amino group transferred with respect to 
the carboxyl group of the substrate. Therefore the TAms have been divided in four 
groups. Groups I, III, and IV are comprised of α-TAm whilst the ω-TAm make up Group 
II  (Mehta et al., 1993; Mehta & Christen, 1994).  The ω-TAm has the potential to access 
a range of substrates not accepted by the α-TAm, as the need for an α-amino acid or α-
keto acid is not necessary (Shin & Kim, 1999; Koszelewski et al., 2010a). Several ω-
TAm have been reported to show catalytic activity towards primary and secondary 
amines which do not need to have a carboxylic group  (Shin &  Kim, 2001; Koszelewski 
et al., 2010). 
 
The α-transaminases have been studied more extensively due to their potential in the 
industrial synthesis of amino acids (Stewart, 2001). However, in part due to the similarity 
between the products and substrates, low equilibrium constants have prevented their 
industrial use (Tufvesson et al., 2011). 
 
The synthetic potential of several ω-TAms have been studied, including  ω-TAms from  
Klebsiella pneumoniae, Bacillus thuringiensis JS64, Vibrio fluvialis JS17, and 
Arthrobacter sp among others (Shin & Kim, 1997; Shin &  Kim, 2001; Iwasaki et al., 
2006; Yun &  Kim, 2008). Among them, the ω−TAm from Vibrio fluvialis showed the 
best performance for kinetic resolution and asymmetric synthesis of chiral amines (Shin 
& Kim ,2001). The enzyme showed high selectivity towards (S)−enantiomers such as 
(S)−α−methylbenzylamine (MBA), and was capable of convert a broad range of ketones, 
making it ideal for asymmetric synthesis (Shin et al., 2003).  Nevertheless the enzyme 
suffered from strong product and substrate inhibition, and different studies using in situ 
product removable have been developed. Examples are using a biphasic media (Shin & 
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Kim, 1997) (Shin & Kim, 1999b), a reduced pressure system (Yun et al., 2004) , or 
membrane reactors (Shin et al., 2001)  among others . 
 
1.5.3.3.   Structure of transaminase 
 
Figure 1.17 shows the ribbon structure of the homodimeric TAm from Vibrio Fluvialis, 
where each subunit had a molecular weight of 50 kDA. 
. 
 
Figure 1. 17. Ribbon structure of homodimeric TAm from V. fluvialis JS17. Figure created from 
the PDB structure file 1qgd using PyMOL Molecular Graphics System (DeLano, 2002) on World 
Wide Web http://www.pymol.org. 
 
An active site model of the TAm has been constructed (Figure 1.18) (Shin & Kim, 2002). 
This resulted in a two-binding site model, which contained two pockets, one large and 
one smaller, the latter one presenting a strong repulsion for a carboxlate, playing an 
important role in the substrate specificity and stereoselectivity. The large pocket showed 
a dual recognition mode for both hydrophobic and carboxyl groups, and corresponded to 
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a carboxylate trap, while the small pocket played the role of a side chain recognition site. 
(Shin & Kim, 2002).  
 
 
Figure 1.18. Two-Binding Site Model of TAm of V. fluvialis showing (a) the binding of the amino 
donor and (b) the binding of the amino acceptor. L and S denote large and small binding pockets 
respectively. Figure adapted from Shin & Kim (2002). 
 
1.5.3.4.  Reaction mechanism of transaminase 
 
The TAm catalyzes the enzymatic amino transfer by a ping-pong bi–bi ordered 
mechanism analogue to the one of TK shown in Section 1.5.2.3 (Bulos & Handler, 1965) 
(Smith et al., 1998). The reaction mechanism is represented in Figure 1.19 where in the 
first half reaction, the amino donor (AN) binds to the enzyme and the amino group is 
transferred to the pyridoxal 5´phosphate (EPLP), which forms pyridoxamine 5-phosphate 
(EPMP), and the respective keto product (A) is released. During the second half reaction, 
the EPMP transfers the amino group to the acceptor substrate (B) and EPLP is 
regenerated, while the new aminated compound is released (B-N) (Christen and Metzler, 
1995). 
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Figure 1.19. Schematic representation of the ping pong bi-bi ordered reaction mechanism used of 
TAm. 
 
Some TAm have been reported to form “dead end complexes” between E-PLP or E-PMP 
and an incorrect substrate (for example an amino acceptor binding E-PLP or an amino 
donor binding E-PMP). Depending of the degree of  inhibition that those abortive 
complexes could cause, they may need to be taken into account in the modelling of the 
reaction (Bulos & Handler, 1965; Shin &  Kim, 1998).  
 
1.5.3.5.  Applications of TAm in multi-step synthesis  
 
TAm has been used in many multi-step syntheses for chiral amine catalysis. The majority 
of the multi-step syntheses involving TAm have had as objective to overcome the low 
equilibrium constant which hampers the reaction (Talylor, 1998). A elegant example is 
the in vivo production of L-2-aminobutyric acid, where the overexpression of E. coli 
aromatic TAm, E. coli K12 threonine deaminase and Bacillus subtilis acetolate synthase 
was achieved in a single host to perform the one-pot synthesis  (Figure 1.20) 
(Fotheringham et al., 1999).  The threonine deaminase catalyzed the in situ formation of 
transaminase substrate, 2-ketobutyrate from L-threonine, while the synthase eliminated 
the pyruvate by-product which enabled to shift the equilibrium towards the forward 
reaction, which normally was 50% using the TAm individually.  
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Figure 1. 20. Engineered multi-step pathway for the synthesis of L-aminoburyric acid.  Figure 
adapted from Fotheringhan et al., (1999). 
 
Also, combining an enzymatic transamination and dehydrogenation step ex vivo, it was 
possible to shift the equilibrium of the bioconversion to produce optically pure amines 
with yields higher than 90%  (Figure 1.21)  (Truppo et al., 2010) .  
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Figure 1.21. Synthesis of chiral amines combining an enzymatic transamination and 
dehydrogenation step in order to shift to equilibrium towards the forward reaction. Figure adapted 
from Truppo et al. ( 2010). 
 
Recently, in our research group, the ω-TAm from Chromobacterium violaceum (TAm 
CV2025),  was identified to be the best TAm for stereoselective ketodiol amination from 
a pool of 17 recombinant  TAms (Kaulmann et al., 2007; Sayer et al., 2007). The enzyme 
had a molecular weight of 51 kDa and exhibited 38% sequence identity to the TAm from 
V. fluvialis studied in Section 1.5.3.3. It was also found to be a homodimer with a similar 
catalytic site as the TAm from V. fluvialis illustrated in Figure 1.18 (no crystal structure 
has been published). The CV2025 TAm was of special interest for the de novo pathway 
design of amino alcohols as the majority of the TAms cannot catalyse the conversion of 
ketodiols, which could be produced by TK. In the next section, a literature review of the 
state of the art of the de novo engineered pathways for the synthesis of amino alcohols 
will be discussed.  
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1.5.4. One-pot synthesis of chiral amino alcohols 
 
The de novo pathway approach for the synthesis of amino alcohols was firstly 
demonstrated for the synthesis of the single syn-diastereoisomer (2S,3R)-2-amino-1,3,4-
butanetriol (ABT) (Ingram et al., 2007). This was performed by using erythrulose (ERY) 
and glycolaldehyde (GA) as achiral substrates for TK, and (S)-(α)-methyl benzylamine as 
amino donor for the TAm, and by overexpressing the E. coli TK and the β-alanine-
pyruvate TAm from Pseudomonas aeruginosa in a single E. coli host to perform the in 
vivo one-pot synthesis as shown in Figure 1.22.  ABT is an important building block in 
the pharmaceutical industry, which for example has the potential to be used to synthesize 
the chiral core of the protease inhibitor drug NelfinavirTM (Kaldor et al., 1997). 
 
 
Figure 1.22. The synthesis of chiral amino alcohol 2-amino1,3,4-buntanetriol (ABT) from achiral 
substrates glycolaldehyde and hydroxypyruvate using a de-novo TK–TAm pathway. TPP is thiamine 
pyrophosphate and PLP is pyridoxal 5´phospahte. 
 
Chapter 1: Introduction and Aims 
 
 
 
 
 
 
     
     66 
 
  
The main limitation of this one-pot synthesis was the low activity of the β-alanine-
pyruvate TAm causing a low overall yield of the reaction, as well as a lack of 
mathematical models to determine the best reaction conditions (Ingram et al., 2007). 
 
Consequently,  several  libraries of engineered TKs and novel TAms have been 
constructed, which could be used as a recruitment source to design new de novo 
engineered pathways for amino alcohols with increased performance (Hibbert et al., 
2007; Kaulmann et al., 2007; Hibbert, et al. 2008; Smith et al., 2008).  Of special interest 
was one work where I collaborated, where the potential of different E. coli TK mutants to 
accept new substrates with high stereoselectivity was predicted using molecular 
modelling bioinformatic tools like direct docking (Full paper attached in Appendix XIV) 
(Cázares et al., 2010).  The TK residue D469 was predicted to have a crucial role in 
accepting new substrates like propionaldehyde (PA), which could be a useful starting 
material for the de novo pathway of amino alcohols (Figure 1.23).  
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Figure 1.23.  Aldehydes propionaldehyde (grey) and butanaldehyde (magenta) docked into the TK 
active site containing the modelled TPP-enamine intermediate (green). A surface plot is shown with 
the key residues D469, H26 and H261 highlighted as sticks beneath the surface. Figure adapted from 
Cázares et al., (2010). 
 
Also, of great relevance was the identification and characterization of the CV2025 TAm, 
which showed great potential for amino alcohols synthesis as mentioned in section 
1.5.3.5.  
  
Recent work has shown that the synthesis of (2S,3S)-2-aminopentane-1,3-diol (APD)  
could be achieved in two separate TK and TAm bioconversions, where the E. coli TK 
mutant D469T and the CV2025 TAm enzymes were selected (Smith et al., 2010). 
Compounds like APD which contains the chiral 2-amino-1,3-diol moiety are an important 
class of pharmaceutical building blocks with their motif  present in antibiotics, antiviral 
glycosidase inhibitors, and sphingolipids (Hailes et al., 2009). The synthesis was 
achieved by using HPA and PA as achiral substrates for the mutant D469T E. coli TK to 
synthesize the intermediate (S)-1,3-dihydroxypentan-2-one (PKD), and after a 
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purification step to isolate PKD,  IPA was used as the achiral amino donor using the 
CV2025 TAm to synthesize APD with a final yield of 13% mol/mol respect to the initial 
TK substrates. The overall reaction pathway without including the separation and 
purification steps is shown in Figure 1.24.  
 
Figure 1.24. Two-step biocatalytic synthesis of 2-amino-1,3-diols using transketolase (TK) and 
transaminase (TAm). PA is propionaldehyde, HPA is hydroxypyruvate, TPP is thiamine 
pyrophosphate, PKD is (S)-1,3-dihydroxypentan-2-one,  PLP is pyridoxal 5´phospahte and APD is of 
(2S,3S)-2-aminopentane-1,3-diol. Figure modified from Hailes et al., (2009). 
 
In this case, the process required many downstream steps to isolate the TK product PKD 
prior to the TAm bioconversion as has been shown in the proposed manufacturing 
process by the authors in Figure 1.25.  
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Figure 1. 25.  Hypothetical manufacturing process flow sheet for the large-scale, two-step TK 
D469T (batch reactor 1) and CV2025 TAm (batch reactor 2) biocatalytic synthesis and purification 
of (2S,3S)-2-aminopentane-1,3-diol (APD). HPA is hydroxypyruvate, IPA is isopropylamine and 
EtOA is ethyl alcohol. Figure adapted from Smith et al., (2010). 
 
 
During the purification steps, more than 30% mol/mol of the intermediate PKD was lost, 
apart from the use of large quantities of waste used in the downstream steps shown 
between the two reactors in Figure 1.25. Those problems could be potentially avoided by 
using a one-pot synthesis strategy, which could be designed combining microscale 
instrumentation with modelling tools, in order to select the best enzyme candidates and 
identify the best reaction conditions, allowing to achieve higher yields of  the final 
product. As far as we know, no de novo engineered pathway has been designed, evaluated 
and completely modelled using high-throughput microscale tools which would be 
predictive of larger scale operations, increasing the challenge and impact of this work. 
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1.6.  Aim and Objectives of the Project 
 
To date most industrial bioconversion processes have focused on single-step enzymatic 
transformations primarily for the synthesis of pharmaceuticals and chiral intermediates. 
As described in Section 1.2.1.2, however, the de novo construction of multi-step 
enzymatic synthesis in whole cell biocatalysts provides a number of advantages. These 
include atom-efficient bioconversions in a single vessel potentially increasing space-time 
yields and reducing the production costs of complex syntheses for a wider range of 
products. Nevertheless, multi-step enzymatic systems have been relatively poorly 
explored (Section 1.2.1.3). In contrast to single enzyme systems they display higher 
levels of complexity, making them more difficult to construct and time consuming to 
characterize and model.  
Microscale bioprocessing techniques, as described in Section 1.3, offer the potential to 
speed up the early characterization and optimization of biocatlaytic processes and the 
design and scale-up of bioprocess unit operations. The linkage of microscale 
experimentation with numerical approaches (Micheletti et al., 2006, Chen et al., 2008) 
further enables modelling and simulation of different biocatalyst and process options.  
 
The aim of this project is therefore to design and characterize whole cell E. coli 
biocatalysts containing de novo engineered, multi-step enzymatic pathways for the 
synthesis of chiral amino alcohols. In particular a generic “toolbox” approach will be 
highlighted in order to simulate and optimize multi-step enzymatic syntheses using high-
throughput microscale methods that are predictive of larger scale operating conditions. 
The enzymes transketolase (Section 1.5.2) and transaminase (Section 1.5.3), which do not 
naturally work in series, were selected in order to exemplify options for the one-pot 
synthesis of chiral amino-alcohols (Section 1.5.4) which are of special interest for the 
pharmaceutical industry (Section 1.5.1). In order to achieve this aim the primary 
objectives of the project are summarized below. 
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• The initial objective was to establish a microscale “toolbox” for the rapid evaluation of 
different variants of TK and TAm for the one-pot synthesis of a range of amino-alcohols. 
This required the construction of de novo engineered pathways that were based on a 
double transformed E. coli expression system, which combined with the microscale high-
throughput experimentation, enabled systematic evaluation of different pairs of enzymes 
with different substrates under a range of reaction conditions. The results of this work are 
presented and discussed in Chapter 3. 
 
• The next objective was to be able to model and simulate the bioconversion reactions. 
In particular the TAm step was identified as the bottleneck of the multi-step synthesis 
(Chapter 3) and so this work focused on a methodology to elucidate and determine the 
TAm kinetic parameters. The kinetic parameters for the TAm mediated synthesis of ABT 
and APD were thus determined based on a novel numerical approach and microscale 
experimentation. As shown in Chapter 4 this enabled simulation of the TAm 
bioconversion under a broad range of substrates concentrations facilitating selection of 
the best reaction conditions. The results of this work are presented and discussed in 
Chapter 4. 
 
 
• The next objective was to scale-up the production of the biocatalyst, while obtaining a 
desired TK-TAm expression that would match the kinetic properties determined in 
Chapter 4. Here different fermentation conditions to manipulate the TK and TAm 
expression levels within the E. coli biocatalyst were studied. The best conditions were 
then used to scale-up the fermentation from shake flasks to a 7.5 litre fermentor, and the 
kinetic properties of the larger and small scale biocatalyst were compared. The results of 
this work are presented and discussed in Chapter 5. 
 
 
• The last objective was to illustrate successful scale-up and predictive modelling of 
selected one-pot syntheses. The scale-up and modelling of the complete one-pot TK-
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TAm synthesis of APD and ABT were successfully performed from µl to preparative 
scale, demonstrating the capacity of the microscale tools to speed up the development of 
multi-step synthetic processes. Finally, the best reactor configurations were determined 
and applied to optimize the de novo one-pot synthesis of chiral amino alcohols. The 
results of this work are presented and discussed in Chapter 6. 
 
• Finally, in Chapter 7, the generic outcomes of this work are highlighted and 
suggestions for future work are presented. 
 
2. MATERIALS AND METHODS 
 
 
2.1. MATERIALS 
 
2.1.1. Reagents and suppliers 
 
Molecular biology enzymes were obtained from New England Bio-laboratories (NEB, 
Hitchin, UK). Nutrient broth and nutrient agar were obtained from Fisher Scientific 
(Leicestershire, UK). Competent E. coli BL21-Gold (DE3) cells were obtained from 
Stratagene (Amsterdam, NL). Primers and oligonucleotides were purchased from Operon 
(Cologne, DE). All other reagents were obtained from Sigma-Aldrich (Gillingham, UK) 
unless noted otherwise and were of the highest purity available. Reverse osmosis (RO) 
water was used in all experimental work. 
 
2.1.2. Media preparation 
 
All batch E. coli fermentations were performed using LB-glycerol medium the contents 
of which are described in Table 2.1.  
 
Table 2. 1. Composition of the LB-glycerol medium used in all batch E. coli fermentations. 
 
Component Concentration (g L-1) 
 
Yeast extract 
 
5.0 
Tryptone 10.0 
NaCl 10.0 
Glycerol 10.0 
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The different components of the media were measured out and dissolved in RO water to 1 
L. The pH of the media was adjusted to pH 7 with a solution of 1 M NaOH when 
necessary. The medium was then autoclaved at 121 oC for 20 min for sterilization.    
 
2.1.3. Luria Bertrani  agar plates 
 
LB-agar was prepared by adding 15 g L-1 of agar to LB-glycerol medium as described in 
Table 2.1. The LB-agar preparation was then autoclaved at 121oC for 20 min. Once 
cooled down to between 40-50 °C, 30 mL of media was poured into each standard size 
Petri dish (Fisher Scientific, UK). 
 
2.1.4. Antibiotic solutions 
 
The antibiotics ampicillin and kanamycin were dissolved individually in RO water to a 
concentration of 150 mg mL-1. The solutions were then sterilized by passing them slowly 
through a 0.2 µm filter (Fisher Scientific, UK) and aseptically transferred into previously 
sterilized 1.5 mL Eppendorf tubes and stored at -20 °C. The antibiotics were added to 
either LB-glycerol medium or to LB-agar before the start of any culture. Ampicillin was 
used when growing cells with plasmid pQR412 for TK expression (Section 2.3.1) at a 
concentration of 150 µg mL-1 and kanamycin was used for growing cells with plasmid 
pQR801 for TAm expression (Section 2.3.3) at a concentration of 150 µg mL-1. For 
double transformed cells containing both plasmids pQR412 and pQR801, a concentration 
of 50 µg mL-1 of each antibiotic was used (Section 2.4.2).  
 
 
2.2. MOLECULAR BIOLOGY TECHNIQUES 
 
2.2.1. DNA extraction and quantification 
 
A QIAprep spin miniprep kit (Qiagen, Crawley, UK) was used to obtain plasmid DNA 
from host E. coli cells, and the method was carried out following the techniques 
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described by the supplier.  The concentration of DNA was determined by measuring 
absorbance at 260nm (A260) using a NanoDrop™ 1000 UV/vis spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA). DNA concentrations were calculated 
internally by the spectrophotometer by considering that 1.0 A260 unit of double-stranded 
DNA was equivalent to 50 ng µL-1. Protein contamination was estimated from the 
A260/A280 ratio. Readings were blanked with the same buffer solution used for DNA 
elution.  
 
2.2.2. Restriction digests and agarose gels 
 
Analytical restriction digests were performed for four hours at 37oC in the recommended 
restriction buffer, according to the enzyme used and following the manufacturer’s 
protocol. To analyze the different DNA fragments, agarose DNA gels were run on 1% 
w/v agarose gels with 1X TBE buffer. Molecular weight markers were lambda DNA 
cleaved with pst1 or a 1 KB ladder (NEB, Hitchin, UK) while staining was performed 
with ethidium bromide.   
 
2.2.3. Preparation of competent cells 
 
Competent cells were prepared in house from E. coli BL21-Gold (DE3) (Stratagene 
(Amsterdam, NL) cells cultured in 250 mL shake flasks containing 20 mL of LB-glycerol 
medium and 20 mM MgCl2 at 37oC, 250 rpm to an optical density of 0.5 (Section 2.9.2). 
Cells were harvested by centrifugation and chilled on ice for 30 minutes. Resuspension 
was carried out in 75 mM CaCl2 and the cells were re-pelleted by centrifugation.  This 
was carried out three times.  Following the final centrifugation cells were suspended in 75 
mM CaCl2 with 15 % v/v glycerol.  Cells were then aliquoted and either placed on ice for 
immediate transformation or stored at -80oC.   
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2.2.4. Transformation of cells by heat shock technique  
 
E. coli BL21-Gold (DE3) cells were used to carry out heat-shock transformations. 
Competent cells were either prepared in house (Section 2.2.3) or purchased 
commercially. Cells were first thawed on ice and 50 µL aliquots transferred into 15 mL 
pre-chilled Falcon tubes. A sample of 1.5 µL of a single plasmid or a mixture of two 
plasmids with a total concentration of 50 ng µL-1 of DNA was added to cells in each tube 
which were then mixed gently and incubated on ice for 30 minutes. The cells were then 
heat shocked in a 42 oC water bath (Grant Instruments, Cambridge, UK) for 30 seconds 
and immediately placed on ice for 5 minutes. A volume of 0.9 mL of preheated (37 oC) 
LB-glycerol media was added to each Falcon tube and the cells were incubated at 37 oC 
for 1 h with shaking at 220 rpm in a SI 50 orbital shaker (Stuart Scientific, Redhill, UK). 
Finally 100 µL of transformed cells were uniformly spread on LB-agar plates with the 
corresponding antibiotic resistance (Section 2.1.4.) and left to incubate at 37oC overnight.  
 
2.2.5. Master glycerol stocks 
 
To prepare master stock cultures a single colony was picked from the plates containing 
the desired transformed cells expressing either single enzymes or pairs of enzymes 
(Section 2.2.4). This was then inoculated into a sterile 250 mL shake flask containing 25 
mL of LB-glycerol medium with the corresponding antibiotic(s). When the culture 
reached an OD of 0.5 at 600 nm (Section 2.9.2), 400 µL aliquots of cell broth were mixed 
aseptically in sterilized 1.5 mL Eppendorf tubes with 200 µL of a 50% v/v filter sterilized 
glycerol solution. The aliquots were then frozen and stored at -80 oC and were used 
throughout the rest of this project.  
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2.3. PLASMIDS  
 
2.3.1. Transketolase plasmid pQR412 
 
Plasmid pQR412 (11.2kb) contained the complete E. coli TK gene, tktA, with its native 
promoter and an N-terminal His6-tag as constructed previously (Ingram et al., 2007). The 
plasmid was provided by Professor John Ward (Institute of Structural and Molecular 
Biology, UCL) and it was assembled using the expression vector pMMB67HE (8.8kb), 
which has a RSF1010 origin of replication, the tac promoter, the Lac repressor and codes 
for resistance to ampicillin (Figure 2.1). Even if the plasmid contained the inducible tac 
promoter, the expression of the E. coli tktA was constitutive because of the presence of its 
native promoter (Ingram et al., 2007).  
 
 
Figure 2.1. Structure of the plasmid pQR412.  Image obtained from Ingram et al. (2007). 
  
2.3.2. Site directed mutagenesis of TK 
 
Site direct mutagenesis on the TK gene was performed using the Quikchange kit 
(Stratagene, Amsterdan, NL) following the supplier’s instructions.  The primers used for 
the TK mutagenesis were the following: 
1
1126
2251
3376
4501
5626
6751
7876
9001
10126
pQR411
11256 bp
tkt1
BamHI 35
SacI 2481
Ori V
AmpR
HindIII 808
HindIII 1138
PstI 1237
EcoRI 1311
XbaI 29
PstI 21
HindIII 5
NdeI 5523
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D469T:  TCGGTCTGGGCGAAACTGGGCCGACTCACCAG 
D469E:  TCGGTCTGGGCGAACAAGGGCCGACTCACCAG 
 
The resulting plasmid was transformed into commercially competent E. coli BL21-Gold 
(DE3) cells as described in Section 2.2.4. 
 
2.3.3. Transaminase plasmid pQR801 
 
Plasmid pQR801 contained the complete Chromobacterium violaceum 2025 TAm gene 
with an N-Terminal His6-tag (GenBank accession no. NP_901695) and was synthesized 
in a previous work (Kaulmann et al., 2007). The plasmid was provided by Professor John 
Ward (Institute of Structural and Molecular Biology, UCL) and was constructed using the 
expression vector pET29(a)+ (5.3kb), which contained an inducible T7 promoter, the Lac 
repressor and codes for resistance to kanamycin. 
 
2.3.4. Plasmids sequencing 
 
DNA sequencing was performed by the sequencing service of the UCL Wolfson Institute 
for Biomedical Research. 12 µL of DNA sample were given to the service at a 
concentration of 100 ng µL-1 in 1.5 mL Eppendorf tubes. Three main custom primers 
were used to sequence the E. coli TK gene which were the following:  
 
TKN 5’-GATCCAGAGATTTCTGA-3’; 
TKmedSeq 5’-GTATGAAAGGCGAAAT GCCG TCTGACT-3’ 
TKC 3’-CAAAAGAACTGCTGTAA-5’.  
 
Two main primers were used to sequence the CV2025 TAm gene which where the 
following: 
 
T7: 5' - GTA ATA CGA CTC ACT ATA GGG C - 3' 
T7term: 5' - GCT AGT TAT TGC TCA GCG G - 3' 
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Primers were prepared at a concentration of 5 pmoles L-1. Results were analyzed using 
Bioedit software available on the internet (www.mbio.ncsu.edu/BioEdit/bioedit.html). 
 
2.4. SHAKE FLASK FERMENTATIONS  
 
2.4.1. TK shake flask fermentations 
 
Competent E. coli BL21-Gold (DE3) cells were transformed with the plasmid pQR412 
using the heat shock technique (Section 2.2.4) and were then grown in LB-agar plates in 
the presence of ampicillin (150 ug mL-1). Using a single colony from the agar plates, an 
overnight culture of the transformed cells was then inoculated in a 100 mL shake flask 
(10 mL working volume) containing LB-glycerol broth as described in Table 2.1 again 
with the addition of ampicillin. Growth was performed at 37 oC with orbital shaking at 
250 rpm using an SI 50 orbital shaker during 8 hr (Stuart Scientific, Redhill, UK). The 
total volume of this culture was used to inoculate a 1 litre shake flask (100 mL working 
volume) which was left to grow for 8 hours. The cells were harvested and following the 
removal of broth using a Universal 320R centrifuge (Buckinghamshire, UK) for 10 min 
at 5000 rpm, they were resuspended in 50 mM TRIS buffer, pH 7.5 unless otherwise 
noted. The cells were either used immediately for whole cell bioconversions (Section 
2.8.1) otherwise they were stored at -20 oC following the removal of broth by 
centrifugation.  
 
2.4.2. TAm and TK-TAm shake flask fermentations 
 
The double transformation of E. coli BL21-Gold (DE3) cells with the plasmid pQR801 
and pQR412 or the single transformation of the cells with plasmid PQR801 and the 
inoculum preparation were performed as described in Section 2.4.1, except that 150 µg 
mL-1 of kanamycin were used for the single transformed cells and 50 µg mL-1 of both 
kanamycin and ampicillin were used for the double transformed strain. To construct the 
double transformed biocatalyst, 50 µL of competent E. coli BL21-Gold (DE3) cells were 
double transformed with a 1.5 µL solution of plasmids pQR412 and pQR801 (50 µg mL-1 
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total plasmid concentration) using the heat shock technique described in Section 2.2.4. 
After inoculation of a 1 litre shake flask (100 mL working volume), when the OD600 
reached a value of 0.8-1.0, Isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to 
final concentration of 0.2 mM. After 4 hr induction, the cells were harvested and 
following the removal of broth by centrifugation, they were suspended in 50 mM HEPES 
buffer, pH 7.5 unless noted otherwise and used for whole cell bioconversions, otherwise 
they were stored at        -20 oC following the removal of broth by centrifugation.   
 
2.5. LABORATORY AND PILOT SCALE FERMENTATIONS 
 
2.5.1. 2 L Adaptive Biosystems batch fermentation 
 
A 2 L fermentor (Adaptive Biosystems, London, England), was used to grow E. coli 
BL21(DE3) Gold double transformed cells with plasmids pQR412 and pQR801 and also 
single transformed cells with plasmid pQR801 (1.4L working volume). The vessel was 
equipped with two 6 bladed Rushton turbine impellers and four baffles equally spaced. It 
also comprised a thermocouple, a pH probe, and a polarographic oxygen probe (Ingold 
Messtechnik, Urdorf, Switzerland). All probes were steam sterilisable.  
 
The vessel was filled with 1.26 L of LB-glycerol media and all the probe calibrations and 
pre-sterilization procedures were performed following the manufacturer’s instructions. 
The fermentor was sterilized as a complete unit in an autoclave at 121oC for 20 min and 
after the media was cooled down the corresponding antibiotic (Section 2.1.4) and pre-
sterilized antifoam, polyethylene glycol (PPG) to a final concentration of 0.2 g L-1, was 
added.  
 
The fermentor was then inoculated with 140 mL of previously grown overnight shake 
flasks cultures as described in Section 2.4.2. The pH was set at 7.0 and was controlled 
with the addition of 85% v/v H3PO4 (acid) and 28% NH4OH v/v (base). The oxygen and 
carbon dioxide content in the exhaust air were measured on-line by a TanDem gas 
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analyzer (Adaptive Biosystems, London, England). Temperature was automatically 
controlled via cold water circulation in the external jacket of the bioreactor and 
maintained at 30 or 37°C using a heating jacket. The stirrer was set at a speed of 1200 
rpm with an aeration rate of 2 L min-1. Ingoing air was sterilized by passage through a 0.2 
μm membrane filter and dispersed in the vessel at the base of the lower turbine with a 
ring sparger. The fermentor was linked to Biodirector proprietary control software to 
control and monitor online the temperature, DOT, speed impeller and pH. Additionally, 
the fermentation was monitored by taking regular OD600 measurements as described in 
Section 2.9.2.  
 
2.5.2. 7.5 L New Brunswick batch fermentation 
 
Batch fermentations were carried out in a 7.5 L fermentor (BioFlo 110, New Brunswick, 
Hertfordshire, UK) with a working volume of 5 L. The fermentor had an aspect ratio of 
1.79:1 and comprised two six-bladed dual Rushton-type impellers (59 mm, di/dt = 0.25) 
and four equally spaced baffles. The Temperature was monitored by a thermocouple and 
automatically controlled at 30 or 37oC via cold water circulation in the external jacket of 
the fermentor in addition to a heating jacket. The pH was measured by a Ingold gel filled 
pH probe (Ingold Messtechnik, Urdorf, Switzerland) and was controlled with the addition 
of 85% v/v H3PO4 (acid) and 28% NH4OH v/v (base). DOT was monitored by a 
polarographic oxygen electrode (Ingold Messtechnik, Urdorf, Switzerland) and was set to 
be maintained at 30% through a cascade control of the impeller speed. Ingoing air was 
sterilized by passage through a membrane filter and dispersed in the vessel at the base of 
the lower turbine with a ring sparger and the flow rate was 5 L min-1.  
 
The vessel was filled with 4.5 L of LB-glycerol media and all the probe calibrations and 
pre-sterilization procedures were performed following the manufacturer instructions. The 
fermentor was then sterilized as a complete unit in an autoclave at 121oC for 20 min, and 
after the media was cool down, the corresponding antibiotic (Section 2.1.4) and sterilized 
antifoam PPG was added to a final concentration of 0.2 g L-1.  
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The fermentor was then inoculated aseptically with five 100 mL shake flasks cultures 
previously grown overnight as described in Section 2.4.2. The progress of the 
fermentation was monitored as in Section 2.5.1. Data was logged by on-line 
measurements of DOT, pH, temperature and speed of the impeller using the 
BioCommand software (BioFlo 110, New Brunswick, Hertfordshire, UK) as well as by 
taking regular OD600 measurements as described in Section 2.9.2.  
 
2.5.3. Fed-batch fermentations 
 
Both the 2 L and 7.5 L fermentors described above were also used to perform fed-batch 
fermentations. This was performed in order to minimize the accumulation of toxic by-
products of an exponentially growing culture by maintaining a limited growth carbon 
source, in order to achieve higher biomass and protein expression yields (Shiloach & Fass 
2005). This protocol described in this work follows a simple glycerol-supplementation 
method where cells were first grown in batch mode as described in Section 2.5.1 and 
2.5.2, in a medium containing 10 g L-1 glycerol. After the initial glycerol was consumed, 
which was detected by a sharp rise in the DOT, indicative of reduced oxygen 
consumption and thus of glycerol becoming limiting, the culture was supplemented using 
a Watson Marlow 501U pump (Cornwall, UK) with an increasing feed rate of pre-
sterilized medium containing 10 g L-1 of NaCL, 10 g L-1 of yeast extract, 20 g L-1 of 
tryptone and 500 g L-1 of glycerol. The feeding rate was calculated according to Equation 
2.1 (Bernard & Payton 2001) and was modified every hour:  
 
 
 
 
where F is the feed rate (L hr-1), µ is the specific target growth rate (hr-1), V is the 
fermentor volume (L), x is the cell biomass (gDCW L-1), Y is the yield of cell mass per unit 
of carbon source of glycerol (g g-1 ), and [Gly] is the concentration of glycerol in the feed 
solution (g L-1). A value of 80% of the maximum growth rate obtained in the batch 
cultures (Sections 2.5.1 and 2.5.2) was used for µ and n standard estimate for Y of 0.3 g g 
L-1 was applied to calculate the feed rate using Equation 2.1 (Bernard & Payton 2001) .  
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2.6. BIOCATALYST PREPARATION 
 
2.6.1. Whole cell and lysate forms  
 
Fresh cells where always used for whole cell bioconversions and were obtained as 
described in Section 2.4.1 and Section 2.4.2. When a cell-free lysate was needed, the cells 
were sonicated with a Soniprep 150 sonicator (MSE, Sanyo, Japan) using 10 seconds 
on/off at 10 µm amplitude for 10 cycles. Cells were placed on ice to stop overheating 
during the sonication. The sonicated lysate was then centrifuged at 5000 rpm in Falcon 
tubes for 5 min to remove cell debris, and the clarified supernatant was finally aliquoted 
into 1.5 mL Eppendorf vials to be stored at -20 oC and used within 1 month. Prior to the 
initiation of a bioconversion, the frozen lysates (300µL) were thawed in a water bath at 
30oC for typically 10 min and then immediately incubated with cofactors. 
 
2.6.2. Purified enzymes (His6-tag purification) 
 
The E. coli TK and CV2025 TAm expressed from plasmids pQR412 and pQR801 
respectively both have an N-terminal His6-tag (Section 2.3.1 and 2.3.3) to facilitate rapid 
single-step purification using a His Bind Quick 900 cartridge (EMD Biosciences, 
Darmstadt, Germany). The cartridges were purchased packed with a pre-charged 
cellulose matrix with tethered Ni2+ complex immobilised on Nα,Nα-Bis [carboxymethyl]-
L-lysine (NTA). The composition of all buffers used for the enzyme purification 
procedure is shown in Table 2.2, the pH of all buffers was 7 for TK and 7.5 for TAm. 
After equilibration of the cartridge with 10 mL binding buffer, the purification was 
performed loading the lysate solution prepared as described in Section 2.6.1, following 
the loading of the sample, the cartridge was washed with 20 mL wash and 10 mL binding 
buffer. Elution was carried out with either strip or elution buffer depending whether or 
not the beads needed to be regenerated.  
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Table 2.2. His6-tag enzyme purification buffers used in Section 2.6.2. 
 
Buffer 
 
Components 
 
 
Binding 
 
 500 mM NaCl, 20 mM Tris-HCl, 5 mM imidazole 
 
Wash 
 
 50 mM Tris-HCl 
 
Strip 
 
 50 mM EDTA, 50 mM Tris-HCl 
 
Elution 
 
 
1 M imidazole, 500 mM NaCl and 20 mM Tris-HCl 
 
 
 
 
Following the elution, in order to remove free EDTA and EDTA-nickel complexes from 
the elution buffer, the enzyme solution was dialyzed against 500 mL of 50 mM TRIS 
buffer at pH 7.0 or 50 mM HEPES pH 7.5 for TK and TAm solutions respectively. The 
buffer exchange was performed using a flat packed semi-permeable membrane with a 
molecular weight cut-off of 14,000 Da (BioDesign, Carmel, NY, USA). The membrane 
was left overnight at 4oC with gentle magnetic stirring. The purity of the dialyzed 
enzymes was determined by SDS-PAGE as described in Section 2.9.5. The dialyzed 
enzyme solution was stored in the fridge at 4°C for a period of up to 2 weeks before use.  
 
2.7. SYNTHESIS OF SUBSTRATES AND PRODUCTS 
 
2.7.1. Chemical synthesis of hydroxypyruvate 
 
Hydroxypyruvate (HPA) was synthesized by reacting bromopyruvic acid with LiOH 
following a previously described method (Morris et al., 1996). The details of the 
synthesis were as follows: bromopyruvic acid (0.06 mol) was dissolved in 100 mL water 
followed by careful addition of aq. LiOH (1M) until a stable pH of 9 was reached. At no 
time during the addition was the pH allowed to exceed 9. The reaction mixture was then 
adjusted to pH 5.0 by addition of glacial acetic acid and concentrated under vacuum to 
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approximately 20 mL. Following refrigeration at -20oC overnight, the crude product was 
washed with ethanol and then suspended in 50 mL ethanol at 25oC for 30 min. After 
filtration the solid product was dried under vacuum to give a white or slightly yellowish 
powder (expected yield is 2-4 g per batch) which was stored at -20oC. 
 
2.7.2. Enzymatic synthesis of PKD 
 
PKD was synthesized in a 100 mL scale bioconversion with 300 mM HPA, 350 mM 
propionaldehyde (PA), 9 mM MgCl2, 2.4 mM thiamine pyrophosphate (TPP), pH 7.0 and 
30% v/v of D469E TK lysate (final TK concentration of 0.3 mg mL-1). The reaction was 
stirred for 10 hours at room temperature in a sealed flask and the pH was maintained at 
7.0 using a 718 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland). The 
solution was dried on silica and purified by column chromatography (ethyl acetate: 
hexane, 1:1) to yield PKD as a colourless oil that crystallized on standing. The PKD ee 
was determined as described in Section 2.9.6. 
 
2.7.3. Chemical synthesis of ABT product standard 
 
The chemical synthesis of ABT was performed as described by Ingram et al. (2007). 
Briefly L-erythrulose (4 g, 33 mmol), was suspended in acetone:dimethoxypropane 9:1 
v/v  (30 mL) and p-toluenesulfonic acid (catalyst) was added.  The mixture was stirred at 
room temperature under N2 for 3 h during which time the reaction mixture became 
homogeneous. The reaction was monitored by TLC using a 2:1 v/v, ethyl acetate:hexane 
running solvent.  
 
Sodium acetate (0.5 g) was added and the reaction stirred for a further hour before the 
mixture was filtered and concentrated to dryness. The residue was purified by flash 
chromatography on silica gel (ethyl acetate/hexane 1:2 v/v) to yield the desired 3,4-O-
isopropylidene acetal. 
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To an aliquot of the produced acetal (487 mg, 3.02 mmol) in methanol (10 mL) was 
added benzylamine (660 µL, 6.04 mmol) and then sodium cyanoborohydride (570 mg, 
9.06 mmol).  The pH was adjusted to pH 6.0 using acetic acid and the reaction was stirred 
at room temperature for 6 hours. The reaction was monitored by TLC (1:1, ethyl 
acetate:hexane).  The mixture was concentrated under vacuum and the residue partitioned 
between dichloromethane (100 mL) and sodium hydrogen carbonate (aq, sat) (100 mL) 
with vigorous stirring.  
 
Solid sodium carbonate was added to the suspension in small portions to ensure that the 
final pH of the aqueous layer was 9. The layers were then separated, the aqueous phase 
was extracted with further dichloromethane (two times 100 mL) and the organic phases 
combined and concentrated to dryness. The residue was purified by flash chromatography 
on silica gel (ethyl acetate/hexane 1:1 v/v then neat ethyl acetate) to yield the desired 
amine as a 1:1 mixture of diastereomers.  
 
To a solution of the previously produced amine (200 mg, 0.80 mmol) in MeOH (5 mL) 
was added drop wise 1 M HCl (aq) to give a mixture that gave a dark red colour to moist 
litmus paper. The reaction was stirred at room temperature and was monitored by TLC 
(1:1 v/v, ethyl acetate:hexane). After 2 h the reaction was complete and the mixture 
concentrated to dryness to yield the crude amine as the hydrochloride salt. This residue 
was re-dissolved in MeOH (5 mL) and hydrogenated (balloon pressure) in the presence of 
palladium on carbon (10% wt/wt, 100 mg) at room temperature overnight.  The catalyst 
was removed by filtration and the solvent removed under vacuum to yield 2-amino-1,3,4-
butanetriol as a 1:1 mixture of threo and erythro diastereomers.  
 
2.7.4. Enzymatic synthesis of ABT and APD 
 
The enzymatic synthesis of APD was performed in a 100 mL scale bioconversion with 
200 mM PKD, 0.2 mM PLP and 30% v/v of CV2025 TAm lysate (final enzyme 
concentration of 0.3 mg mL-1). To this mixture, a solution of 300 mM IPA (pH 7.5) was 
added in a fed batch mode using a P-1 peristaltic pump (Pharmacia Fine Chemicals, 
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Uppsala, Sweden) with a volume rate of 2.1 mL hr-1 for 48 hr until the total volume of the 
reaction was approximately 200 mL.  The temperature of the TAm catalyzed reaction was 
maintained at 30oC using a circulating water bath (Grant Instruments, Cambridge, UK), 
and the pH was kept at 7.5 by the automatic addition of 1 M NaOH using a 718 STAT 
Titrino pH controller (Metrohm Ion Analysis, Switzerland).  
 
After the bioconversion, the enzyme was spun down (5000 rpm, at 4 °C for 15 min) and 
the mixture was additionally filtered through a 0.2 μm sterile filter. 50 g of Amberlite 
IRA-410 resin (Sigma-Aldrich, Gillingham, UK) were added to the reaction mixture for 1 
hr, and the resin was then removed by filtration. The remaining aqueous mixture was then 
passed through 80 g of an Isolute SCX-2 ion exchange column (Biotage, Uppsala, 
Sweden), and the column was washed with 400 mL of methanol.  The column was then 
eluted with 500 mL 4 M NH3 and the eluent was evaporated to yield the desired product. 
The enzymatic synthesis of ABT was performed the same way as the one for APD, 
expect that ERY was used instead of PKD as initial substrate. 
 
2.7.5. Synthesis of derivatizing reagent 
 
The derivatizing agent 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (AQC) was 
synthesized ‘in house’ according to a previously published protocol (Cohen & Michaud, 
1993). Di(N-succinimidyl)carbamate (3 g, 6 mmol), was refluxed in 25 mL of dry 
acetonitrile. Dropwise addition of a 6-aminoquinoline (1.5 g, 5 mmol) solution in dry 
acetonitrile was carried out over 45 minutes. Following a further 30 minutes reflux, 
concentration was carried out to half the original volume. The solution was stored at –
20oC overnight. The crystals were then filtered off and stored in vacuo.  
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2.8. BIOCONVERSION KINETICS 
 
2.8.1. Microscale experimental platform 
 
All microscale bioconversions were performed in a glass 96-well, flat-bottomed 
microtiter plate with individual wells having a diameter of 7.6 mm and height of 12 mm 
unless noted otherwise (Radleys Discovery Technologies, Essex, UK). The microplate 
was covered with a thermo plastic elastomer cap designed to work with automated 
equipment (Micronic, Lelystad, Netherlands). 
 
All the bioconversions were performed using 300 µL total volume at 30 oC unless noted 
otherwise, and orbital shaking was provided at 300 rpm with a Thermomixer Comfort 
shaker (shaking diameter of 6 mm, Eppendorf, Cambridge, UK). TK single step reactions 
were performed in 50 mM TRIS buffer and the concentration of cofactors MgCl2 and 
thiamine pyrophosphate (TTP) were 9 mM and 2.4 mM respectively for all reactions.  
 
TAm single step reactions and all the two step syntheses were carried out in 50 mM 
HEPES buffer pH 7.5 unless noted otherwise and the concentration of TAm cofactor 
pyridoxal-5-phosphate (PLP) was 0.2 mM in all cases. The whole cell suspension or 
lysate with the cofactor solutions were always added first in the corresponding well and 
left to incubate for 20 min at 30 oC, prior to initiation of the reaction by addition of the 
substrate solutions.  
 
Preliminary experiments showed that the initial cofactor incubation helped to ensure all 
expressed TK or TAm was in the active holo-form. This practice also enabled more 
consistent measurement of specific activity results, by avoiding initial non linear reaction 
kinetics believed to be caused in some cases by the binding of the enzyme and cofactors.  
 
Aliquots of 20 μL were taken at various time intervals and quenched with 180 or 380 μL 
of a 0.1% v/v trifluoroacetic acid (TFA) solution for TK and TAm experiments 
respectively. They were then centrifuged for 5 min at 5000 rpm and transferred into an 
Chapter 2: Materials and Methods 
 
 
     89  
  
HPLC vial for further analysis. The specific activities were determined as the amount of 
PKD, ERY, AP, APD and ABT formed per unit of time normalized by the amount of 
enzyme used in the reaction. The specific activity was based on the measured mass of 
TAm or TK present in each bioconversion. For whole cell experiments, it was calculated 
based on 50% of the dry cell weight of the cells being protein (Watson, 1972), combined 
with the measured result of the percentage of TK and TAm by SDS-PAGE analysis 
described in Section 2.95. 
 
2.8.2. Preparative scale bioconversions 
 
Bioconversions at preparative scale (volumes from 30 to 120 mL) were performed in a 
150 mL titration vessel with thermostat jacket (Metrohm Ion Analysis, Switzerland). 
Temperature was maintained at 30oC using a circulating water bath (Grant Instruments, 
Cambridge, UK), mixing was achieved using a magnetic stirrer at 300 rpm, and the pH 
was maintained at pH 7.5 unless noted otherwise by the use of an automated addition of 1 
M NaOH using a 718 STAT Titrino pH controller (Metrohm Ion Analysis, Switzerland). 
For preparative scale fed batch reactions, a peristaltic P-1 pump (Pharmacia Fine 
Chemicals, Uppsala, Sweden) was used to add the desired substrate solution over time. 
Sampling procedures were performed in the same way as in Section 2.8.1.  
 
2.9. ANALYTICAL METHODS 
 
2.9.1. Dry cell weight (DCW) measurement 
 
1.5 mL aliquots of cell suspension were added to pre-dried and pre-weighed 2.2 mL 
Eppendorf tubes which were then centrifuged at 13,000 rpm for 5 minutes (Eppendorf 
AG, Germany).  The supernatant was discarded and the vials were left to dry at 90oC for 
24 hours. The biomass concentration in gDCW L-1 of the culture could then be calculated.  
 
2.9.2. Optical density measurements for biomass quantification 
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Optical density measurements were performed at a wavelength of 600 nm (OD600) using 
an Ultraspec 4000 variable wavelength spectrophotometer (Pharmacia Biotech, USA). A 
small aliquot of E. coli BL21 culture medium was taken from the shake flask cultures of 
the bioreactors and diluted with RO water so that the optical density measurement was 
between 0.1-0.8 absorbance units. A calibration curve relating the OD600 measurement 
from a serial dilution of broth sample to the corresponding gDCW L-1 measurement was 
constructed and is shown in Appendix I. The calibration relationship determined was that 
1 unit of (OD600) was equal to 0.4 gDCW L-1. This relationship was unaltered for cells 
transformed with TK, TAm or the double transformed cells. 
 
2.9.3. Bradford assay for lysate total protein quantification 
 
Protein concentrations of the lysates were obtained using the Bradford assay method 
(Bradford, 1976) following the instructions of a commercial protein assay kit (Bio-Rad 
Laboratories Inc., Hemel Hempstead, UK). The protein concentration was calibrated 
against a bovine serum albumin standard curve which was generated for each assay 
(Appendix II).  Absorbance measurements at 595 nm were carried out on an ATI Unicam 
UV/VIS spectrophotometer (Spectronic, Leeds, United Kingdom).  
 
2.9.4. Purified enzyme quantification by UV absorbance. 
 
The quantification of pure enzyme concentration was performed by UV absorbance at 
280 nm using an ATI Unicam UV/VIS spectrophotometer (Spectronic, Leeds, United 
Kingdom). Readings were blanked with the appropriate buffer solution. Absorbance 
measurements were converted to protein concentration using the Beer-Lambert law: 
 
A = ελc                Equation 2.2 
 
where A was the absorbance at 280 nm, ε was the extinction coefficient previously 
determined as 93,905 M.cm-1 for TK  (Martinez-torres et al., 2007) and 78,000 M.cm-1 
for TAm  (Matosevic, 2009) , λ was the path length equal to 1 cm, and c  was the protein 
concentration in mol L-1.  
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2.9.5. SDS-PAGE electrophoresis 
 
SDS-PAGE for protein analysis was carried out on a Mini-Protean II system (Bio-Rad 
Laboratories Inc., Hemel Hempstead, UK) using 8% w/v Tris-Glycine comercial gels (1.5 
mm, 10 well, Invitrogen, Paisley, UK). Clarified lysate or pure enzyme solutions were 
mixed (1:1) with 2X protein sample buffer (Sigma-Aldrich, UK) and heated to 99o C in a 
PCR machine (Techne LTD, Cambridge, UK) for 10 min. Samples were subsequently 
loaded onto the gel using 20 µL per well. A range of 15 to 20 µg of total protein was 
applied per lane to avoid saturation of the bands. 
 
The gel was stained with 50 mL of Coomassie Blue staining solution containing 0.1% 
(w/v) Coomassie Blue R-250, 40% (v/v) methanol and 10% (v/v) acetic acid and it was 
microwaved for 1 minute. After washing the Coomassie Blue solution, the gel was de-
stained overnight with a solution 10% acetic acid and 40% v/v methanol. All gels were 
visualized and quantified (where appropriate) on a Gel–Doc–it bioimaging system with 
Labworks 4.5 software (Bioimaging systems, Cambridge). 
 
2.9.6. HPLC methods 
 
Separation and quantification of PKD, ERY and HPA was performed on a Dionex HPLC 
system (Camberley, UK) with a Bio-Rad Aminex HPX-87H reverse phase column (300 x 
7.8 mm, Bio-Rad Labs., Richmond, CA, USA), controlled by Chromeleon client 6.60 
software . The system comprised a GP50 gradient pump, a FAMOS autosampler, an 
LC30 chromatography column oven and an AD20 UV/Vis absorbance detector. The 
HPLC method used has been described previously (Chen et al., 2008).  
 
Separation and quantification of MBA, AP, APD and ABT was performed on an 
integrated Dionex ultimate 3000 HPLC system (Camberley, UK) with an ACE 5 C18 
reverse phase column (150mm×4.6 mm, 5 µm particle size; Advance Chromatography 
Technologies, Aberdeen, UK) controlled by Chromeleon client 6.60 software. The HPLC 
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method has been reported elsewhere (Kaulmann et al, 2007). To analyse ABT and APD, 
the samples were derivatized by addition of an excess of 6-aminoquinolyl-N-
hydroxysuccinimidyl carbamate. The derivatizing reagent was synthesized in house as 
described in Section 2.7.5, and the HPLC method used has been described previously 
(Ingram et al, 2007). 
 
The enantiomeric excess (ee) of the ketodiols was determined by derivatization via 
dibenzoylation for satisfactory peak resolution by chiral HPLC. This was performed on a 
Varian Prostar instrument equipped with a Chiracel AD chiral column (Daicel; Chiral 
Technologies Europe, France, 25 cm × 0.46 cm) and a mobile phase of n-hexane/2-
propanol solvent mixture (90:10 v/v) was used. The method has been described in more 
detail elsewhere (Cázares et al., 2010). The ee of ABT and APD was determined by first 
derivatizing the amino alcohol to the respective benzoate form. The assay was performed 
against the four diastereomer samples of the benzoate synthesized as described elsewhere 
(Smith et al., 2010) using chiral HPLC: Chiracel-OD column (Daicel); mobile phase, 
isopropanol/hexane (5:95); flow rate, 0.8 mL/min, detection, UV 210 nm.  
 
Figure 2.2 shows examples of HPLC profiles for the chiral separation and ee 
determination of (3S)-1,3-dihydroxypentan-2-one (S-PKD)  and (3R)-1,3-
dihydroxypentan-2-one (R-PKD), as well as the HPLC profiles for the detection and 
quantification (non chiral) of  APD , HPA, ERY, PKD, AP and MBA.  The standard 
graphs for all of the above methods can be found in Appendix III. 
 
2.9.7.  LC−ECI−MS analysis  
 
Liquid chromatography-electrospray ionisation-mass spectrometry (LC−ESI –MS) was 
performed on an Agilent 1100 Series System with a Finnigan LTQ mass spectrometer. 
Operating conditions of the ESI interface in positive ion mode: capillary temperature 
300◦C, capillary voltage 9V, spray voltage 4.5 kV, sheath gas 80, auxiliary gas 30, and 
sweep gas 0 arbitrary units. Results are shown in Appendix XII.  
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Figure 2.2. HPLC profiles from different reaction mixtures obtained as described in Section 2.8.1 
for (a) the chiral separation and ee determination of  (3S)-1,3-dihydroxypentan-2-one (S-PKD)  and 
(3R)-1,3-dihydroxypentan-2-one (R-PKD), and for the detection and quantification (non chiral) of (b) 
APD, (c) HPA and ERY, (d) HPA and PKD, (e) AP and (f) MBA. HPLC conditions and sample 
preparation as described in Section 2.9.6. 
 
 
 
† The results presented in this chapter have been published as: Rios-Solis L., M. Halim, A. Cázares, P. 
Morris, J. M. Ward, H. C. Hailes, P. A. Dalby, F. Baganz, and G. J. Lye. 2011. A toolbox approach for the 
rapid evaluation of multi-step enzymatic syntheses comprising a “mix and match” E. coli expression 
system with microscale experimentation. Biocat and Biotrans.  29:192-203. 
 
3. EVALUATION OF DE NOVO TK- 
TAM PATHWAYS IN A WHOLE 
CELL BIOCATALYST† 
 
 
3.1.  INTRODUCTION 
 
As described in Section 1.2.3.1, it is now possible to design de novo non-native pathways 
in heterologous hosts, to carry out specific non-natural bioconversions producing chiral 
compounds difficult to obtain by existing biosynthetic pathways or chemical synthesis 
(Burkart, 2003; Roessner and Scott, 2003; Prather and Martin, 2008; Dalby et al., 2009).  
 
The de novo design of synthetic pathways has recently been demonstrated for the 
sequential two-step reaction of carbon-carbon bond formation using a transketolase (TK) 
enzyme, followed by a transaminase (TAm) as described in Section 1.5.4 for the 
synthesis of ABT (Scheme 3.1) (Ingram et al., 2007). 
 
 
 
 
 
Scheme 3.1. Reaction scheme of the de-novo TK-TAm pathway for the synthesis of chiral amino 
alcohol (2S,3R)-2-amino-1,3,4-butanetriol (ABT), from achiral substrates glycolaldehyde (GA) and 
hydroxypyruvate (HPA). 
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However, in that work, low yields were achieved due to the low specific activity of the 
TAm from Pseudomonas aeruginosa. Recently, new libraries of engineered and 
recombinant TKs and TAms have been built (Hibbert et al., 2007, Kaulmann et al., 2007, 
Hibbert et al., 2008, Cázares et al., 2010). Those libraries have the potential to be applied 
to improve the performance of the de novo pathway, as well as expanding its synthetic 
potentials to chiral 2-amino-1,3-diol like APD (Scheme 3.2), which are an important 
class of pharmaceutical building blocks as described in Section 1.5.4.  
 
 
Scheme 3.2. Reaction scheme of the de-novo TK-TAm pathway for the synthesis of chiral amino 
alcohol (2S,3S)-2-aminopentane-1,3-diol (APD) from achiral substrates propionaldehyde (PA) and 
hydroxypyruvate (HPA). 
  
 
Nevertheless as described in Section 1.3.1, the design and assembly of synthetic 
pathways is a complex process, and a methodology is necessary to be able to cope with 
the expanded possibilities of synthesis that de novo pathways offer. In particular testing 
several pairs of enzymes, under different reaction conditions can be time consuming. 
Also the evaluation of kinetic data is necessary in order to determine the compatibility 
and the bottlenecks of the one-pot synthesis. Developing a microscale “toolbox” to be 
able to do this quickly and with minimal cost emerge as a powerful solution to optimize 
de novo pathways.  
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3.2.  AIM AND OBJETIVES  
 
The aim of this chapter is to establish a microscale “toolbox” for the rapid evaluation of 
different variants of TK and TAm for the one-pot synthesis of a range of amino-alcohols. 
The approach will involve the construction of de novo engineered pathways that are 
based on a double transformed E. coli expression system, which combined with the 
microscale high-throughput platform and the gathering of kinetic data, could enable 
systematic evaluation of different pairs of enzymes with different substrates under a 
range of reaction conditions. The key objectives of this chapter are thus:  
 
• Construction of various de novo engineered TK-TAm pathways based on a 
double transformed E. coli expression system and previously constructed TK and TAm 
libraries. 
 
• Evaluation of cell growth kinetics and protein expression profiles in shake flasks 
for cells containing different de novo TK-TAm pathways. 
 
• Determination of appropriate reaction conditions for various multi-step syntheses, 
evaluating the compromises to made from each enzyme-substrate combination. 
 
• Determination of the best TK candidate for the synthesis of PKD and ERY and 
the best TAm candidate for the synthesis of APD and ABT. 
 
• Demonstration of the microscale toolbox approach by achieving the one-pot 
syntheses of ABT and APD using the most appropriate forms of TK-TAm 
expressing biocatalysts. 
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3.3. RESUTLS 
 
3.3.1.  Biocatalyst production (TK-TAm) 
 
In order to separately regulate expression of the TK and TAm enzymes in E. coli, a dual 
plasmid system was selected to facilitate the “mix and match” approach first proposed by 
Hussain & Ward (2003). This was based on two plasmids with different origins of 
replication and antibiotic resistance genes that would enable the rapid evaluation of 
different variants of TK and TAm (Section 2.3.1 and 2.3.3).  
 
The verification that the double transformations were successful was performed by 
running DNA agarose and SDS PAGE gels as described in Section 2.2.2 and 2.9.5. To 
establish the metabolic burden of the two plasmids on the host cells, five different whole 
cell biocatalysts were initially generated and evaluated in shake flask fermentations. 
Growth kinetics were obtained with cultures of E. coli BL21-Gold (DE3) containing 
either no plasmid, the single TK or TAm gene expressing plasmids, or both the TK and 
TAm plasmids, in each case either induced or non induced. The results are shown in 
Figure 3.1. 
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Figure 3.1. Shake flask fermentation kinetics for E. coli BL21-Gold (DE3) grown in LB-glycerol 
medium at 37 oC with (▼) untransformed cells, and cells transformed with (Δ) pQR412 (TK), (●) 
pQR801 (CV2025 TAm), (ο) double transformed uninduced strain with pQR801 and pQR412, (□) 
double transformed strain induced with 0.2 mM IPTG after 6 hours of cell growth. Fermentations 
performed as described in Section 2.4. Error bars represent one standard deviation about the mean 
(n=3).  
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Single transformed strains with plasmid pQR412 (TK) or pQR801 (TAm) reached 
biomass concentrations of 2.1 and 1.8 gDCW l-1 respectively. These were 12.5% and 25% 
less than for the non transformed strain respectively. The double transformed and 
induced strain obtained a final biomass concentration of 1.2 gDCW l-1, representing nearly 
a 50% decrease compared with the non transformed strain. This decrease in growth, 
however, was compensated by the increase in enzyme synthesis which was expected due 
to the metabolic burden caused by the maintenance and expression of two plasmids. 
 
In terms of enzyme expression levels, TK and TAm (induced with IPTG) in the single 
transformed cells were found to represent 20% and 40% w/w of the total protein 
respectively. For the double transformed strain, the TK concentration diminished 
compared to the single TK plasmid strain, and after inducing at a biomass concentration 
of 1 gDCW l-1 for 4 hours, the final enzyme expression of TK and TAm represented 8% 
and 36% w/w of the total protein. No difference in growth or enzyme expression was 
found by using engineered TKs D469T and D469E in the double transformed catalyst. 
Figure 3.2 shows the SDS-PAGE gel from cell extracts expressing individually TK and 
TAm and also for the double transformed biocatalyst.  
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Figure 3.2. SDS-PAGE gels showing expression of TK and TAm in cellular extracts of E. coli 
BL21(DE3)-Gold cells.  Lane 1 is protein marker, lane 2 is cellular extracts with single plasmid 
pQR412 (TK), lane 3 is the cellular extracts with single plasmid pQR801, lane 4 and 5 are cellular 
extracts of  double transformed cells with plasmid pQR412 (TK) and pQR801 (TAm). Biocatalysts 
produced as described in Figure 3.1 and Section 2.4. Molecular weight of TK is 73 kDa (Section 
1.5.2.1) and molecular weight of TAm is 51 kDa (Section 1.5.3.1.) 
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Because of the significantly lower activity of the TAm compared to the TK (Chen et al., 
2006; Ingram et al., 2007), this method of induced expression of TK and TAm was 
considered acceptable and was used to prepare all the biocatalysts for the later two-step 
bioconversions performed in Section 3.7. 
 
3.3.2.  Considerations for one-pot  TK-TAm synthesis 
 
The use of multi-step enzymatic syntheses necessarily requires some compromises to be 
made regarding the optimum reaction conditions for each enzyme. This is particularly 
acute with isolated enzymes but can be alleviated, to some extent, by the use of whole 
cell biocatalysts. In order to rapidly collect the necessary data that will enable informed 
compromises to be made, all the following experiments have been performed using the 
microscale tools described in Section 2.8.1. This allowed an efficient and accelerated 
selection of the global reaction conditions that would be use in the one-pot syntheses 
(Section 3.7). 
 
Optimum conditions reported for the in vitro TK-catalyzed synthesis of ERY was pH 7.0 
using TRIS buffer at 25 oC (Hibbert et al., 2007; Ingram et al., 2007). Here, for PKD 
synthesis using whole cells with E. coli TK D469E, the optimum pH was found to be in 
the range pH 6.5-7 as shown in Figure 3.3. This value was similar to the optimum pH of 
7.0 reported the E. coli TK D469T for the synthesis of PKD (Chen et al., 2008). 
 
For the CV2025 TAm the optimum temperature reported for the synthesis of amino 
alcohols was 37oC (Kaulmann et al., 2007; Smith et al., 2010).  The optimum pH for the 
whole cell TAm synthesis of ABT was found in this work to be pH 7.5 (Figure 3.4). This 
pH was in agreement with the pH of 7.5 found using the CV2025 TAm for the synthesis 
of APD (Smith et al., 2010). 
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Figure 3.3. Effect of pH on the initial rate of PKD production by whole cells of E. coli expressing 
TK D469E. Reaction conditions: [PA] and [HPA] were 50 mM,  25oC; 300 rpm in 50 mM TRIS-HCL 
buffer ; total volume of 300 ul in 96 glass microplate. Bioconversions performed as described in 
Section 2.8.1. Error bars represent one standard deviation about the mean (n=3). 
 
 
 
 
 
 
 
 
 
Chapter 3: Evaluation of de novo pathways 
 
 
 
 
    103    
 
 
Figure 3.4. Initial rate of ABT production by whole cell TAm in function of pH. [MBA] and [ERY] 
were 50 mM,  37oC; 300 rpm in 50 mM HEPES buffer ; total volume of 300 ul in 96 glass microplate. 
Bioconversions performed as described in Section 2.8.1. Error bars represent one standard deviation 
about the mean (n=3). 
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Given the different optimum conditions for TK and TAm, a number of compromises on 
selected reaction conditions needed to be made. In order to evaluate these compromises, 
the synthesis of 10 mM ABT using MBA as amino donor was used as a reference 
reaction (Scheme 3.1). TK bioconversions in the presence of the working concentration 
of the TAm cofactor PLP demonstrated that this did not have any effect on the TK 
reaction. The same finding was obtained for the effect of TPP and Mg2+ on the TAm 
bioconversion (data not shown). Reactions of TK carried at a pH of 7.5 showed a 
decrease of TK activity of 33% as shown in Figure 3.3, nevertheless this pH was selected 
for subsequent studies considering the generally higher activity of TK compared to TAm 
(Figures 3.3 and 3.4). 
 
In terms of reaction temperature, a control reaction using a lysate of untransformed E. 
coli BL21-Gold (DE3) showed that at 37 oC up to 50% of the HPA substrate was 
consumed by non-specific side reactions after 2 hours (Figure 3.5). In contrast at    30 oC, 
less than 5% of HPA was consumed over the same time. 
Chapter 3: Evaluation of de novo pathways 
 
 
 
 
    105    
 
Figure 3.5. Non-specific consumption of reactatnts by TK E. coli cells at 37oC incubated only with 
(●) HPA, (▲) ERY, (■) PKD and (Δ) HPA at 30oC. Initial concentration of compound was 50 mM; 
total concentration of protein in the whole cell was 1 mg mL-1, 300 rpm;  300 μl total reaction volume 
in 96 covered polystyrene microwell; pH 7.0 in 50 mM TRIS buffer. Control experiments performed 
as described in Section 2.8.1. 
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Consequently the TK-TAm reactions were performed at 30 oC to avoid non-specific 
HPA metabolism. With regards to buffer selection, control experiments using TRIS and 
phosphate buffer inhibited the CV2025 TAm compared to HEPES buffer (Figure 3.6). 
 
It has been reported that HEPES buffer catalyzes biomimetic reactions between HPA and 
aldehydes at 37 oC (Smith et al., 2006), nevertheless at 30 oC, control experiments 
showed that less than 5% of HPA was lost by the biomimetic activity of 50 mM HEPES 
after two hours (data not shown). Based on all these considerations, the reaction 
conditions selected for the in vitro evaluation of the different TK-TAm variants were 30 
oC and pH 7.5 in 50 mM HEPES buffer. 
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Figure 3.6. Effect of buffer composition on initial rate of ABT production by TAm in whole cell 
form. [MBA] and [ERY] were 50 mM, TAm was 0.3 mg mL-1,  37oC; 300 rpm in 50 mM of each 
buffer ; total volume of 300 ul in 96 glass microplate. Bioconversions performed as described in 
Section 2.8.1. Error bars represent one standard deviation about the mean (n=3). 
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3.3.3.  Bioconversion with TK 
 
Both the TK and TAm bioconversions were initially studied individually under 
conditions suitable for later two-step reactions (Section 3.4). Information on specific 
activities, ee and final yields gathered from those experiments would then enable to 
successfully “mix and match” the best pair of enzymes to synthesize specific amino 
alcohols.  
 
Initial TK kinetics experiments showed that the activities and final yields obtained with 
E. coli TK lysates and whole cells were similar (Appendix IV), therefore data reported 
here for TK bioconversions were performed only with lysates containing the different 
TK variants. From TK mutant libraries developed previously (Hibbert et al., 2008; Smith 
et al., 2008, Cázares et al.,2010), the TK variants D469E, D469T and the wild type TK 
were selected as candidates due to their catalytic potential for the synthesis of ERY 
and/or PKD. Using HPA, the TK reactions were irreversible due to the release of CO2 as 
a side product (Mitra & Woodley, 1996), and yields of more than 90% mol/mol were 
obtained using concentrations up to 300 mM of HPA and the aldehyde GA or PA (data 
not shown). In contrast, TAm reaction yields were severely hampered in concentrations 
higher than 10 mM using MBA as amino donor (Appendix VI), hence initial TK 
bioconversions studies were performed at this lower concentration.  
 
Figure 3.7 shows the kinetics of ketodiol production for different combinations of TKs 
and aldehyde acceptors. The quantified activities, yields and measured ee values are 
summarized in Table 3.1.  
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Figure 3.7. Bioconversion kinetics showing ketodiol synthesis using different TK lysates and 
aldehyde acceptors: (●) ERY with wild type TK, (▼) ERY with D469T TK, (■) ERY with D469E 
TK, (Δ) PKD with D469T TK, (□) PKD with D469E TK, (ο) PKD with wild type TK. Reaction 
conditions: 10 mM [HPA] and 10 Mm [GA] or [HPA], 2.4 mM TTP, 9 mM Mg2+, 0.3 mg mL-1 TK, 
pH 7.5 in 50 mM TRIS, 30 oC. Bioconversions performed as described in Section 2.8.1. Error bars 
represent one standard deviation about the mean (n=3). 
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Table 3.1.  Measured specific activities, product yields and ee for the TK lysate catalyzed 
bioconversions shown in Figure 3.7. The specific activities were determined as described in Section 
2.8.1. 
TK 
variant Aldehyde 
Initial specific 
activitya,c 
(µmol min-1 mg-1) 
ee 
(%) 
Final 
conversionb 
(%mol/mol) 
Wild 
type GA 6.62 ± 0.13 >95 100 
Wild 
type PA < 0.1 ndd < 1 
D469T GA 5.13 ± 0.43 85 95 
D469T PA 1.98 ± 0.27 64 98 
D469E GA 4.96 ± 0.39 nd 100 
D469E PA 1.49 ± 0.26 >90 90 
 
 
 
aThe initial specific activity is based on the measured mass of TK in each bioconversion. 
bFinal conversion was determined at t=70 min. 
c The error of the specific activity represents one standard deviation about the mean (n=3). 
nd = not determined 
 
 
The wild type TK was selected for ERY synthesis because it presented the highest 
activity and ee of 6.6 µmol min-1 mg-1 and >95% respectively. Gyamerah & Willetts 
(1997) obtained an activity of 13.2 µmol min-1 mg-1 for the same HPA and GA reaction 
using wild type E. coli TK. This was in agreement with the work described here 
considering the differences in concentration of substrates used. 
For the synthesis of PKD, the highest activity was 1.98 µmol min-1 mg-1 using the TK 
mutant D469T, while no activity after 70 min of reaction was detected using the wild 
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type enzyme. The ee of PKD obtained with TK D469E was >90%, compared to a 64% 
ee of D469T. Due to the importance of the ee in the synthesis of optically pure amino 
alcohols, the TK mutant D469E was selected even though it had a 25% lower activity 
than D469T. The D469E mutation is in the pyrimidine binding domain of TK, and is 
assumed to enable activity towards PA because it replaces the original interaction of Asp 
with the C-2 hydroxyl group of GA, by creating a specific interaction between the Glu 
and the methyl group of the new substrate  (Hibbert et al., 2008; Cázares et al., 2010). 
 
3.3.4.  Bioconversions with TAm 
 
Single step TAm bioconversions focused on the CV2025 TAm as it had already been 
shown to be the best candidate for amino alcohol synthesis among several other 
transaminases cloned in previous work (Kaulmann et al., 2007). The comparison of in 
vitro and in vivo catalytic activity of CV2025 TAm had not previously been reported, so 
it was investigated here where a whole cell TAm biocatalyst was compared with a lysate 
for the synthesis of a number of ketodiols.  
 
Figure 3.8 shows product formation kinetics using either MBA or IPA as amino donors 
and PKD as amino acceptor. Due to the volatility of IPA, an excess concentration of 100 
mM IPA was initially used instead of 10 mM MBA to compensate for any loss due to 
evaporation. The results of activities and final yields of both amino alcohols are 
summarized in Table 3.2. 
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Figure 3.8. Bioconversion kinetics showing APD synthesis using CV2015 TAm in either lysate or 
whole cell form with different amino donors: (●) whole cell with MBA, (▲) whole cell with IPA, (○) 
lysate with MBA, (Δ) lysate with IPA. Reaction conditions : 10 mM [MBA] or 100 mM [IPA], 10 mM 
[PKD], 0.2 mM PLP, 0.3 mg mL-1 TAm, pH 7.5 in 50 mM HEPES, 30 oC. Bioconversions performed 
as described in Section 2.8.1. Error bars represent one standard deviation about the mean (n=3).  
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Table 3.2. Measured specific activities and product yields for the TAm catalyzed conversion of PKD and 
ERY. The specific activities were determined as describe in Section 2.8.1. 
Biocatalyst 
form 
Amino 
donor 
Amino 
acceptor 
Initial specific 
activitya,c (µmol 
min-1 mg-1) 
Final 
conversionb 
(%mol/mol) 
Whole cell MBA PKD 0.074 ± 0.006 
  
95 
Lysate MBA PKD 0.034 ± 0.003 83 
Whole cell IPA PKD 0.029 ± 0.0035 96 
Lysate IPA PKD 0.015 ± 0.003 75 
Whole cell MBA ERY 0.096±0.005 92 
Lysate MBA ERY 0.045±0.003 86 
Whole cell IPA ERY 0.035±0.05 91 
Lysate IPA ERY 0.026±0.04 71 
 
 
 
aThe specific activity was based on the measured mass of TAm present in each bioconversion. For 
whole cell experiments, it was calculated based on 50% of the dry cell weight of the cells being 
protein (Watson, 1972), and SDS-PAGE analysis that showed that 40% of the protein was TAm.  
bYield was determined at t=30 hours. 
c The error of the specific activity represents one standard deviation about the mean (n=3). 
 
 
The CV2025 TAm showed a 4 fold increase in yield and a 40 fold improvement in 
specific activity (Figure 3.8 and Table 3.2) compared to initial work with a β-alanine-
pyruvate transaminase from Pseudomonas aeruginosa (Ingram et al., 2007).  
The final yield of ABT of 92 and 86 % mol/mol using whole cell and lysates respectively 
improved the previously reported values of 14-22% mol/mol (Kaulmann et al., 2007).  
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The quantitative conversion of the reaction observed in Figure 3.8 and Table 3.2 was in 
agreement with the equilibrium constants obtained for a similar transamination of 
pyruvate with MBA using the ω-transaminase from Bacillus thuringiensis JS64, showing 
that the forward reaction was thermodynamically more favourable than the reverse 
reaction (Shin & Kim, 1998).  
 
Smith et al., (2010) obtained a 93% mol/mol yield for the synthesis of APD with the 
CV2025 TAm using an excess of PKD (molar ratio of 1.5 PKD/IPA). In this work, the 
use of whole cells enabled to reach an almost complete conversion of the substrates with 
a final yield of 96 % mol/mol without having to use an excess of the chiral ketodiol.  
Nevertheless, working with higher concentrations severely inhibited the bioconversion as 
shown in Figure 3.9, which illustrates the kinetics of TAm production of APD using 
initial equimolar concentration of substrates of 50 mM PKD with IPA or MBA as amino 
donors. 
 
After 40 hours, the final yields were 52 and 23 % using IPA and MBA respectively, 
underlying the strong inhibition caused by MBA. This inhibitory effect of MBA has also 
been reported in the literature with transaminases from Klebsiella pneumonia and Vibrio 
fluvialis (Shin and Kim, 1997; Yun et al., 2004).  In this case the use of in situ product 
removal by ion exchange resins or coupled reactions could be a possible solution as has 
been shown by others (Truppo et al., 2010). 
 
Analyzing the results of Table 3.2 and Figure 3.8, similar yields were obtained using 
ERY or PKD as substrates, but the specific activities using ERY were between 17% and 
42% higher than those of PKD. 
.  
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Figure 3.9. Bioconversion kinetics showing APD synthesis using CV2015 TAm in whole cell form 
with different amine donors: (●) 50 mM PKD and MBA and (Δ)  50 mM [PKD] and [IPA]. Reaction 
conditions: 0.2 mM PLP, 0.3 mg mL-1 TAm, pH 7.5 in 50 mM HEPES, 30 oC. Bioconversions 
performed as described in Section 2.8.1. Error bars represent one standard deviation about the 
mean (n=3).   
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For synthesis of both amino alcohol products, the whole cell biocatalysts performed 
better than the lysates demonstrating the beneficial effect of using TAm in vivo for these 
bioconversions. This phenomenon has also been reported in the literature, where higher 
yields using whole cell TAm biocatalysts have been attributed to better stability of the 
enzyme inside the cell (Shin & Kim 1997), to metabolism consumption of inhibitory 
compounds (Shin & Kim, 1999), or to the effect of the cell membrane in partitioning 
inhibitory components between the inside and outside of the cell (Yun et al., 2004).  
 
In this work, the inhibitory product acetophenone (AP) was not further metabolized by 
the whole cells and MBA and AP where found to be more inhibitory than IPA and 
acetone (Figure 3.9). In contrast, when using TAm lysates lower yields were obtained 
using IPA (75 % and 71 % mol/mol for APD and ABT respectively) compared to MBA 
(83 % and 86 % mol/mol respectively). Addition of more enzyme and PLP after the 
initial reaction had stopped partially restored the biocatalytic activity, suggesting that the 
improved yield using whole cells could be attributed to an increase in stability of the 
enzyme.  
 
Based on the results in Table 3.2, the whole cell TAm biocatalyst was selected for further 
study because of its superior performance compared to the lysate. IPA appears preferable 
as amine donor because of its advantages in terms of economy, downstream processing 
and reduced inhibition compared to MBA. However, both amine donors were evaluated 
for one-pot synthesis reactions in Section 3.7. 
 
3.3.5.  One-pot synthesis of amino alcohols 
 
In order to achieve the one-pot synthesis of amino alcohols, two whole cell biocatalysts 
were constructed both with plasmid pQR801 expressing the CV2025 TAm, and with 
either pQR412 expressing the TK mutant D469E or the wild type variant for APD and 
ABT syntheses respectively. 
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The first one-pot synthesis of APD using MBA as amino donor gave a poor yield (15 % 
mol/mol) of amino alcohol after 20 hours but another product was detected by HPLC 
analysis after derivatizing the samples (Section 2.9.6). This compound was identified as 
serine, which was possibly produced by the transamination of HPA. To overcome this 
problem, MBA was subsequently added in fed batch mode after the TK reaction was 
complete. A typical reaction kinetic profile for this mode of operation is shown in Figure 
3.10. 
 
The volume added of the solution of MBA was equal to the volume of the reaction 
mixture; hence the original concentration of the reactants was diluted 2-fold after MBA 
addition. The first step comprising the TK reaction reached completion after 4 hours with 
a specific activity of 2.68 µmol min-1 mg-1. The second step TAm reaction had a specific 
activity of 0.067 µmol min-1 mg-1 and reached a maximum APD yield of 90 % mol/mol 
after 21 hours of reaction with MBA. This measured activity was in agreement with the 
one found for the single TAm reaction (Table 3.2).  
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Figure 3.10. Typical bioconversion kinetics for the sequential whole cell TK-TAm catalytic 
synthesis of APD with addition of amine donor (MBA) after 4 hours : (▼) PKD, (●) HPA, ( Δ) APD, 
(◊) MBA and (ο) AP. Reaction conditions (TK step): 20 mM [HPA] and [PA], 0.4 mM PLP, 2.4 mM 
TTP, 9 mM Mg2+, 0.095 mg mL-1 TK, 0.43 mg mL-1 TAm, pH 7.5 in 50 mM HEPES, 30 oC. TAm 
step was initiated by adding MBA solution to reach a concentration of 10 mM which resulted in a 2 
fold dilution of reactants. Bioconversions performed as described in Section 2.8.1. 
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When using IPA as amine donor at the compromise temperature of 30 oC (Section 3.4), 
the TAm did not show any noticeable activity towards HPA, GA or PA over 5 hours. 
This was not the case at 37 oC, where activity towards TK substrates was detected in that 
period of time (data not shown). This suggested it was possible to perform the 
bioconversion of APD using IPA in a true one-pot synthesis at 30 oC as shown in Figure 
3.11, were the TK reaction was completed after 5 hours, leading to a 90 % mol/mol yield 
of APD after 25 hours. 
 
The specific activities of TK and TAm in the one-pot synthesis were 1.46 and 0.022 
µmol min-1 mg-1 respectively, which were also in agreement with the corresponding TK 
and TAm specific activities for the single bioconversions (Table 3.1 and 3.2). Similar 
results were obtained for the one-pot synthesis of ABT using IPA as amine donor, 
reaching a final yield of 87 % mol/mol after 25 hours as shown in Figure 3.12. 
 
The TK reaction for the ABT synthesis was completed in 1.5 hours instead of the 5 hours 
required for the APD synthesis. This was in agreement with the higher activity of the 
wild type TK enzyme towards ERY synthesis in comparison to the activity of the D469E 
variant towards PKD synthesis (Table 3.1). 
 
The 87% mol/mol yield for ABT synthesis represented an improvement of 4-fold in yield 
in a quarter of the reaction time compared to previous work (Ingram et al, 2007). The 90 
% mol/mol yield for APD represented a 7-fold improvement in a third of the reaction 
time compared to the previously reported two separated steps synthesis (Smith et al., 
2010).  
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Figure 3.11. Typical bioconversion kinetics for the one-pot, whole cell TK-TAm catalytic synthesis 
of APD using IPA as amine donor: (▼) PKD, (● ) HPA, and (Δ) APD. Reaction conditions: 10 mM 
[HPA] and [PA], 100 mM [IPA], 0.2 mM PLP, 2.4 mM TTP, 9 mM Mg2+, 0.095 mg  mL-1 TK , 0.42 
mg mL-1 TAm, pH 7.5 in 50 mM HEPES, 30 oC. Bioconversions performed as described in Section 
2.8.1. 
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Figure 3.12. Typical bioconversion kinetics for the one-pot, whole cell TK-TAm catalytic synthesis 
of ABT using IPA as amine donor: (▼) ABT, (●) HPA, and ( ο) ERY. Reaction conditions: 10 mM 
[HPA] and [GA], 100 mM [IPA], 0.2 mM PLP, 2.4 mM TTP, 9 mM Mg2+, 0.095 mg mL-1 TK , 0.42 
mg mL-1 TAm, pH 7.5 in 50 mM HEPES, 30 oC. Bioconversions performed as described in Section 
2.8.1. 
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3.4.  SUMMARY 
 
The work presented in this Chapter has shown that it is possible to rapidly evaluate and 
“mix and match” pairs of TK and TAm enzymes, in order to facilitate the design of the 
one-pot synthesis of various optically pure amino alcohols. The use of microscale 
experimentation (as described in Section 2.8.1) has enabled rapid collection of the 
reaction kinetic data, which was required to optimise overall reaction conditions (Figures 
3.3 to 3.6), as well as  selecting the best enzyme candidates (Figure 3.7 and 3.8). 
Together these two technologies comprise the experimental “toolbox” for the rapid 
evaluation of multi-step enzymatic synthesis of amino alcohols, that it was the aim of 
this Chapter to establish. 
 
TK-TAm biocatalysts were successfully constructed (Figure 3.1), achieving a final 
enzyme expression of TK and TAm of 8% and 36% w/w of the total protein (Figure 3.2). 
The best reaction conditions were determined to be at 30oC using a pH of 7.5 (Figure 3.3 
to 3.6). The engineered TK D469E and the wild type TK were found to be the best 
candidates for the synthesis of APD and ABT respectively (Figure 3.7). Also, the 
CV2025 TAm was discovered to display better catalytic activity when used in vivo rather 
than in vitro (Figure 3.8). This lead to the design and construction of whole cell 
biocatalysts to perform the one-pot synthesis of the single diastereoisomers APD (Figure 
3.11) and ABT (Figure 3.12). IPA was identified as a preferable amine donor compared 
to MBA for the one-pot syntheses, because side reactions with the initial TK substrates 
(catalysed by TAm) were negligible and higher yields could be obtained at higher 
concentrations (Figure 3.9). The TAm step was found as the bottleneck of the de novo 
pathway, due to its one order of magnitude lower specific activities compared to TK 
(Table 3.1 and 3.2), as well as been inhibited by higher concentrations of substrates 
(Figure 3.9). Therefore Chapter 4 was focused in obtaining the corresponding kinetic 
parameters in order to optimize the TAm bioconversion. 
 
† The majority of the results presented in this chapter have been submitted for publication as: L.Rios-
Solis, N. Bayir, M. Halim., J. Hao, F. Baganz., G.J. Lye. Kinetic modeling of a transaminase to 
produce optically pure amino alcohols. Biochem. Eng. J. Submitted.  
 
4. KINETIC MODELLING OF 
TRANSAMINASE SYNTHESIS OF 
CHIRAL AMINO ALCOHOLS† 
 
4.1 INTRODUCTION 
 
The ω-TAm from C. violaceum 2025 was shown in Chapter 3 to be a promising 
candidate to integrate the TK-TAm de novo pathway for the synthesis of chiral amino 
alcohols. Nevertheless it was also identified as the bottleneck of the one-pot synthesis 
presenting low specific activities and yields relative to the preceding TK 
bioconversion (Table 3.2).  
 
The determination of the full TAm kinetic model would allow simulation of the 
conversion, enabling determination of the best reaction conditions, bioreactor design 
and integration within multi-step enzymatic syntheses (Chen et al., 2006; Sin et al., 
2009; Santacoloma et al., 2011). 
 
The determination of the required data for establishment of full kinetic models can be 
time and resource consuming, especially when using the traditional linear methods 
like the Lineweaver and Burk plot (Ranaldi 1999; Chen et al., 2009). This problem is 
further emphasised for non-natural bioconversions used in the pharmaceutical 
industry, that often present strong substrate and product inhibition (Yazbeck et al., 
2004), as commonly found with TAm bioconversions as described in Section 1.5.3.  
 
Nonlinear regression methods can use programmable optimization algorithms to 
determine the kinetic parameters, consequently been less time and resource 
consuming (Blackmond, 2005). 
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However, the determination of model parameters can suffer from global convergence 
problems, in particular the estimation procedure can be strongly dependent on the 
initial values of the parameters (Moros et al., 1996).  
 
Hybrid methods combining traditional initial rates experiments to identify a solution 
in the vicinity of the global minimum, with non linear regression methods to 
determine the exact location of the solution emerge as an ideal solution to be 
integrated in the microscale toolbox (Katare et al., 2004;  Chen et al., 2008).  
 
 
4.2  AIM AND OBJECTIVES 
 
Based on the discussion in Section 4.1 the aim of this Chapter is to develop a 
methodology to rapidly establish the TAm kinetic parameters in order to determine 
the optimum reaction conditions. The methodology was based on combining non 
linear numerical techniques (Katare et al., 2004; Morbiducci et al., 2005; Chou & 
Voit, 2009; Chen et al., 2008) with microscale experimentation (Lye et al., 2003; 
Micheletti & Lye, 2006). The approach will be exemplified for the TAm mediated 
synthesis of ABT as indicated in Scheme 3.1. The key objectives of this Chapter are 
thus: 
 
• Extension of the non linear parameter estimation method first proposed by 
Chen et al., (2008) for application to equilibrium-controlled enzymatic 
reactions. 
• Illustrate the new approach by determination of the apparent kinetic 
parameters of the TAm mediated synthesis of ABT using whole cells, which 
was found to be best biocatalyst form in Section 3.3.4.  
• Validate the kinetic parameters obtained against additional experimental data. 
• Identify main bottlenecks of the reaction. 
• Identify the best reaction conditions for the synthesis of amino alcohols. 
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4.3 RESULTS 
 
4.3.1 Model driven methodology for TAm kinetic parameters identification 
 
In  previous works (Chen et al. 2008; Chen et al. 2009), a microscale model driven 
methodology for determining the kinetic parameters of transketolase (TK) 
bioconversions was developed and validated for the synthesis of several ketodiols.  
The method consisted in obtaining preliminary values of kinetic parameters on a step-
by-step basis, reducing the number of estimated parameters to 3 or 4. These 
preliminary values where then used as initial guesses for a final parameter estimation 
step via nonlinear regression. Compared with the conventional linear plotting 
methods, this approach demonstrated to significantly reduce the number of 
experiments and materials required for kinetic parameter estimation, making it useful 
to rapidly simulate and optimize large scale bioconversions (Smith et al. 2010).  
 
The TAm reaction is reversible and usually present strong substrate and/or product 
inhibition (Koszelewski et al., 2010), in addition the TAm model was only partially 
elucidated as described in Section 1.5.3.4, therefore the methodology should be able 
to test different kinetic models in order to determine the correct reaction mechanism. 
However, the previous methodoliges were developed for TK bioconversions, which 
were irreversible and their kinetic model included less parameters and was already 
fully elucidated. Therefore several modifications had to be made to the original 
methodology, in order to enable the rapid and accurate elucidation of the Tam 
reaction model, as well as the determination of the kinetic parameters of a reversible 
reaction which may include strong substrate and/or product inhibition. 
 
The methodology developed incorporates 5 main Steps as described in Figure 4.1 
which are as follows: 
 
1) Determination of the region of linear proportionality between the enzyme   
concentration and the initial rate. 
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2)  Gathering of initial rate data for both forward and reverse reaction, testing of 
different kinetic models to elucidate the preliminary reaction pathway and 
determining the preliminary Michaelis and rate constants. 
3) Determination of the stability of the enzyme under actual bioconversion 
conditions. 
4) Determination of the preliminary values of equilibrium and inhibition 
constants through non linear regression of experimental progress curves. 
5) Reconciliation of the parameters through a new round of non linear regression 
of the progress curves, using all the preliminary values of the kinetic 
parameters as initial guess for the final regression, and verification of the 
selected reaction pathway.  
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Figure 4.1. Schematic representation of the systematic procedure for rapid apparent kinetic 
parameter identification for an equilibrium controlled bioconversion such as the whole cell TAm 
mediated synthesis of ABT from ERY and MBA (Scheme 3.1). 
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In order to implement the procedure illustrated in Figure 4.1, a programme was 
developed using Matlab software (MathWorks, Natick, MA, USA) in order to 
automatically perform all the non linear regressions and statistical analyses. The 
complete Matlab code can be found in Appendix V.  
 
The synthesis of ABT using MBA as amino donor was selected initially to develop 
the methodology in this chapter, because the analytical tools to follow the reaction 
were simpler and more established than using IPA as amino donor (Section 2.9.6).  
 
4.3.2 Proportionality between reaction rate and enzyme concentration 
 
As described in Figure 4.1, the first Step to obtain the kinetic parameters was to 
determine the region of linear proportionality between the TAm concentration in 
whole cell form and the initial reaction rate. This was necessary to ensure that any 
increase in enzyme concentration would contribute fully to the measured kinetics 
(Chen et al., 2008). It is common that increasing the enzyme concentration in a 
reaction will not correspond to a proportional increase in the initial rate of the 
bioconversion; the reasons are usually mass transfer limitations or certain forms of 
inhibition (Law et al., 2006). The substrate concentrations used were 10 mM MBA 
and 50 mM ERY for each enzyme concentration and the linear relationship could be 
maintained up to a TAm concentration of 0.8 mg mL-1 as can be seen in Figure 4.2. 
This value was thus set as the upper limit for all subsequent experiments.  
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Figure 4.2. Apparent initial rate of ABT and AP TAm mediated synthesis (Scheme 3.1) as a 
function of TAm concentration in whole cell form.  Reaction conditions: 10 mM [MBA] and 50 
mM [ERY], 0.2 mM PLP, 30oC and pH 7.5 in 200 mM HEPES. Experiments performed as 
described in Section 2.8.1. Whole cells produced as described in Section 2.4.2. Solid line fitted by 
linear regression (R2 0.99885).  Error bars represent one standard deviation of the mean (n=3). 
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This upper limit result of 0.8 mg mL-1 was one order of magnitude lower when 
compared to other types of enzymes like TK (Chen et al., 2009). The observation of a 
lower limit of proportionality among transaminases has been reported before (Banks 
et al. 1959). A possible explanation is that the enzyme can show self-inhibition where 
an end amino group of one TAm molecule might bind the pyridoxal phosphate 
associated with the active site of another enzyme molecule (Ellis & Davies, 1961). In 
the case of whole cells mass transfer limitations across the cell wall might also be the 
cause (Ni &  Chen, 2004; Woodley, 2006). 
 
4.3.3 Kinetic model of TAm and initial rate experiments 
 
In the second Step of the methodology described in Figure 4.1, a set of initial rate data 
varying the concentration of one substrate, while maintaining the other one fixed was 
obtained for both forward and reverse reactions (Scheme 3.1).  
 
Figure 4.3 shows a plot of the measured initial reaction rate for the forward reaction 
as a function of varying concentrations of substrate ERY while maintaining the 
concentration of MBA fixed at 10 mM. A second plot is shown in Figure 4.3 for the 
variation of the concentration of MBA while maintaining ERY at 200 mM.  
 
The same procedure was followed for the reverse reaction, where Figure 4.4 shows a 
plot of the measured initial reaction rate as a function of varying the concentration of 
substrate ABT, while maintaining the concentration of AP fixed at 35 mM. For AP 
this is close to the maximum solubility of 42 mM at 25oC (Siegel, 2000). A second 
plot in Figure 4.4 shows the initial rate of the reverse reaction as a function of the 
variation of the concentration of AP while maintaining ABT concentration at 100 
mM. The whole cell TAm concentration for all the experiments shown in Figures 4.3 
and 4.4 was 0.2 mg mL−1.  
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Figure 4.3. Apparent initial rate of the forward TAm reaction for ABT and AP synthesis 
(Scheme 3.1) as a function of the substrate concentration: (●) [MBA] was varied while 
maintaining [ERY] fixed at 200 mM, (Δ) [ERY] was varied while maintaining [MBA] fixed at 10 
mM.  In all experiments 0.2 mg mL-1 of TAm in whole cell form was used with 0.2 mM PLP, 30oC 
and pH 7.5 in 200 mM HEPES. Experiments performed as described in Section 2.8.1. Whole cells 
produced as described in Section 2.4.2.  
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The reverse reaction was considerably slower compared to the forward reaction 
(Figure 4.3 and 4.4). This created some experimental difficulties to obtain the initial 
rate data using whole cells for the reverse reaction. The cause of those difficulties 
were the necessity to measure very small concentrations of MBA or ERY (in the order 
of 0.05 mM) which required very fine analytical detection tools with minimum noise. 
In addition, MBA and ERY in such small concentrations were easily consumed by 
side reactions of the whole cells.  
 
To demonstrate that the products that were quantified were actually produced by the 
TAm bioconversion and not by whole cell side reactions, a set of experiments to 
obtain reverse initial reaction rates using pure TAm (see Section 2.6.2 for the 
purification procedure) were also performed and the results are shown in an extra plot 
in Figure 4.4.  
 
Obtaining the reverse initial rates using pure enzyme eliminated the problems of 
whole cells side reactions and analytical noise, making the experimental procedure 
straight forward.  
 
 In Section 3.3.4 it was found that the TAm biocatalyst in vivo form was more stable 
than ex vivo.  This stability effect was negligible for initial rate data, where both plots 
using TAm in pure and whole cell form showed a similar trend with the same order of 
magnitude of initial rates (Figure 4.4). This indicated that the bioconversion was not 
mass transfer limited using 0.2 mg mL-1 of TAm in whole cell form. Similar results 
were found for the initial rates of Figure 4.3 comparing lysates and whole cells (data 
not shown). 
 
Because of the higher quality of data obtained with pure TAm and its similar initial 
rate behaviour compared with the whole cell biocatalyst (Figure 4.4), it was decided 
in this chapter to use the pure enzyme reverse kinetic data, in conjunction with the 
whole cell forward kinetic data to obtain the preliminary parameters of the reaction. 
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Figure 4.4. Apparent initial rate of the TAm reverse reaction  for the synthesis of ABT and 
MBA  as function of the concentration of substrates: (Δ) varying[ ABT] while maintaining [AP] 
fixed at 35 mM using pure enzyme and (▲) TAm in whole cell form , (○)  varying [AP] while 
maintaining [ABT] fixed at 100 mM  using pure enzyme and (●)  TAm in whole cell form.  In all 
experiments 0.2 mg mL-1 of TAm in whole cell or pure form were used with 0.2 mM PLP, 30oC 
and pH 7.5 in 200 mM HEPES. Experiments performed as described in Section 2.8.1. Whole cells 
produced as described in Section 2.4.2. Purification of the enzyme was performed as described in 
Section 2.6.2. 
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As was described with more details in Section 1.5.4.4, TAm requires the coenzyme 
pyridoxal 5´-phosphate and catalyze enzymatic amino group transfer by a ping-pong 
bi–bi mechanism (Bulos & Handler 1965; Kuramitsu et al., 1990). It has been 
reported for TAm bioconversions that a substrate or product can bind an incorrect 
enzyme form, creating dead end complexes that cannot react further, causing a 
potentially strong form of inhibition (Bulos & Handler, 1965; Shin & Kim, 1998; 
Shin & Kim, 2002). 
 
For the CV2025 TAm synthesis of ABT, the presence of abortive complexes in the 
reaction mechanism was not known, therefore different kinetic models were initially 
fitted by non linear regression to the experimental initial rate data shown in Figures 
4.3 and 4.4. This was necessary to explore the possibility of the formation of different 
dead end complexes and identify the most suitable preliminary kinetic model. Among 
all those models, the reaction mechanism which included substrate inhibition by the 
formation of the complex E-PMP-MBA gave the best statistical fitting (statistical 
results will be discussed the next paragraph). The resulting King-Altman figure for 
the selected reaction pathway is represented in Figure 4.5, and the corresponding rate 
model is derived in Equation 4.1 (Segel, 1975; Shin & Kim, 1998). 
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Figure 4.5. Proposed King-Altman figure for the TAm mediated synthesis of ABT. Solid lines 
arrows represent the basic model without the formation of abortive complexes. The dashed 
arrows represent the substrate inhibition by the formation of dead end complex E-PMP-MBA. 
 
 
 
 
 
Where v represents the reaction rate, kf and kr represents the catalytic rate constants for 
the forward and reverse reaction respectively, KERY, KAP, KABT and KMBA are the 
Michaelis constants of ERY, AP, ABT  and MBA, KiABT and KiMBA are the inhibition 
constants of ABT and MBA respectively, KiMBAc is the inhibition constant for the 
MBA-PMP abortive complex, EiTAm represents the TAm concentration and Keq is the 
equilibrium constant. 
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In the absence of products for the forward reaction, Equation 4.1 can be simplified to 
Equation 4.2: 
 
 
 
The initial data from Figure 4.3 was fitted using non linear regression to Equation 2 
obtaining an R2 of 0.98 and the sum of squares was of 0.24, which was one order of 
magnitude below compared to the R2 of 0.87 and sum of squares of 14.2 for the 
second best fitting model which did not include substrate inhibition by a dead end 
complex (Equation 4.2 without including the last two terms).  
The preliminary values of the constants kf, KMBA, KERY and KiMBAc were 97.2 mM 
min-1, 0.5, 101.2 and 23.9 mM respectively. 
 
A statistical F-test (Markowski and Markowski, 1990) was performed in order to 
determine if the addition of the parameter KiMBAc gave a significantly better fit to the 
data. The result of the F-test was equal to 282.4, which was considerably higher than 
the critical value of 6.6 from the F distribution tables with false-rejection probability 
of 0.05, showing that the addition of the parameter KiMBAc was statistically significant. 
 
The plots of reverse initial rate as a function of substrate concentration in Figure 4.4 
did not suggest the presence of strong inhibition that could be caused by a dead end 
complex. This was corroborated by non linear fitting regression, where all the models 
including the formation of dead end complexes in the reverse reaction failed to give a 
statistically better fit than the model represented by Equation 4.3, which is a 
simplification of Equation 4.1 without including products. 
 
 
 
The initial rate data was fitted to equation 4.3 by non linear regression, and the 
preliminary parameters of kr, KAP and KABT were found to be 13.1 min-1, 19.6 and 
39.4 mM respectively. Both non linear regressions for the forward and reverse 
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reaction had upper and lower bounds of 0.0001 and 2000 and both converged with 
any arbitrary initial value. 
 
4.3.4 Enzyme stability 
 
An underlying assumption is that the TAm activity should be stable for the duration of 
the progress curve experiments, which are needed to determine the rest of inhibition 
and equilibrium constants (Figure 4.1). Good stability of TAm would also 
demonstrate that the total enzyme concentration was constant during the complete 
assay; therefore any decrease in the reaction rate could be attributed to inhibition or 
equilibrium effects and not to irreversible enzyme deactivation.  
 
To test the enzyme stability, the whole cell TAm was incubated with each substrate or 
product over different incubation times, and the enzyme activity was determined at 
intervals and plotted as a function of the incubation time in Figure 4.6 (forward 
reaction activity data was used for substrate incubation tests, and reverse reaction 
activity for product incubation tests).  
 
No significant decrease in enzyme activity was detected for up to 35 hr of incubation 
with ERY, ABT and AP. In contrast there was a 10% decrease in initial reaction rate 
for the whole cell TAm while incubated with MBA. Because improving TAm 
stability was out of the scope of this project, a maximum of 10% deactivation of 
enzyme was set as the tolerance limit for the kinetic parameters identification. 
Therefore the maximum reaction time allowed in all the progress curves was set to be 
35 hr. 
 
When incubating the enzyme with MBA, PLP had to be added again so that the 
enzyme activity would be restored. This was not necessary when incubating the 
enzyme with ERY, AP or ABT, and the reason could be attributed to a full conversion 
of PLP to PMP through completion of the first half reaction due to the absence of 
amino-acceptor, as has been shown previously using the CV2025 TAm  (Schell et al., 
2009).  
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Figure 4.6. Stability experiments using the whole cell TAm biocatalyst: apparent forward 
initial reaction rates after different times of incubation with (●) 50 mM ERY or (○) 50 mM MBA, 
and apparent reverse reaction initial rates after different incubation times with (▼) 100 mM 
ABT or (Δ) 35 mM AP. In all experiments 0.2 mg mL-1 of TAm in whole cell form were used with 
0.2 mM PLP, 30oC and pH 7.5 in 200 mM HEPES. Reaction conditions for forward reaction were 
50 mM equimolar concentration of substrates, and for the reverse reaction 100 mM ABT or 35 
mM AP were added to start the reaction. Experiments performed as described in Section 2.8.1. 
Whole cells produced as described in Section 2.4.2.  
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4.3.5 Kinetic parameter identification using progress curves 
 
Step 4 in the proposed methodology (Figure 4.1) involved obtaining complete 
progress curves at higher substrate concentrations, where equilibrium as well as 
substrate and product inhibition effects would have a stronger weight. A set of 9 
progress curves for the forward reaction, each with 12 sampling points at different 
intervals were obtained to ensure the accuracy of the model fit to the experimental 
data. This set was complemented with the addition of 3 reverse reaction progress 
curves, to ensure that the model would fit both forward and reverse reaction profiles.  
The substrate concentrations chosen are shown in Table 4.1, and included those under 
which the final bioconversion process might be performed. Also included are 
experiments at the lower and higher range of the concentration spectrum, to ensure 
that the inhibition and equilibrium constants would be accurately determined over a 
range of bioconversion conditions. 
 
 
Table 4.1. Initial experimental substrate and enzyme concentrations for the 12 progress curves 
used to obtain the kinetic parameters in Steps 4 and 5 of the methodology described in Figure 4.1. 
The first 9 progress curves represent forward reaction bioconversions, while the last 3 represent 
reverse reaction bioconversions. 
 
Progress 
curve  
number 
1 2 3 4 5 6 7 8 9 10 11 12 
[ERY] 
(mM) 
50 70 150 250 300 150 200 10 20 0 0 0 
[MBA] 
(mM) 
100 250 250 40 30 15 50 120 200 0 0 0 
[AP] 
(mM) 
0 0 0 0 0 0 0 0 0 10 20 40 
[ABT] 
(mM) 
0 0 0 0 0 0 0 0 0 120 200 100 
Ei  
(mg ml-1) 
0.3 0.4 0.3 0.15 0.15 0.15 0.15 0.3 0.45 0.15 0.44 0.3 
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Initial non linear regressions highlighted the importance of the data points before 60 
min of reaction. Those points were crucial involving low products concentration, 
giving weight to the preliminary parameters Kf, Kr, and the Michaelis constants 
previously obtained, allowing a better convergence of the optimization. Therefore 
care was taken to include several points within that time range, in order for the 
optimization to converge around the vicinity of the preliminary values determined in 
Section 4.3.3. 
 
The preliminary results of kf and kr, of 97.2 and 13.1 min-1, and of KMBA, KERY, 
KiMBAc, KAP and KABT of 0.5, 101.2, 23.9, 19.6 and 39.4 mM respectively obtained in 
Section 4.3.3 were used as fixed values in the full kinetic model (Equation 4.1). This 
was done in order to be able to determine the rest of the kinetic constants by non 
linear regression of the progress curves. The equilibrium constant was calculated 
simultaneously in the iteration process using the Haldane equation 4.4: 
 
 
 
The two remaining inhibition constants KiERY and KiAP were calculated using the 
following Haldane equations: 
 
 
 
 
 
The partial equilibrium constant K1 for the first half reaction, where MBA reacts with 
E-PLP to produce AP and E-PMP (Figure 4.5) was calculated using Equation 4.7: 
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In the same way, the partial equilibrium constant K2 for the second half reaction, 
where E-PMP is converted to E-PLP through the formation of ABT from ERY 
(Figure 4.5) was obtained using Equation 4.8: 
 
 
 
It should be noted that the global equilibrium constant Keq can also be expressed as 
the product of the two partial constants as shown in Equation 4.9, and the value 
obtained should be the same as the one obtained with Equation 4.4. 
 
 
 
The global optimization was obtained using the pattern search algorithm available in 
the `Genetic Algorithm and Direct Search Toolbox' in Matlab (Appendix V) 
(MathWorks, Natick, MA, USA). Following this approach, the optimization solution 
was relatively independent of the initial values of the inhibition constants, because 
only 3 parameters needed to be estimated. The preliminary values of KiMBA, KiABT and 
Keq were determined to be 0.004 and 2.2 mM and 829.9 respectively. The lower and 
upper bounds for both non linear regressions were set at 0.0001 and 800, and the 
optimization was always found to converge to the same result for any given initial 
value within the bounds. 
 
4.3.6 Reconciliation Step for determination of final kinetic parameter values 
 
The preliminary parameters obtained up to Section 4.3.5 were usually very close to 
the “true” values, but they still presented some inaccuracies because they were based 
on the catalytic and Michaelis-Menten constants determined using the simplified 
kinetic models in Equations 4.2 and 4.3. Any error obtained using such simplified 
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models in Section 4.3.3 would be propagated to the values of all the next parameters 
determined in the Section 4.3.5. Therefore in Step 5 of the methodology described in 
Figure 4.1, the kinetic constants were reconciled by using the corresponding full 
kinetic model combined with non linear regression of the 12 progress curves, where 
all the preliminary parameters were used as initial values for the optimization. 
 
The lower and upper bounds were set as 0.1 and 2000 (expect for KMBA and KiMBA 
where the lower bound was set to 0.01 and 0.0001 respectively), and because the 
initial estimates were close to the final parameter values, the global optimization was 
quickly achieved around the vicinity of the initial estimates. The preliminary and 
“reconciled” kinetic values obtained this way are summarized in Table 4.2, where a 
description in terms of rate constants of each parameter is also included. 
 
The preliminary and final values were relatively similar and the major difference 
(33%) was found for the inhibition constant KAPi. Such changes to the final values of 
the kinetic parameters at this point was considered acceptable for a non linear 
regression approach methodology (Moros et al., 1996; Blackmond 2005). 
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Table 4.2. Initial and final “reconciled” values for the parameters obtained in Step 5 of Figure 
4.1 using the full kinetic model represented by Equation 4.1.  
 
Kinetic parameter Kinetic parameter in terms of rate constants 
Initial 
value 
Reconciled 
value 
Catalytic rate constants (min -1) 
Rate constant forward 
reaction: kf 
 97.2 95.1 
Rate constant reverse 
reaction: kr 
 13.1 12 
Michaelis-Menten constants (mM) 
Michaelis constant for 
MBA : KMBA 
 0.49 0.51 
Michaelis constant for 
ERY : KERY 
 101.2 95.5 
Michaelis constant for 
AP :  KAP 
 19.6 16.1 
Michaelis constant for 
ABT : KABT 
 39.4 37 
Inhibition constants (mM) 
Inhibition constant for 
MBA:  KiMBA 
 4.0×10-3 4.0×10-3 
Inhibition constant for 
ERY:  KiERY 
 0.75 1.0 
Inhibition constant  for 
AP:  KiAP 
 1.2 1.1 
Inhibition constant  for 
ABT:  KiABT 
 2.2 3.1 
Inhibition constant for 
MBA abortive 
complex: KiMBAc 
 23.9 24 
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Equilibrium constants 
Global equilibrium 
constant 
 829.9 842.9 
Equilibrium constant 
for the first half 
reaction : K1 
 301 275 
Equilibrium constant 
for the second half 
reaction : K2 
 2.9 3.1 
 
 
In order to perform a complete statistical analysis, the full methodology described in 
Figure 4.1 was also performed using the kinetic model without including substrate 
inhibition by the formation of dead end complexes (Equation 4.1 without including 
the last two terms). The final non linear regression performed with this model in Step 
5 to reconcile the parameters was not stable and failed to converge successfully. 
Instead it reached the upper limit for KERY and showed relatively high discrepancies 
between the initial and “reconciled” values, presenting a residual of 16.3 compared to 
0.55 using the full model of Equation 4.1. A statistical F-test (Markowski and 
Markowski, 1990) was performed in order to determine if the addition of the 
parameter KiMBAc gave a significantly better fit to th progress curve data. The result of 
the F-test was equal to 15.7, which was higher than the critical value of 3.9 from the F 
distribution tables with false-rejection probability of 0.05, showing that the addition 
of the parameter KiMBAc was also statistically significant to fit the progress curves.  
 
These statistical results, in addition to those in Section 4.3.3, showed that the kinetic 
model described by Equation 4.1 presented the best fitting for both initial rate data 
and the complete progress curves. This finding strongly supports the formation of the 
abortive complex E-PMP-MBA. Further experiments using LC-MS or other sensitive 
analytical tools could demonstrate the existence of such complex but those studies 
were out of the scope of this work as described in Section 1.4.  
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4.3.7 Validation of the kinetic parameters 
 
In order to validate the kinetic parameters obtained in Table 4.2, experimental and 
predicted data of reactant concentrations as a function of time were compared. Very 
good agreement was found for all the concentrations described in Table 4.1 
(Appendix VI).  
 
Figure 4.7 shows a set of experimental and model data comparisons, using progress 
curves from Table 4.1 that were used to determine the kinetic parameters. Figure 4.7a 
specifically compares experimental ABT data points from different progress curves 
with the predicted model where excellent agreement was found.  Figure 4.7b focuses 
on the initial period until 60 min where, as described in Section 4.3.5, several key data 
points were collected.  
 
Figure 4.8 shows the experimental data points of MBA for the 3 reverse progress 
curves described in Table 4.1, where also excellent agreement was observed between 
the data and the model.  
 
To further test the kinetic model, Figure 4.9 shows the comparison of model predicted 
data with an extra set of experimental progress curve data, which was not included in 
Table 4.1 to establish the kinetic parameters. 
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Figure 4.7. Forward reaction experimental and predicted progress curves following (a) [ABT] 
for the complete length of the bioconversions and (b) [ABT] for the first 50 min of reaction time. 
The initial substrate concentrations for each progress curve was (●) 150 mM [ERY], 250 mM 
[MBA] and 0.3 mg mL-1 [TAm], (▲) 50 mM [ERY], 100 mM [MBA] and 0.3 mg mL-1 [TAm] and 
(■) 10 mM [ERY], 120 mM [MBA] and 0.3 mg mL-1 [TAm]. Dotted lines show model predictions 
based on Equation 4.1 and final kinetic parameters in Table 4.2. For all the experiments 0.2 mM 
PLP was used at 30oC and pH 7.5 in 200 mM HEPES buffer. Experiments were performed as 
described in Section 2.8.1. 
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Figure 4.8. Reverse reaction predicted and experimental progress curves following MBA with 
initial substrate concentrations of (○) 10 mM [AP], 120 mM [ABT] and 0.15 mg m L-1 [TAm] (Δ) 
20 mM [AP], 200 mM [ABT] and 0.44 mg mL-1 [TAm]  and (□) 40 mM [AP], 100 mM [ABT] and 
0.3 mg mL-1 [TAm]. For all the experiments 0.2 mM PLP was used at 30oC and pH 7.5 in 200 
mM HEPES buffer. Dotted lines show model predictions based on Equation 4.1 and final kinetic 
parameters in Table 4.2. Experiments were performed as described in Section 2.8.1. 
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Figure 4.9. Verification of model predictions with an experimental data set not included in the 
original experimental design. Progress curve following (●) MBA and (○) ABT . Initial [ERY] 
concentration was 250 mM and MBA was [40] mM, 0.2 mg mL-1 of TAm in whole cell form,  0.2 
mM PLP, 30oC and pH 7.5 in 200 mM HEPES. Dotted lines show model predictions based on 
Equation 4.1 and final kinetic parameters in Table 4.2. Experiments were performed as 
described in Section 2.8.1. 
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Excellent agreement was found between the experimental values and the model 
prediction for both the short and longer reaction time scale in Figure 4.7, as well as 
for the reverse reactions shown in Figure 4.8. In addition, perfect agreement was also 
found between the independent progress curve which was not used for determining 
the kinetic parameters and the model predictions, verifying the appropriate 
determination of the kinetic model (Equation 4.1) and its corresponding parameters 
(Table 4.2). 
  
 
4.4 DISCUSSION OF TAM KINETIC PARAMETER RESULTS 
 
4.4.1 Analysis of Michaelis-Menten constants 
 
 The Michaelis constant of ERY was 200 times bigger than the one for MBA, while 
the Michaelis constant of ABT was half compared to the one for AP.  In contrast to 
the reverse reaction, the kinetic parameters of the forward reaction did not follow the 
general trend where the Michaelis constant of each amino donor were higher than the 
corresponding amino acceptor (Henson & Cleland, 1964; Christen & Metzler, 1985; 
Shin & Kim, 1998; Lain-guelbenzu et al., 1991; Lo et al., 2005; Martin et al., 2007).  
 
The value of the Michaelis constant of KAP was determined to be two orders of 
magnitude higher than KMBA. This result was unexpected due to the similar chemical 
structures of both compounds containing an aromatic ring and would indicate that the 
amino group of MBA plays an important role for its high affinity towards the CV2025 
TAm. A similar low KMBA and higher KAP value was determined for the ω-TAm from 
Vibrio fluvialis (Shin & Kim, 2002) which shares 38% sequence identity towards the 
CV2025 TAm (Kaulmann et al., 2007). Interestingly, the opposite result was found 
for the ω-TAm from Bacillus thuringiensis, where the Michaelis constant for MBA 
and AP were two orders of magnitude higher and lower respectively than the ones 
determined in this work for the CV2025 TAm (Section 1.5.3.2) (Shin & Kim, 1998).  
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4.4.2 Analysis of equilibrium constants 
 
The uses of transaminases to synthesize chiral amines have been generally hampered 
by equilibrium constants near unity or constants which favours the ketone starting 
material (Taylor et al., 1998; Stewart, 2001; Truppo et al., 2010). For the conversions 
studied here however, the value of the partial equilibrium constants K1 and K2 for the 
first and second half reactions were 275 and 3.1 as determined by Equations 4.7 and 
4.8 respectively. The high value of K1 has also been suggested in literature for the 
synthesis of pyridoxamine 5´-phopsate using CV2025 TAm (Schell et al., 2009). The 
values of K1 and K2 lead to a global equilibrium constant of 842 following Equation 
4.9, which strongly favoured the asymmetric synthesis of ABT. 
  
In addition, the catalytic constant for the forward reaction was almost one order of 
magnitude higher than the constant for the reverse reaction. Similar differences in 
catalytic constants have been found for the  ω-TAm from B. thuringiensis to produce 
L-alanine from pyruvate and MBA (Shin & Kim, 1998), yet in general these results 
are not common among other TAms where kf and kr do not differ greatly (Henson & 
Cleland, 1964; Bulos & Handler, 1965; Christen & Metzler, 1985; Kuramitsu et al., 
1990; Hayashi et al., 1993; Taylor et al., 1998).  
 
4.4.3 Bottlenecks of the bioconversion 
 
4.4.3.1  Michaelis constant of ERY 
 
A number of bottlenecks need to be solved to reach the full potential of the CV2025 
TAm for the asymmetric synthesis of chiral amino alcohols. After evaluating the 
kinetic constants in Table 4.2, and performing a sensitivity analysis for each 
parameter (Appendix VII), it was found that one of the key obstacles to improve the 
amino-alcohol productivity was the high value of KERY of 96 mM. For similar 
reaction conditions, Michaelis constants for pyruvate were reported to be one order of 
magnitude smaller than KERY using the ω-TAm from V. fluvialis and B. thuringiensis 
(Shin & Kim, 1998; Shin, 2002). This result could be explained because the 
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previously mentioned enzymes, including the CV2025 TAm, belong to the β-
Ala:pyruvate transaminases containing a two pocket binding catalytic site, which 
appears to be evolved for the recognition of pyruvate through a carboxylate trap via a 
salt bridge and a hydrogen bond (Section 1.5.3.4) (Liu et al., 2004; Cho et al., 2008). 
Therefore those enzymes present less affinity towards α-ketoglutarate and even less 
affinity towards ketones which do not contain carboxylic groups (Shin & Kim, 2002; 
Kaulmann et al., 2007).  
 
The high value of KERY prevented the enzyme from reaching its full catalytic potential 
(maximum catalytic rate) at ERY concentrations below 200 mM (Figure 4.3). In 
contrast, the determined value of KMBA in this work was of 0.5, which was between 1 
to 2 orders of magnitude smaller compared to the reported KMBA constants for TAms 
of V. fluvialis, B. thuringiensis and Arthrobacter citreus (Shin & Kim, 1998; Shin & 
Kim, 2002; Martin et al., 2007). 
 
KMBA was found to be more than 200 times smaller than KERY, (Table 4.2), and 
therefore any increase of MBA above 2 mM did not predict to significantly increase 
the reaction rate and would even cause inhibition and enzyme deactivation (Figures 
4.3 and 4.5).  
 
4.4.3.2  Second half reaction 
 
The higher stability of the complex E-PLP-MBA compared to E-PMP-ERY was 
evidenced by the value of the dissociation constant KiMBA of 4.0×10-3 mM, which was 
3 orders of magnitude smaller compared to the value of KiERY of 1.0 mM. By 
analyzing the expressions of the parameters as rate constants in Table 4.2, it can be 
concluded that the higher values of KERY and KiERY compared to KMBA and KiMBA 
make the second half reaction the limiting step of the overall bioconversion. 
Mutagenesis improving this step would be very beneficial in improving the catalytic 
rate of the TAm synthesis of ABT. 
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4.4.3.3  Catalytic constant 
 
The value of the kinetic parameter kf, which is a function of the forward catalytic 
constant rates k3 and k7, was found to be 97.4 min-1, and as expected, had also a 
strong influence in the productivity of ABT as determined by the sensitivity analysis 
(Appendix VII). 
This value of kf was of the same order of magnitude as that reported for a similar ω-
TAm using MBA and pyruvate as substrates (Shin & Kim, 1998;  Shin & Kim, 2002), 
but it was found to be several orders of magnitude lower compared with other classes 
of TAms when used with natural substrates ex vivo (Kuramitsu et al., 1990; Markova 
et al., 2005).  
 
The simulations predicted that using a higher concentration of TAm would lead to 
significant improvements in the productivity of the bioconversion. Nevertheless as it 
has been shown in Figure 4.2, the region of linear proportionality between the initial 
rate and the enzyme concentration faded away after values higher than 0.8 mg mL-1. 
Therefore experimental progress curves using TAm concentrations above that limit 
did not correlated well with the predicted results (data not shown).  
 
The catalytic constant of TAm found in this work was 5 and 20 folds smaller than the 
published catalytic constants for TK D469T and the wild type (Chen et al., 2008, 
Chen et al., 2009). Those results should be taken in consideration when expression 
both enzymes in the biocatalyst in order to match their kinetics. 
 
4.4.3.4  Side reactions 
 
Using TAm concentrations above 1 mg mL-1 also lead to significant side reactions 
caused by the whole cells that consumed the substrates and products, affecting the 
final balance and overall quality of the asymmetric synthesis. One solution to 
overcome the side reactions is to use pure enzyme instead of whole cells, this has 
been shown in literature where concentrations one order of magnitude higher of the 
CV2025 TAm were used successfully without side reactions (Schell et al., 2009). 
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Another solution to overcome side reactions is to employ non natural ketodiols more 
stable than ERY like PKD (Scheme 3.2), which is a good target for bioconversion 
with similar catalytic activity compared to ERY as shown in Chapter 3 (Table 3.2), 
with the advantage of producing more stable amino alcohols (Smith et al., 2010). 
 
4.4.3.5  Product inhibition 
 
Product inhibition in the forward reaction was found to be not so severe compared to 
other similar ω-TAm bioconversions (Shin & Kim, 1998; Shin & Kim, 2002). In 
those works, some of the product inhibition constants were found to be one order of 
magnitude smaller than the value of KiAP and KiABT of 1.1 and 3.1 mM obtained in 
this work respectively (Table 4.2). A low product inhibition of AP and ABT was also 
suggested in literature using a TAm from Pseudomonas aeruginosa for the 
asymmetric synthesis of ABT (Ingram et al., 2007). 
 
 Non-linear fitting suggested that substrate inhibition proceeded through the formation 
of the dead end complex E-PMP-MBA, which is a common form of inhibition for 
enzymes that follow a ping pong kinetic mechanism (Segel, 1975). The dissociation 
constant KiMBAd of the abortive complex was found to be 24 mM (Table 4.2), which is 
similar to other values found in literature (Henson & Cleland, 1964; Lombardo et al., 
1989). Nevertheless it has been shown that this type of inhibition only becomes severe 
with values of dissociation constants one order of magnitude smaller than the value of 
KiMBAd (Shin & Kim 1998; Shin & Kim 2002). Although inclusion of the extra 
parameter KiMBAd was justified by performing an F-Test as well as other statistical 
analysis (see section 4.2 and 4.5), the sensitivity analysis showed that this inhibition 
would only become a major bottleneck with values of KiMBAc below ~5 mM 
(Appendix VII).  
 
4.4.3.6  Reverse reaction 
 
The reverse reaction catalytic constant kr and the Michaelis constants KABT and KAP 
were determined to be 12 min-1, 16 and 37 mM respectively. The sensitivity analysis 
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showed that those had a smaller impact in the modelling compared to the forward 
reaction constants. This is explained because the value of kr was determined to be 8 
times smaller compared to kf. In addition, the relatively high values of KABT and KAP, 
and the high equilibrium constant makes the reverse reaction almost negligible, as it 
can be seen in the low product yield of the reverse progress curves shown in Figure 
4.8. 
 
 
4.4.3.7  Toxicity of MBA towards TAm 
  
Several simulations predicted that high reaction yields of more than 95% should be 
obtained using high equimolar concentrations of substrates, with the condition that 
longer reactions times were used. However, the experimental data started to diverge 
gradually from the predicted model data after longer reaction times (data not shown), 
probably due to irreversible enzyme inactivation by MBA. As it was shown in Figure 
4.6, 10 % of the TAm was deactivated after being incubated for 35 hr with 50 mM 
MBA. This deactivation percentage was considered negligible for the purposes of 
determining the kinetic parameters using the methodology of Figure 4.1; but the 
deactivation may become more significant if longer residence times and also higher 
concentrations of MBA were used. 
 
TAm inactivation by the amino donor has also been reported in literature  (Yun et al., 
2004b), and in some cases whole cell TAm biocatalyst have been shown to maintain 
the TAm more stable versus the inactivation of the amino donor (Yun et al., 2004a), 
which is in agreement with the results found in Chapter 3. Further addition of PLP or 
TAm (individually) when the reaction stopped did not restore the catalytic activity. In 
contrast, addition of PLP and TAm (together) after the reaction stopped did restore 
partially the activity (data not shown), suggesting both enzyme and PLP were 
degraded after longer reaction times. 
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4.4.4 Optimum reaction conditions 
 
Taking into account all the previously discussed kinetic and stability results, it was 
identified that maintaining a high concentration of ERY (more than 250 mM) while 
minimizing the concentration of MBA proved to enhance the final yield of ABT. 
Figure 4.10 shows a simulated progress curve along with experimental verification for 
a reaction with 250 mM of ERY and 40 mM MBA with 0.4 mg mL-1 of TAm. In 
order to compare the effect of each substrate in the bioconversion, a set of 
experimental data and simulation is also shown using the inverse initial 
concentrations of 250 mM of MBA and 40 mM ERY, with the same concentration of 
TAm. 
 
Very good agreement was found in Figure 4.10 between the experimental and 
predicted data sets. The simulation that considered and excess of ERY predicted a 
99% conversion with respect to the limiting substrate MBA in 500 min corresponding 
to the maximum theoretical yield achievable for the reaction.  
 
In contrast when an excess of MBA was used a final yield of only 37 % mol/mol was 
predicted and obtained. Using the concentration of 250 mM MBA and 40 mM ERY, 
the model predicted a final 90% yield in 5500 min, which was one order of magnitude 
higher than using an excess of ERY. In addition, the experimental ABT yield using an 
excess of MBA did not increase after 500 min (data not shown), probably due to 
complete inactivation of the enzyme by the high concentration of MBA. Future work 
is been performed in applying a systematic statistical approach to determine with 
more details the optium reaction conditions using the determined kinetic model.  
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Figure 4.10. Experimental progress curves and simulations following TAm mediated synthesis 
of ABT using an initial concentration of (▲) 250 mM ERY and 40 mM MBA and (○) 250 mM 
MBA and 40 mM ERY. Dotted and dashed lines represent kinetic model predictions based on 
Equation 4.1 and the parameters listed in Table 4.2. TAm concentration was 0.4 mg mL-1 in 
whole cell form,  0.2 mM PLP, 30oC and pH 7.5 in 200 mM HEPES. Experiments were 
performed as described in Section 2.8.1. 
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4.5 SUMMARY 
 
A microscale standardized methodology was developed, in order to rapidly establish 
the kinetic parameters of a reversible TAm bioconversion, where the kinetic model 
was no fully elucidated, in order to optimize the reaction conditions (Figure 4.1).  
The hybrid procedure gave strong weight to both the initial rate data to identify a 
solution in the vicinity of the global minimum, and also to non linear regression 
methods to determine the exact location of the solution.  
 
The full reaction kinetic model with its corresponding parameters for the TAm 
mediated synthesis of ABT using whole cells was established (Equation 4.1 and Table 
4.2). The kinetic parameters were validated using 12 progress curves including 
reverse reaction data (Figure 4.7 and 4.8), as well as using a independent experimental 
data set not involved in the methodology to determine the parameters (Figure 4.9). 
 
The TAm reaction was found to be very suitable for the asymmetric synthesis of 
ABT, due to the high equilibrium constant of determined of 843 (Table 4.2).  
 
The main bottlenecks of the reaction were found to be the high Michaelis constant of 
ERY and the low catalytic constant of TAm (Figure 4.3), coupled with the high 
toxicity of the enzyme towards MBA. Therefore using a low concentration of MBA 
combined with a high concentration of ERY were considered to be the best reaction 
conditions, achieving more than 90 % yield in less than 10 hr (Figure 4.10).  
 
Chapter 5 was focused in scaling up the production of the biocatalyst, while rationally 
controlling the level of expression of TAm and TK, in order to match their kinetic 
characteristics as discussed in section 4.4.3.3. 
 
 
   
 
† The majority of the results presented in this Chapter were submitted for publication as: Rios-Solis L., P. 
Morris, A. Odeleye, P. A. Dalby, F. Baganz and G. J. Lye. Scale-up and enzyme expression tuning of an E. 
coli whole cell biocatalyst with a de novo engineered pathway. Biotechnol. Bioeng. Submitted.  
 
5. PRODUCTION OF THE DUAL TK-
TAM E. COLI BIOCATALYST AT 
LABORATORY AND PILOT SCALE † 
 
 
5.1. INTRODUCTION 
 
As discussed in Section 4.4.3.3, the activity of the whole cell TAm was a factor of 
approximately 20 to 5 times slower than TK for reactions converting both ERY and PKD 
respectively. An ideal E. coli biocatalyst expressing dual TK-TAm activities would need 
therefore high Tam expression while maintaining a TAm/TK ratio of 5- 20 in order for 
the overall conversion rates of the two steps to be as similar as possible. 
 
 A whole cell E. coli biocatalyst with such characteristics was constructed and 
successfully produced in shake flask fermentations (Section 3.3.3), achieving more than 
90% mol/mol yield for the one pot synthesis of amino alcohols (Section 3.3.5). 
In principle, multi-step enzymatic conversions in whole cell biocatalysts offer a unique 
opportunity for synthesis of complex chiral molecules (Santacoloma et al., 2011). 
However, this opportunity has rarely been exploited beyond research scale. This has been 
attributed in part to difficulties in scaling-up biocatalyst production while maintaining the 
appropriate enzymes expression levels and without lowering their operational 
productivity (Meyer et al., 2007).  
 
In general, the three main scales for fermentation process development are laboratory, 
pilot plant and production scales. Typical volumetric scale-up ratios between each stage 
are around 1:10, although lower ratios of about 1:5 have usually been applied 
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commercially to avoid unexpected performance on scale-up (Ju & Chase, 1992; Votruba 
& Sobotka, 1992). Factors which could affect biocatalyst performance upon scale-up 
include: mutation probability, plasmid stability and segregation, pellet formation, pH 
control agents interference, foam formation, enzyme stability, temperature and aeration 
gradients and sheer stress among many others (Young, 1979; Reisman, 1993; Humphrey, 
1998). Therefore, for industrial application, identification of key issues related to pilot 
plant scale performance is critical for efficient bioprocess development (Junker, 2004). 
 
5.2. AIM AND OBJETIVES 
 
The aim of this chapter is to scale-up the production of the dual TK-TAm E. coli 
biocatalyst from laboratory to small pilot plant scale whilst maintaining overall 
biocatalyst productivity. Suitable fermentation conditions will be identified and applied to 
small pilot scale fermentations, trying if possible to increase enzyme concentration while 
maintaining the desired TAm/TK ratio. The kinetic performance of the biocatalyst 
produced at laboratory and pilot scales will be compared. The key objectives of this 
chapter are thus:   
 
• Scale-up of the whole cell E. coli biocatalyst production from shake flask (100 mL) to 
laboratory (2 L) and small pilot scale (7.5 L) stirred tank fermentors. 
• Evaluation of cell growth kinetics and protein expression profiles at different 
temperatures and induction times. 
• Determination of the suitable cell growth conditions to obtain high TAm concentration 
while maintaining a suitable TAm/TK ratio. 
• Comparison of bioconversion kinetic performance of the dual E. coli biocatalyst 
produced at laboratory and pilot scale for the one pot synthesis of APD. 
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5.3. RESULTS 
 
5.3.1. 2 L fermentation with different temperatures and induction times 
 
The shake flask fermentations of E. coli cells double transformed with plasmids pQR801 
and pQR412 were previously shown to reach a final biomass concentration of 1.2 gDCW L-
1 (Figure 3.1), with final TAm and TK concentrations of 0.2 and 0.05 g L-1 respectively. 
In order to increase the total volume of the fermentation, and the overall amount of 
biocatalyst produced, the fermentation was initially scaled up to a 2 L stirred tank 
fermentor with a working volume of 1.4 L. The media was LB-glycerol as described in 
Table 2.1, and the pH, impeller speed and air flow were set to be 7.0, 1200 rpm and 1.4 L 
min-1 (1 vvm) respectively (Section 2.5.1). The biocatalyst used was the E. coli BL21-
Gold (DE3) cells expressing TK D469E and the CV2025 TAm due to its high activity 
and ee shown for the synthesis of APD (Sections 3.3.3). 
 
The co-expression level of several recombinant enzymes in a single E. coli host can be 
affected by many fermentation factors, such as temperature, media, pH and the time of 
induction among others (Tolia & Joshua-Tor, 2006). Therefore in this section, in addition 
to performing a 14-fold scale-up of the fermentation volume, the effects of temperature 
and time of induction (with 0.1 mM IPTG) were studied for the co-expression of the TK 
and TAm. Stirred tank bioreactors are more appropriate than shake flasks for such 
induction studies due to the improved environmental monitoring and control (Humphrey, 
1998). 
 
Figure 5.1 shows four growth profiles of the dual E. coli strain expressing the de novo TK 
and TAm pathway. Experiments were performed using fermentation temperatures of 
30oC and 37oC, with early and late exponential phase induction. Figure 5.2 shows the 
logged data of DOT, pH, temperature and impeller speed for the fermentations performed 
at 37oC. The temperature had the largest impact on cell growth rate and final biomass 
concentration. The cells grown at 37oC presented a specific growth rate of 0.57 and 0.54 
h-1, and reached a maximum biomass concentration of 6.6 and 6.8 gDCW L-1 for the early 
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and late induced fermentations respectively (Figure 5.1). The cells grown at 30oC had a 
specific growth rate of 0.35 and 0.30 h-1, while reaching an 11 and 14% higher biomass 
concentration than the fermentations at 37oC. The higher biomass obtained at 30oC could 
be attributed to the better solubility of O2 at lower temperature, as well to less toxic waste 
produced by the slower cell metabolism (Shiloach & Fass, 2005). In general the induction 
time did not have a significant effect in the growth of the cells at both temperatures. This 
suggests that the synthesis of the recombinant TAm was not a considerable metabolic 
burden for cell growth (Figure 5.1). The DOT profiles shown in Figure 5.2 suggest that 
upon early induction both cell growth and enzyme production continued whereas for late 
induction cell growth largely ceased upon IPTG addition.  
 
Figure 5.3 shows the corresponding profiles for production of TK and TAm for each of 
the four fermentations described in Figure 5.1. Table 5.1 summarizes the derived growth 
kinetics parameters and final enzyme concentrations measured in Figures 5.1 and 5.3. 
 
Even though a higher biomass concentration was achieved with the 30oC fermentations, 
the percentage of TAm expression was higher at 37oC, leading to similar final TAm 
concentrations of 1.3 and 1.25 g L-1 for the fermentations at 37 and 30oC with early 
induction respectively (Figure 5.3a and 5.3b). These TAm concentrations were 40 and 74 
% higher than the corresponding fermentations with late induction, highlighting the 
relevance of inducing in the early exponential phase to promote the TAm synthesis when 
the carbon source was still abundant. The final TAm concentration of 0.8 g L-1 obtained 
at 37oC with late induction contrasted with the concentration of 0.3 g L-1 at 30oC also 
with late induction (Figure 5.3c and 5.3d). This could be explained due to the temperature 
sensitive repressor used in plasmid pQR801 which was constructed using a PET vector 
(Section 2.3.2); it is well known that this system displays leaky protein expression at 
higher temperatures (Doublié, 2007). 
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Figure 5.1. Effect of temperature on batch growth profiles for 2 L fermentations of the double 
transformed E. coli BL21-Gold (DE3) cells with plasmids pQR412 and pQR801 constructed as 
described in Section 2.3.3 and 2.3.5. The temperature was set at 37 oC (▲) with TAm induction in the 
early exponential phase after 3.5 hr of growth and (●) with induction in the late exponential phase 
after 6hr, and at 30 oC (Δ) with induction in the early exponential phase after 5 hr and (○) induction 
in the late exponential phase after 11.5 hr. Fermentation conditions were pH 7.0, 1200 rpm and air 
flow of 1.4 L min-1 (Section 2.5.1). 
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Figure 5.2. Online measurements of pH (- -), temperature (•••) and DOT(−) for the fermentations 
shown in Figure 5.1 performed at (a) 37oC with early induction after 3.5 hr of growth and at (b) 30oC 
with late induction after 11.5 hr. Operating conditions as described in Figure 5.1. 
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Figure 5.3. Typical TK (●) and TAm (○) expression profiles for the 2 L fermentations shown in 
Figure 5.1 performed at 37 oC with (a) induction in the early exponential phase after 3.5 hr growth 
and (b) at 30oC with induction in the early exponential phase after 5hr, and at 37 oC with (c) 
induction in the late exponential phase after 6 hr and (d) at 30oC with induction in the late 
exponential phase after 11.5 hr. The concentration of each enzyme was calculated considering that 
50% of the total dry cell biomass of E. coli cells were proteins (Watson. 1972), and by obtaining the 
% of total protein of the corresponding enzyme by SDS-PAGE (Section 2.9.5). 
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Table 5.1. Growth and enzyme expression results for the dual E. coli biocatalyst produced in shake flasks, 2 L and 7.5 L fermentations as 
shown in Figures 3.1, 5.1 and 5.4 respectively. When available, the reported error represents one standard deviation of the mean (n=3). 
 
aResults from shake flask fermentations performed in Section 3.3. 
b Induction time refers to addition of  0.1 mM IPTG for expression of TAm  in the early or late exponential phase. 
c µ refers to the specific growth rate in h-1. 
dThe concentration of each enzyme was calculated considering that 50% of the total dry cell biomass of E. coli cells were proteins (Watson. 
1972), and by obtaining the % of total protein of the corresponding enzyme by SDS-PAGE (Section 2.9.5). 
 
Vessel  
volume 
(total) 
Temperature 
(oC) 
Induction 
timeb 
µc (h-1) 
Biomass  
(gDCW L-1) 
TK 
(%w/w)  
TAm  
(% w/w)  
[TK]d  
(g L-1) 
[TAm]d  
(g L-1)  
TAm/TK 
ratio 
100 mLa 37 Early 0.55±0.05 1.5±0.1 8.0±0.9 36.0±3.8 0.06±0.005 0.27±0.04 4.5 
2 L  37 Early 0.57 6.6 6.7 39.1 0.22 1.30 5.8 
2 L  37 Late 0.54 6.8 8.9 23.5 0.37 0.80 2.6 
2 L  30 Early 0.35 7.4 3.8 34.0 0.14 1.26 8.9 
2 L  30 Late 0.3 7.9 10.2 8.4 0.40 0.33 0.82 
7.5 L  37 Early 0.43±0.07 8. 5±0.5 7.2±1.0 39.0±3.0 0.31±0.05 1.7±0.1 5.5 
7.5 L 30 Late 0.36±0.04 9.5±0.4 9.5±0.4 7.6±0.5 0.45±0.03 0.36±0.03 0.80 
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In Section 3.3.3, it was found that the TK expression in shake flasks of the single 
transformed E. coli host with plasmid pQR412 represented 20% of total protein. This was 
higher than the TK expression levels summarized in Table 5.1, especially when the TAm 
expression was predominant (higher TAm/TK ratio). This implied that once induced, the 
high expression rate of TAm by the T7 RNA polymerase (Section 2.3.3) retarded TK 
expression which had a constitutive expression (Section 2.3.1). Following this reasoning, 
the fermentation at 30oC with late induction, which did not leak TAm expression, 
produced the highest TK concentration and lower TAm/TK ratio of 0.4 g L-1 and 0.8 
respectively (Figure 5.3d and Table 5.1). This “expression switch” phenomenon has been 
previously observed and applied to tune enzyme co-expression using PET vectors in E. 
coli hosts (De Marco & De Marco, 2004). 
 
As discussed in Section 4.3, a high TAm/TK ratio is desirable due to the slower 
bioconversion rate of TAm compared to TK. The fermentation at 30oC with early 
induction achieved the highest TAm/TK ratio of 8.9 compared to the value of 5.8 
obtained with the corresponding fermentation at 37oC. However, the high ratio at 30oC 
was achieved due to a 43% decrease in TK expression compared to the result at 37oC. 
This was not desirable for the one pot synthesis of amino alcohols, where a higher 
TAm/TK ratio is favourable at the expense of producing more TAm, but not at the 
expense of reducing the TK synthesis. Overall, not only was the TK expression higher at 
37oC with early induction, but also the TAm expression was higher, making the 
biocatalyst produced at 37oC with early induction the most suitable for the multi-step 
synthesis of amino alcohols.  
 
5.3.2. Scale-up to a 7.5 L fermentor  
 
In Section 5.3.1, it was concluded that the most suitable conditions to produce the dual 
TK-TAm whole cell E. coli biocatalyst for the synthesis of amino alcohols were at 37oC 
with early induction. This fermentation was therefore scaled-up to a 7.5 L fermentor with 
a working volume of 5 L. In order to verify the “expression switch” phenomenon 
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observed in Figure 5.3, the fermentation at 30oC with late induction (maximum TK 
concentration) was also scaled-up to the 7.5 L fermentor. 
The fermentation conditions where the same as Section 5.3.1, expect that the DOT was 
set to a minimum of 30% through a cascade control of the impeller speed (Section 2.5.2). 
Figure 5.4 shows the growth profile for the two 7.5 L fermentations. 
 
The fermentation at 37oC had a specific growth rate of 0.43 h-1 and a final biomass 
concentration of 8.5 gDCW L-1, which was 22 % higher than the corresponding 2 L 
fermentation (Table 5.1). The fermentation at 30oC presented a specific growth rate of 
0.36 h-1 and a final biomass concentration of 9.5 gDCW L-1, which was 17 % higher than 
the corresponding 2 L fermentation.  
 
These results were in agreement with the ones found in Section 5.3.1, where the 2 L 
fermentations at 30oC presented a lower specific growth rate but a higher final biomass 
compared to the fermentations at 37oC. The higher biomass achieved in the 7.5 L 
fermentor compared to the 2 L was attributed to better oxygen mass transfer in the larger 
fermentor, due to the higher level of DOT maintained.  
 
The protein expression concentration of TK and TAm were analyzed over different 
interval times. Figure 5.5 shows the SDS-PAGE result for different interval samples of 
the fermentation performed at 37oC with an early induction after 3 hr. A clear increase of 
TAm and a decrease in TK expression can be observed in the corresponding protein 
bands after the induction. The expression results have been plotted in Figure 5.6 for both 
fermentations. 
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Figure 5.4. Growth profiles for 7.5 L fermentations of the double transformed E. coli BL21-Gold 
(DE3) cells with plasmids pQR412 and pQR801. The temperature was set at 37 oC (○) with induction 
in the early exponential phase after 3 hr growth, and at 30 oC (●) with induction in the late 
exponential phase after 11.5 hr of growth. Fermentation conditions were pH 7.0, DOT set to 30% 
through impeller speed and air flow of 5 L min-1 (Section 2.5.2). Error bars represent one standard 
deviation about the mean (n=3). 
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Figure 5.5.  SDS-PAGE gel of cellular extracts of the 7.5 L fermentation at 37 oC with induction in 
the early exponential phase after 3 hr growth shown in Figure 5.4.  Bands 1 and 10 are protein 
markers. Bands 2 to 9 are cellular extracts at different interval times of the fermentation. TK and 
TAm molecular weight are 72 kDa and 51 KDa respectively.  SDS-PAGE gel was prepared as 
described in Section 2.9.5. 
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Figure 5.6. TK (●) and TAm (○) expression profiles for the 7.5 L fermentations shown in Figure 5.4 
performed at (a) 37 oC with induction in the early exponential phase after 3 hr growth and at (b) 30 
oC with induction in the late exponential phase after 11.5 hr. The concentration of each enzyme was 
calculated as described in Figure 5.3. 
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The kinetic growth results and final enzyme concentrations of the 7.5 L fermentations of 
Figure 5.4 are summarized and compared with the 2 L (Section 5.3.1) and shake flask 
fermentation results (Section 3.3.3) in Table 5.1 shown in Section 5.3.1. The level of 
expression of TK and TAm were similar than those achieved in the shake flask and 2 L 
fermentor, demonstrating the successful scale-up while maintaining the desired TK-TAm 
expression profile. 
 
The final concentrations of TK and TAm for the fermentation at 37oC with early 
induction were 5 and 6 folds greater than the shake flask fermentations, and 29 and 24% 
higher than the corresponding concentrations for the 2 L fermentation (Table 5.1). For the 
fermentation at 30oC with late induction, the TK and TAm concentrations were 11 and 
17% higher than those using the 2 L fermentor.  
 
5.3.3. Comparison of single and dual enzyme expression levels  
 
In the previous Sections the simultaneous expression of TK and TAm enzymes in the 
duel E. coli strain was studied. In addition a series of fermentations were also performed 
under similar conditions where the expression of TAm was evaluated. The results of 
these fermentations are included in Appendix VIII. 
 
In general it was found that conditions for the optimum independent TAm expression 
were the same as in the dual enzyme expressing strain, obtaining a total protein 
expression of up to 40%. 
 
5.3.4. Kinetic comparison of the laboratory and pilot scale biocatalyst 
 
As illustrated in Table 5.1, the production of the dual TK-TAm E. coli biocatalyst was 
successfully scaled-up 50-fold from sake flask to a small pilot scale (7.5 L) stirred tank 
fermentor. High levels of both TK and TAm expression were achieved while maintaining 
a desired TAm/TK ratio greater than 5. Nevertheless it was important to verify the 
bioconversion kinetics of the biocatalyst produced, as these could have been impacted on 
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by enzyme stability issues or whole cell integrity problems, which may have arisen 
during the scale-up process (Junker, 2004). Gradients of temperature and oxygen, shear 
stress by the impeller and higher mutations probability due to longer fermentations times 
among other causes could have also affect the quality of the biocatalyst (Reisman, 1993; 
Humphrey, 1998).   
 
In order to compare the bioconversion kinetic performance of the dual TK-TAm E. coli 
biocatalyst produced at different scales, two microscale one pot syntheses of APD were 
performed using both biocatalysts as described in Section 2.8.1.  
 
The initial concentration of substrates was 10 mM of PA and HPA, while the cofactors 
concentrations were 2.4 mM of TTP, 9 mM Mg2+ and 0.2 mM of PLP in 200 mM HEPES 
buffer.  
 
As has been shown in Section 3.3.5, the TK substrate HPA can be aminated by the  TAm 
using MBA, producing serine as a side product and therefore consuming HPA and MBA 
in an undesirable reaction. To overcome these lose of substrates, the amino donor MBA 
was subsequently added in the multi-step synthesis after the TK reaction was completed. 
A stock solution of 300 mM of the amino donor was prepared to be added to the TK-
TAm bioconversions. Therefore the volume added of the MBA solution represented only 
3% of the original reaction volume, consequently the dilution of substrates and products 
was considered negligible. 
 
The biocatalyst produced in the laboratory and pilot scale fermentor had slightly different 
expression of TK and TAm, which represented 8 and 37% of the total protein for TK and 
TAm in the shake flask fermentation, compared to 7 and 39 % of for the 7.5 L fermentor 
(Table 5.1). A fixed concentration of 0.4 mg mL-1 of TAm was used in both 
bioconversions. Considering than 50% of the total dry cell biomass of E. coli cells were 
proteins (Watson. 1972), then a final concentration of cell biomass of 2.2 and 2.1 gDCW L-
1 was used of the laboratory and pilot scale biocatalyst respectively. By fixing the TAm 
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concentration, the TK concentration varied slightly from the two bioconversions, with 
values of 0.085 and 0.07 mg mL-1 for the smaller and larger scale biocatalysts.   
 
Figure 5.7 shows the experimental progress curves for the TK reaction step of the one pot 
synthesis of APD using both the shake flasks and 7.5 L fermentor biocatalysts. Excellent 
agreement was found between the experimental data, where the conversion was only 
marginally faster using the shake flask biocatalyst as expected due to its higher 
concentration of TK. The TK initial activities were found to be 1.16 and 1.11 µmol min-1 
mg-1 for the biocatalysts produced in the smaller and larger scale fermentations 
respectively, showing that the TK activity was not affected during the scale-up process. 
After 7 hours of reaction, final conversions of PKD of 97 and 96 % mol/mol were 
achieved and no HPA was detected, therefore MBA was added to start the TAm 
bioconversion. 
 
Figure 5.8 shows the continuation of the progress curves shown in Figure 5.7 for the 
TAm step in the one pot synthesis of APD, using the laboratory and pilot scale 
biocatalysts. Again excellent agreement was observed between the TAm experimental 
data, which presented a specific activity of 9.6×10-3 and 9.2×10-3 µmol min-1 mg-1, and a 
final conversion of 93 and 92% mol/mol for the laboratory and pilot scale biocatalysts 
respectively. Those results showed that the activity of TAm was also not affected during 
the scale-up process.  
 
Tables 5.2 summarize the kinetic results of both bioconversions. Similar activities and 
final yields of the TK and TAm bioconversions were found for both biocatalysts. This 
demonstrated that the enzyme stability and kinetic characteristics of the TK-TAm 
biocatalysts were not affected during the scale-up process. 
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Figure 5.7. Bioconversion kinetics comparison of the dual TK-TAm expressing E. coli BL21-Gold 
(DE3) cells produced at shake flask and 7.5 L fermentor scales. Figure shows TK bioconversion step 
kinetics in the one pot synthesis of APD following: (■) PKD and (▼) HPA using the laboratory scale 
biocatalyst, and (□) PKD, and HPA (Δ) using the pilot scale biocatalyst.  Reaction conditions: 10 mM 
[HPA] and [PA], 0.2 mM [PLP], 2.4 mM [TTP], 9 mM [Mg2+], 30 oC, pH 7.5 in 200 mM HEPES. 
[TK] was 8.6×10-2 and 7.2×10-2 mg mL-1 for the laboratory and pilot scale biocatalyst respectively. 
[TAm] was 0.4 mg mL-1 for both whole cell biocatalysts. The microscale bioconversions were 
performed as described in Section 2.8.1.  Error bars represent one standard deviation about the 
mean (n=3).   
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Figure 5.8. Continuation of the one pot synthesis profiles shown in Figure 5.4 using a TK-TAm 
shake flask and 7.5 L biocatalyst showing the TAm bioconversion step after addition of MBA 
following: (●) APD and (▲) PKD using the laboratory scale biocatalyst, and (Δ) APD, and PKD (○) 
using the pilot scale biocatalyst. Reaction conditions: 10 mM [HPA] and [PA], 0.2 mM [PLP], 2.4 
mM [TTP], 9 mM [Mg2+], 30 oC,  pH 7.5 in 200 mM HEPES,.  [TK] was 8.6×10-2 and 7.2×10-2 mg mL-
1 for the laboratory and pilot scale biocatalyst respectively. [TAm] was 0.4 mg mL-1 for both whole 
cell biocatalysts. The microscale bioconversions were performed as described in Section 2.8.1.  Error 
bars represent one standard deviation about the mean (n=3).   
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Table 5.2. Bioconversion kinetics comparison of the one pot APD synthesis shown in Figures 5.6 
and 5.7 using biocatalyst produced at shake flask (Section 3.3.3) and 7.5 L fermentor (Section 5.3.1.2) 
scales. Microscale bioconversions and the calculation of the kinetic results were performed as 
described in Section 2.8.1. 
 
Biocatalyst production scale Laboratory Pilot scale 
Biomass concentration 
(gDCW L-1) 
2.2 2.1 
TK concentration 
(mg mL-1) 
0.086  ± 0.007 0.072 ± 0.009 
TK Initial rate 
(mM min-1) 
0.10 ± 0.01 0.08 ± 0.009 
TK initial specific activity 
(µmol min-1 mg-1) 
1.2 ±0.1 1.1 ±0.1 
TAm concentration  
(mg mL-1) 
0.4 ± 0.05 0.4±0.02 
TAm initial rate 
(mM min-1) 
0.038 ±  0.003 0.037 ± 0.003 
TAm initial specific activity   
(µmol min-1 mg-1) 
0.096 ± 0.014  0.092 ±0.009  
Final APD conversion  
(% mol) 
93 ± 6 92 ± 7 
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5.4. SUMMARY 
 
In summary, an overall scale-up of 50-fold for the production of the dual TK-TAm E. coli 
biocatalyst was performed from shake flasks to a 2 L and then a 7.5 L stirred tank 
fermentors. The growth kinetics and protein expression profiles at different temperatures 
and induction times were also investigated (Figures 5.1 and 5.3). The best fermentation 
conditions were determined to be 37oC with an early exponential phase induction, where 
the TAm expression was highest (Figure 5.4 and 5.6a). Under those conditions, a 6 fold 
increase in TK and TAm concentrations were obtained respectively in comparison with 
the shake flask fermentations, while a suitable TAm/TK ratio of 5 was maintained (Table 
5.1). 
 
When used for the one pot synthesis of  APD, the bioconversion kinetics of the pilot scale 
biocatalyst were in excellent agreement with the biocatalyst initially produced at shake 
flask scale (Figure 5.7 and 5.8). This clearly demonstrates that no lose in either TK or 
TAm activity occurred during the scale-up process. In the following Chapter, the scale-up 
of the TK-TAm one pot synthesis will be evaluated, as well as the complete kinetic 
modelling of the de novo engineered pathway for preparative scale bioconversions.  
 
 
  
 
 
† The majority of the results presented in this Chapter will be submitted for publication as: Rios-Solis 
L., P. Morris, A. Odeleye, P. A. Dalby, F. Baganz, and G. J. Lye. Scale-up and modelling of de novo 
pathway for the synthesis of chiral amino alcohols. In preparation. 
 
6.  SCALE-UP AND MODELLING OF 
THE  DE NOVO ONE-POT 
SYNTHESIS OF AMINO ALCOHOLS† 
 
 
6.1. INTRODUCTION 
 
A defining feature of the microscale bioprocesses studies, like the ones performed in 
Chapter 3 and 4, is to inform early stage bioprocess design and to aid predictions of 
larger scales of operation (Lye et al., 2003; Micheletti & Lye, 2006). However, the 
scale-up of in vivo de novo multi-enzymatic syntheses and the validation of the 
corresponding microscale data have been poorly explored to date. In part because 
such systems are difficulty to assemble and model accurately (Meyer et al., 2007).  
 
Microscale, preparative and process scale bioreactors can present differences in fluid 
dynamics, solvent evaporation, shear stress, mass and heat transfer phenomena, and 
the methods used for pH control. These can cause significant and often unpredictable 
discrepancies in the bioconversion behaviour at the different scales (Doig et al., 
2002; Micheletti et al., 2006; Nealon et al., 2006; Matosevic et al., 2008).  
 
Therefore the detection of the main complications in the scale-up of the multi-step 
synthesis is crucial for adequate bioprocess design and implementation (Pollard & 
Woodley, 2007). Once the direct scale-up of the bioconversion can be guaranteed, 
mathematical microscale models could be used to predict larger scale synthesis. Such 
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models can then be applied  in order to evaluate different bioconversion scenarios, 
and to select the best operating conditions and reactor configurations (Sin et al., 
2009; Santacoloma et al., 2011). 
 
6.2. AIM AND OBJECTIVES 
 
The aim of this Chapter is to scale-up and model the one-pot synthesis of amino 
alcohols using the de novo engineering whole cell E. coli biocatalyst. In order to do 
so, the methodology developed in Chapter 4 will be used to establish microscale 
kinetic models of the synthesis of PKD and APD using the TK D469E and the 
CV2025 TAm. Subsequently, the microscale TK-TAm multi-step bioconversions of 
amino alcohols ABT and APD will be scaled-up to preparative synthesis. The models 
developed using the microscale tools will be then validated for the larger scale 
syntheses. Finally, using the model predictions, the best bioconversion operating 
strategies and reactor configuration will be determined and applied. The key 
objectives of this chapter are thus: 
 
• Determination of the kinetic models for the TK D469E and CV2025 TAm 
mediated synthesis of PKD and APD respectively.  
• Scale-up of the one-pot syntheses of APD and ABT from micro to 
preparative scale. 
•  Kinetic modelling of the TK-TAm one-pot syntheses and validation of the 
kinetic parameters by comparing the experimental and predicted data at the 
different scales. 
• Identification of the best bioconversion conditions and reactor configurations 
using the predictions of the mathematical models. 
• Application of the best reaction conditions to optimize the preparative scale 
one-pot syntheses of APD and ABT. 
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6.3. RESULTS 
 
6.3.1. Determination of kinetic parameters  
 
In Chapter 3, using microscale experimentation, the E. coli wild type TK and the 
CV2025 TAm were found to be the best candidates for the one-pot synthesis of ABT, 
while the mutant TK D469E combined with the CV2025 TAm were selected for the 
synthesis of APD (Figure 3.7 and 3.8). The kinetic parameters of the TK synthesis of 
ERY, from GA and HPA, have been reported previously (Gyamerah & Willetts, 
1997; Chen et al., 2009), while the full kinetic model of the TAm mediated synthesis 
of ABT was established in Chapter 4 (Equation 4.1 and Table 4.2).  
 
In contrast the kinetic parameters for the TK D469E catalyzed synthesis of PKD and 
the subsequent CV2025 TAm mediated synthesis of APD were still unknown. Hence 
these kinetic parameters were rapidly determined here following the systematic 
procedure summarized in Figure 4.1. Sections 6.3.1.1 and 6.3.1.2 will focus on the 
results obtained for the kinetic models, which will be applied in Section 6.3.2 to 
model the full one-pot synthesis of APD. For more details about the complete set of 
progress curves used to determine the parameters, and its modelling predictions, refer 
to Appendix IX and X. 
 
6.3.1.1. Kinetic model of the E. coli D469E TK mediated synthesis of PKD  
 
The synthesis of PKD catalyzed by the TK D469E in whole cell form from HPA and 
PA is an irreversible reaction due to the release of CO2 as a side product (Scheme 
3.2). The bioconversion follows a previously elucidated ping-pong bi-bi mechanism 
with competitive substrate inhibition, which requires thiamine pyrophosphate and 
Mg2+ as cofactors as was described in Section 1.5.2.3 (Gyamerah & Willetts, 1997; 
Chen et al., 2008). The full kinetic model can be written as follows in Equation 6.1: 
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where kcat represents the catalytic rate constant, KPA and KHPA are the Michaelis 
constants of PA and HPA, KiPA, KiHPA and KiPKD are the inhibition constants of PA, 
HPA and PKD respectively, and EiTK is the TK enzyme concentration.  
 
Following the methodology illustrated in Figure 4.1, the values of the kinetic 
parameters were determined here and are summarized in Table 6.1. Figure 6.1 shows 
the resulting Michaelis-Menten plots, as well as two progress curves used to validate 
the kinetic parameters. (Refer to Appendix IX for the complete experimental 
progress curves used to determine the kinetic parameters as well as their modelling 
predictions). 
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Figure 6.1. (a) Apparent initial rate of PKD formation using TK D469E as a function of [PA] 
while maintaining [HPA] fixed at 30 mM, and (b) as a function of [HPA] while maintaining [PA] 
fixed at 100 mM.  For the experiments (a) and (b) [TK] concentration was 0.15 mg mL-1 in 
whole cell form. Experiments (c) and (d) represent typical TK experimental progress curves and 
model predictions using an initial concentration of (c) 10 mM [PA] and [HPA] and 0.1 mg mL-1 
[TK] and (d) 100 mM [PA] and [HPA] and 0.4 mg mL-1 [TK] following (●) HPA and (▲) PKD. 
Dotted lines show model predictions based on Equation 6.1 and final kinetic parameters in 
Table 6.1. For all the experiments TK biocatalyst was used in whole cell form with 2.4 mM 
[TPP] and 9 mM [Mg2+] at 30oC and pH 7.5 in 50 mM TRIS buffer using microscale 
experimentation (Section 2.8.1).  
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Table 6.1. Experimental values of the apparent kinetic parameters of Equation 6.1 for the 
synthesis of PKD catalyzed by a whole cell E. coli biocatalysts containing the TK mutant D469E. 
Parameters were obtained following the methodology summarized in Figure 4.1 using 
microscale experimentation (Section 2.8.1).  
 
Apparent kinetic parameter Value 
Rate constant: kcat (min−1) 642.3 
Michaelis constant for HPA: KHPA (mM) 5.3 
Michaelis constant for PA: KPA (mM) 47.4 
Inhibition constant for HPA: KiHPA (mM) 86.7 
Inhibition constant for PA: KiPA (mM) 542.2 
Inhibition constant for PKD: KiPKD (mM) 886.9 
  
 
 
The catalytic constant in Table 6.1 was found to be similar to the previously 
published value for the synthesis of PKD using E. coli TK mutant  D469T in lysate 
form (Chen et al., 2008). It is important to mention that the kinetic parameters of TK 
D469E in this work were determined at 30oC, while the authors used a temperature 
of 25oC. Therefore, it could be assumed that at the same temperature, the TK D469T 
would have a higher catalytic rate constant. Interestingly, both Michaelis constants 
found in this work are half the value than the ones published for TK D469T. 
 
 
6.3.1.2. Kinetic model of the CV 20205 TAm mediated synthesis of APD 
 
Following the systematic approach developed in Chapter 4, the kinetic model for the 
TAm mediated synthesis of APD was elucidated and is represented by Equation 6.2. 
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where kf and kr represents the catalytic rate constants for the forward and reverse 
reaction respectively, KPKD, KAP, KAPD and KMBA are the Michaelis constants of PKD, 
AP, APD  and MBA, KiAPD and KiMBA are the inhibition constants of APD and MBA 
respectively, EiTAm represents the TAm concentration and Keq is the equilibrium 
constant.  
 
The kinetic parameters were determined following the procedure represented in 
Figure 4.1, and their values are summarized in Table 6.2. Figure 6.2 shows the 
resulting Michaelis-Menten plots, as well as two progress curves used to validate the 
kinetic parameters. (Refer to Appendix X for the complete experimental progress 
curves used to determine the kinetic parameters as well as their modelling 
predictions) 
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Figure 6.2. (a) Apparent TAm initial rate of AP for the forward reaction as a function of (○) 
[MBA] while maintaining [PKD] fixed at 100 mM, and as a function of (Δ) [PKD] while 
maintaining [MBA] fixed at 10 mM. b) Apparent TAm initial rate of MBA for the reverse 
reaction as a function of (○) [AP] while maintaining [APD] fixed at 100 mM, and as a function of 
(Δ) [APD] while maintaining [AP] fixed at 35 mM. For the experiments (a) and (b) [TAm] 
concentration was 0.3 mg mL-1 in whole cell form. Experiments (c) and (d) represent typical 
experimental TAm progress curves and model predictions using an initial concentration of (c) 
20 mM [PKD] and  10 mM [MBA] and 0.2 mg mL-1 [TAm] and (b) 100 mM [PKD] and 50 mM 
[MBA] and 0.3 mg mL-1 [TAm] following (●) PKD and (▲) MBA. Dotted lines show model 
predictions based on Equation 6.2 and final kinetic parameters in Table 6.2. For all the 
experiments TAm biocatalyst was used in whole cell form with 0.2 mM [PLP] at 30oC and pH 
7.5 in 200 mM HEPES buffer using microscale experimentation (Section 2.8.1).  
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Table 6.2.  Experimental values of the apparent kinetic parameters of Equation 6.2 for the 
synthesis of APD catalyzed by a whole cell E. coli biocatalyst containing the CV2025 TAm. The 
parameters were obtained following the methodology summarized in Figure 4.1 and using 
microscale experimentation (Section 2.8.1). 
 
Apparent kinetic parameter Value 
Forward rate constant: kf (min−1) 37.1 
Reverse rate constant :kr (min−1) 1.9 
Michaelis constant for MBA: KMBA (mM) 1.2 
Michaelis constant for PKD: KPKD (mM) 20.4 
Michaelis constant for AP : KAP (mM) 17.6 
Michaelis constant for APD : KAPD (mM) 23.3 
Inhibition constant for MBA: KiMBA (mM) 0.05 
Inhibition constant for APD: KiPA (mM) 5.3 
Equilibrium constant  6407 
 
The forward catalytic rate constant for the TAm mediated synthesis of PKD was 3-
fold smaller than the one for the synthesis of ERY (Table 4.2).  In contrast, the 
Michaelis constant of PKD was 5 times smaller than the one for ERY, while the rest 
of the constants were in the same order of magnitude as the determined for ERY 
(Table 4.2 and 6.2). These results indicate that using the same enzyme concentration, 
the conversion rate of ERY by TAm to ABT would relatively faster than the one of 
PKD to APD at concentrations above 200 mM. Nevertheless, at concentration below 
30 mM, the low Michaelis-Menten constant of PKD compared to ERY would 
compensate the higher catalytic constant for ERY, giving comparable reaction rates 
for both amino acceptors. 
 
 
6.3.2. Scale-up and modelling of the one-pot synthesis of APD 
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The one-pot synthesis of APD (Scheme 3.2) was scaled-up from 300 µL parallel 
microwell bioreactors (Section 2.8.1) to a 50 mL working volume laboratory scale 
stirred bioreactor (Section 2.8.2). This represented a 167-fold increase in volume. 
Table 6.3 compares the different conditions and bioreactors used for the micro and 
preparative scale multi-step synthesis.  
 
Table 6.3. Comparison of the different reaction conditions and bioreactors used for the scale-
up of the multi-step syntheses from microscale parallel bioreactors (Section 2.8.1) to preparative 
scale synthesis (Section 2.8.2).   
 
Bioconversion scale Microscale Preparative scale 
Temperature (oC) 30 30 
Temperature control 
Under plate heated 
platform 
Circulating water 
bath 
Mixing (rpm) 300 300 
Mixing device 
Orbital Shaking platform 
(diameter= 6 mm) 
Magnetic stirrer 
Working reaction 
volume 
300 µL 50 mL 
Reactor vessel 
550 µL micro reactors  
(96 glass microplate) 
100 mL glass stirred 
bioreactor 
pH 7.5 7.5 
pH control 200 mM HEPES buffer 
pH stat  with  1M 
NaOH (aq) 
   
 
The pH of the preparative scale bioconversion was maintained at 7.5 by the use of 
automated pH stat addition of 1 M NaOH in comparison to 200 mM HEPES buffer 
used in the microscale system (Table 6.3). The TAm was shown to be more stable in 
whole cell form than in lysates (Section 3.3.6), therefore 25 mM HEPES were added 
to the larger scale bioconversion in order to avoid cell lysis by difference in osmotic 
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pressure. The temperature was kept constant at 30oC using a circulating water bath in 
contrast to an “under plate” heated platform used for the microscale experiments 
(Section 2.8.1 and 2.8.2).  
 
In the case of mixing, previous results reported an increase in transfer rates of 
substrates for TK bioconversions in the µL scale compared to the mL scale, causing 
differences up to 40% in the scale-up process (Matosevic et al., 2008). In order to 
overcome this problem, the authors demonstrated that using a magnetic stirrer at 300 
rpm reduced the discrepancies between the larger and small scale results. This 
mixing system was then chosen for the lab bench vessel in comparison with the 
orbital shaking platform used for the microscale experiments (Section 2.8.1 and 
2.8.2). 
 
For the one-pot synthesis of APD, the microscale bioconversion results obtained in 
Section 5.3.3 using a shake flask biocatalyst, were used as a reference to compare the 
scale-up process (Figure 5.6 and 5.7). For the preparative scale synthesis, the TK-
TAm biocatalyst produced at the small pilot plant scale using the 7.5 L fermentor 
(Section 5.3.2) was applied to perform the bioconversion. The concentration of TAm 
was also fixed at 0.4 mg mL-1; therefore the biomass and the TK concentration were 
2.1 gDCW L-1 and 0.07 mg mL-1 (Table 5.2).  
 
The initial concentration of substrates PA and HPA were 10 mM, and MBA was 
added after 7 hours of starting the bioconversion, the same was for the microscale 
synthesis described in Section 5.3.3. 
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Figure 6.3. Scale-up and modelling of the whole cell E. coli TK-TAm sequential synthesis of 
APD following: (□) HPA, (○) PKD and (Δ) APD using microscale experimentation (data was 
obtained from Section 5.3.3), and (■) HPA, (●) PKD and (▲) APD for the preparative scale 
synthesis (Section 2.8.2). Reaction conditions: 10 mM [HPA] and [PA], 0.2 mM [PLP], 2.4 mM 
[TTP], 9 mM [Mg2+], 30 oC,  pH 7.5 in 200 mM HEPES. 10 mM MBA was added after 420 min.  
[TK] and [TAm] were 0.07 and 0.4 mg mL-1 respectively for both whole cell biocatalysts. The 
modelling was performed combining Equations 6.1 and 6.2 with the corresponding kinetic 
parameters from Table 6.1 and 6.2 and is shown as a solid line.  Error bars represent one 
standard deviation about the mean (n=3).   
 
 
 
Chapter 6: Scale-up and Modeling of the One-pot Synthesis 
 
 
 
 
190 
 
     
 
  
Figure 6.3 shows the complete experimental progress curves of the micro and 
preparative scale bioconversions. Combining equations 6.1 and 6.2, the complete 
modelling of the one-pot synthesis was also achieved in Figure 6.3. 
 
The microscale results scaled excellently as shown in Figure 6.3, resulting in very 
similar kinetic profiles after a 166-fold scale-up. The experimental kinetic results 
from the different scales and the kinetic model predictions are shown in Table 6.4. 
 
Table 6.4. Experimental and predicted apparent kinetic results for the one-pot synthesis of APD 
shown in Figure 6.3 using microscale experimentation (Section 3.8.1) and a preparative scale 
bioreactor (Section 3.8.2). The predicted data was obtained using Equations 6.1 and 6.2 with the 
kinetic parameters from Table 6.1 and 6.2. The calculation of the kinetic experimental results 
was performed as described in Section 2.8.1. 
 
Apparent kinetic parameter Model prediction 
Microscale 
data 
Preparative 
scale data 
E. coli D469E TK initial 
specific activity 1.1 1.3 ± 0.2 1.2 ± 0.2 
(µmol min-1 mg-1) 
CV2025 TAm initial specific 
activity 0.12 0.1 ± 0.01 0.1 ± 0.02 
(µmol min-1 mg-1) 
Final APD yield 
(% mol/mol) 98 93 ±6 85 ± 6.5 
 
The difference in TK and TAm specific activities of both scales were statistically not 
significant (Table 6.4). This indicates that the biocatalyst did not lose activity in the 
scale-up process, and also that the preparative scale synthesis did not suffer greater 
mass transfer limitations compared to the microscale bioconversion. 
 
Excellent agreement was found between the predicted specific activities and the 
experimental data (Table 6.4), which shows that the mathematical models developed 
in Section 6.3.1 using microscale data were still valid for preparative scale multi-step 
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syntheses. After 1500 min of bioconversion, a small difference could be observed 
between the predicted and experimental data, which was higher than the 
experimental error, especially for the preparative scale synthesis. This discrepancy 
could also be detected in the maximum final yield (% mol/mol) of the large scale 
bioconversion which was 13 and 7% smaller than the predicted and microscale yield. 
Because the predicted initial specific activities were in agreement with the 
experimental results of both scales (Table 6.3), and the discrepancies only appeared 
after 1500 min of reaction time, the difference in the final conversion was attributed 
to a decrease in stability of TAm, probably caused by the toxicity of MBA as was 
discussed in Section 4.4.3.7. Also the stirring of the 100 mL bioreactor may have 
caused lysis of the cells, further reducing the stability of the TAm as was shown in 
Section 3.3.6. In addition, although APD was a non natural substrate, consumption of 
APD by the whole cells could also contribute to the difference in final yields, as it 
has previously been previously shown for similar amino alcohols (Ingram et al., 
2007). 
 
An individual TK synthesis of PKD had been successfully scaled-up in a previous 
work (Smith et al., 2010) obtaining a maximum difference between predicted and 
experimental data of 30%, which was 2-fold higher than the differences found in this 
work (Figure 6.3). A previous work scaling up a TAm bioconversion from the µL to 
mL scale reported a 30% difference in the final yield (% mol/mol), mainly due to pH 
fluctuations in the small scale system (Truppo et al., 2009). The use of 200 mM 
HEPES here enabled to maintain the pH of the microscale bioconversion constant, 
improving the agreement of the results towards the larger scale synthesis.  
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6.3.3. Scale-up and modelling of the one-pot synthesis of ABT 
 
To be able to model the TK-TAm one-pot synthesis of ABT (Scheme 3.1), the 
kinetic models of the E. coli wild type TK and CV2025 TAm mediated synthesis of 
ERY and ABT respectively were necessary. The required TAm model was 
established in Chapter 4 and is represented by Equation 4.1 with the kinetic 
parameters from Table 4.2. The TK model previously mentioned had been published 
before (Gyamerah & Willetts, 1997; Chen et al., 2009), and is represented by 
Equation 6.3 with the corresponding parameters shown in Table 6.5.  
 
 
 
 
 
 
where kcat represents the catalytic rate constant, KGA and KHPA are the Michaelis 
constants of GA and HPA, KiGA, KiHPA and KiERY are the inhibition constants of GA, 
HPA and ERY respectively, and EiTK is the TK enzyme concentration. 
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Table 6.5. Reported values by Chen et al., (2009) for the kinetic parameters of Equation 6.3 for 
the synthesis of ERY catalyzed by E. coli wild type TK. The parameters reported by the authors 
were obtained at 25oC and pH 7 using TK in lysate form. 
 
Apparent kinetic parameter Value 
Rate constant: kcat (min−1) 2442 
Michaelis constant for HPA: KHPA (mM) 18 
Michaelis constant for GA: KGA (mM) 16 
Inhibition constant for HPA: KiHPA (mM) 40 
Inhibition constant for GA: KiGA (mM) 570 
Inhibition constant for ERY: KiERY (mM) 536 
  
 
A 167-fold scale-up of the one-pot synthesis of ABT was performed, from 300 µL 
parallel micro reactors (Section 2.8.1) to a 50 mL working volume laboratory stirred 
bioreactor (Section 2.8.2) in a similar way as Section 6.3.2. 
 
The microscale bioconversion was performed using a shake flask biocatalyst 
(Section 2.4.2 and Figure 3.1), while for the preparative scale synthesis, a wild type 
TK and TAm biocatalyst was produced using the 7.5 L fermentor (Section 5.3.2). For 
both biocatalysts, the TK and TAm expression represented on average 39 and 6.5% 
of the protein when analyzed by SDS PAGE (Section 2.9.5), which were in 
agreement with the enzyme expression of the biocatalysts summarized in Table 5.1 
with the TK D469E.  
 
Due to the higher susceptibility  of ERY and ABT to be consumed by whole cell side 
reactions compared to PKD and APD (Ingram et al., 2007), 25% less biomass 
concentration was used in the ABT bioconversion in comparison with the synthesis 
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of APD performed in Section 6.3.2. Therefore the concentration of TK and TAm 
were 0.06 and 0.3 mg mL-1 for both bioconversion scales. 
 
The starting concentration of substrates GA and HPA was 30 mM. Equation 6.3 
predicted that after 250 min, the TK bioconversion would reach completion. After 
this time, MBA was added to a final concentration of 10 mM the same was as in 
Section 6.3.2. An excess of ERY to MBA 3:1 was maintained in the bioconversion 
due to the lower TAm Michaelis constant of ERY compared to MBA (Table 4.2). 
This was done with the aim to speed up the one-pot synthesis and avoid enzyme 
deactivation by MBA, as well as ABT and ERY degradation by the whole cells.  
 
Figure 6.4 shows the complete experimental progress curve of the micro and 
preparative scale bioconversions. Combining equations 6.3 and 4.1 with their 
respective parameters (Table 6.4 and 4.2), the complete modelling of the one-pot 
synthesis of ABT was also performed and shown in Figure 6.4. 
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Figure 6.4. Scale-up and modelling of the whole cell one-pot synthesis of ABT following: (□) 
HPA, (○) ERY and (Δ) ABT using microscale instrumentation (Section 2.8.1), and (■) HPA, (●) 
ERY and (▲) ABT for the preparative scale synthesis (Section 2.8.2). Reaction conditions: 30 
mM [HPA] and [PA], 0.2 mM [PLP], 2.4 mM [TTP], 9 mM [Mg2+], 30 oC,  pH 7.5 in 200 mM 
HEPES. 10 mM [MBA] were added after 250 min. [TK] and [TAm] was 0.05 and 0.3 mg mL-1 
for both whole cell biocatalysts. The modelling was performed combining Equations 4.1 and 6.3 
with the corresponding kinetic parameters from Table 4.2 and 6.5 and is shown as solid lines.  
Error bars represent one standard deviation about the mean (n=3).   
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The results from the micro reactors scaled excellently as shown in Figure 6.4, 
resulting in very similar progress curves between the two scales. The maximum 
experimental difference for the synthesis of ABT between the two scales was found 
to be 11%, which was not statistically significant. This demonstrates the microscale 
experimentation was predictive of the preparative scale multi-step bioconversion of 
ABT. The kinetic results from the different scales and the model are summarized in 
Table 6.6. 
 
Table 6.6. Experimental and predicted apparent kinetic results of the one-pot synthesis of ABT 
shown in Figure 6.4 using microscale experimentation (2.8.1) and a preparative scale bioreactor 
(Section 2.8.2). The predicted data was obtained using Equations 4.1 and 6.3 with the kinetic 
parameters from Table 4.2 and 6.5 respectively. The calculation of the kinetic experimental 
results was performed as described in Section 2.8.1. 
 
Apparent kinetic parameter Predicted data Microscale 
Preparative 
scale 
Wild type TK initial specific 
activity 1.5 2.0 ± 0.17 1.9 ± 0.22 
( µmol min-1 mg-1) 
CV2025 TAm initial specific 
activity 0.19 0.21 ± 0.02 0.18 ± 0.02 
(µmol min-1 mg-1) 
Final ABT conversion 
(% mol/mol) 99 94 ± 9 84 ± 11 
 
A difference of 25% between the TK experimental and predicted specific activity 
was found (Table 6.6). This was probably due because the TK kinetic model was 
established at 25oC and pH 7.0 (Chen et al., 2009), instead of 30oC and pH 7.5 which 
were used for the one-pot synthesis shown in Figure 6.4. The difference was 
considered acceptable, and good agreement could be concluded between the 
predicted and experimental data (Figure 6.4), validating the microscale mathematical 
models for preparative scale multi-step syntheses. 
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Similar to the one-pot synthesis of APD in Section 6.3.2, the ABT yield (% mol/mol) 
of the preparative conversion was 10 and 15% smaller than the microscale and 
predicted model respectively (Table 6.6). Also some consumption of ERY by the 
whole cell was observed in both scales (Figure 6.4). Nevertheless, by using an excess 
of 3:1 ERY:MBA, the reaction time to reach completion was reduced by 3 folds 
compared to an equimolar concentration of 10 mM (Equation 6.3 and Table 6.5). The 
reduction in time allowed less consumption of ABT and ERY by the whole cells, as 
well as less inactivation of TAm by MBA. This shows how using the mathematical 
models, it was possible to design the one-pot synthesis of ABT with 25% less 
biocatalyst while  reaching completion in 3-folds less time than the synthesis of APD 
(Figure 6.3 and 6.4). This was done in order to minimize the consumption of ERY 
and ABT by the whole cells.  
 
6.3.4. Selection of the best reactor configuration  
 
6.3.4.1. One-pot synthesis of ABT with fed-batch addition of MBA 
 
After the kinetic models were validated for the preparative scale syntheses of the two 
different amino alcohols (Section 6.3.2 and 6.3.3), the microscale results could be 
used to select the best reactor configuration and operating conditions (Sin et al., 
2009).  
 
As discussed in Sections 4.4.3.7, MBA was found to be inhibitory to TAm in 
concentrations above 10 mM, in contrast ERY and PKD did not affect the enzyme 
stability (Figure 4.6). This limited the yield of the TAm bioconversion in equimolar 
concentrations above 10 mM as was shown in Figure 3.9. A solution to avoid MBA 
toxicity was to use a continuous fed-batch addition of the amino-donor. The 
Michaelis Menten constant of ERY was found to be 97 mM in comparison with the 
one of MBA of 0.5 mM (Table 4.2). These values predicted that the production rate 
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of ABT would not be severely affected by maintaining a MBA concentration below 
10 mM in the reaction.  
 
Therefore a one-pot synthesis of ABT was performed in preparative scale with fed-
batch addition of MBA. The initial volume of the bioconversion was 50 mL, and the 
pH and temperature were controlled at 7.5 and 30oC the same way as in Section 
6.3.1. The initial concentration of HPA and GA was 100 mM, and the concentration 
of TK and TAm were 0.75 mg mL-1 and 0.14 mg mL-1 using a whole cell biocatalyst 
produced in the 7.5 L fermentor (Section 5.3.2).  
 
 To model the one-pot synthesis with fed-batch addition of MBA, the TK Equation 
6.3 was combined with the following differential equations to model the TAm step: 
 
 
 
 
 
 
 
where Ri (mM min-1) is the kinetic reaction rate of each compound defined by 
equation 4.2, FeedRate (L min-1) is the rate of MBA solution, MBAFeed (mM) is the 
concentration of MBA in the feed and Vol (L) is the working reaction volume. 
Equation 6.3 predicted that under the previously mentioned conditions, the TK 
reaction would reach completion after 180 min, at this time MBA was fed 
continuously using a 300 mM solution (Section 2.8.2).  
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A varied flow rate of the MBA solution that would match the predicted  rate of the 
consumption of the amino donor by Equation 4.2 would have been desirable (Sayar 
et al., 2009). Nevertheless, such a programmable pump was not available when this 
work was performed.  
 
Therefore several simulations were performed using equations 6.4, 6.5, 6.6 and 6.7 to 
identify an appropriate constant flow rate, which would maximize the reaction rate 
while maintaining a low concentration of MBA below 10 mM for the maximum 
possible time. The selected flow rate was found to be 0.31 mL hr-1, which combined 
with a calculated duration of the fed-batch operation of 53 hr, meant that a total of 5 
mmol of MBA would be added to the reaction. This amount of MBA was equivalent 
to the total number of mmol of ERY that were predicted to be produced by the TK 
using a solution 100 mM of GA and HPA with an initial working volume of 50 mL. 
Hence the initial concentration of substrates was 10 folds higher than the 
concentration used in the previous one-pot synthesis represented in Figures 6.3 and 
6.4.     
 
Figure 6.5 shows the experimental progress curves and the predicted data for the 
amount of each compound (mmol) for the one-pot synthesis of ABT. In order to 
compare the performance of the different addition modes of MBA, another one-pot 
synthesis using a single shot addition of 5 mmol of pure MBA (carefully added to 
allow the system to adjust pH) after 180 min was also performed. The results of this 
multi-step bioconversion are also shown in Figure 6.5, including its corresponding 
modelling with Equations 4.1 and 6.3 and the parameters from Table 4.2 and 6.5. 
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Figure 6.5. Typical progress curves and modelling of the TK-TAm sequential one-pot 
synthesis of ABT with continuous fed-batch addition of MBA following the equivalent 
concentration (reference volume of 50 ml) of: (■) HPA, (●) ERY and (▲) ABT, and with a single 
shot addition of MBA following (Δ) ABT. The bioconversions were performed using preparative 
scale experimentation described in Section 2.8.2. Initial reaction conditions : 50 mL working 
volume, 100 mM [HPA] and [GA], 0.2 mM [PLP], 2.4 mM [TTP], 9 mM [Mg2+], 30 oC,  pH 7.5, 
25 mM HEPES. After 180 min, a solution of 300 mM [MBA] was added with a constant flow 
rate of 0.31 mL hr-1 for the fed-batch addition or 5 mmol of pure MBA were added for the single 
shot addition of the amino donor. [TK] and [TAm] were 0.14 and 0.75 mg ml-1 respectively using 
a whole cell biocatalyst produced in the 7.5 L fermentor (Section 5.3.2). The modelling of the 
fed-batch bioconversion was performed combining Equations 6.3, 6.4, 6.5, 6.6 6.7 and 4.1 with 
the corresponding kinetic parameters from Tables 6.5 and 4.2 and is represented by a solid line. 
The modelling of the TAm step with a single shot addition was performed combining Equations 
4.2 and 6.3 with the kinetic parameters from Table 6.5 and 4.2 and is represented by a dashed 
line.  
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Reasonable agreement was again found between the experimental and predicted data 
for the synthesis with fed-batch addition of MBA shown in Figure 6.5. After 2000 
min, the consumption rate of MBA by TAm was overcome by the feed rate of MBA, 
therefore accumulation of the amino donor above 10 mM started to occur (data not 
shown). This probably caused deactivation of the enzyme and no further conversion 
was obtained after 3200 min. 
 
In the multi-step synthesis with a single shot addition of MBA, as Equation 6.3 
predicted, the rate of ABT synthesis was initially faster than for the fed-batch 
bioconversion, resulting in higher ABT yields for the first 1000 min of reaction. 
Nevertheless, it appears TAm was totally inactivated after 1000 min by the higher 
concentration of MBA in comparison with the fed-batch bioconversion, and no 
further production of ABT was quantified after that time. The result was a final 
conversion yield of 62 % mol/mol for the bioconversion with fed-batch addition, 
which was 40% higher than the corresponding yield using the one shot addition of 
MBA. 
 
6.3.4.2. One-pot synthesis of APD with fed-batch addition of IPA 
 
The selection of IPA as amino donor instead of MBA could attenuate the problems 
of accumulation and toxicity of MBA in the previous fed-batch multi-step synthesis 
(Section 6.3.4.1). IPA showed great potential in the microscale one-pot synthesis of 
APD using low concentration of substrates (Figure 3.11). In addition, any excess of 
IPA could potentially evaporate if the bioreactor was not sealed due to its high 
volatility  (Smith et al., 2010).  
A one-pot synthesis of APD was performed with fed-batch addition of IPA in a 50 
mL preparative scale bioreactor (Section 2.8.1). The reaction conditions were the 
same as the multi-step bioconversion performed in Section 6.3.4.1, except that the 
initial concentration of PA and HPA were 200 mM (20 folds higher than the 
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concentrations used in the microscale synthesis shown in Figure 3.11 and 6.3). The 
concentration of TK D469E and the CV2025 TAm were 0.75 and 0.14 mg mL-1 
using a whole cell biocatalyst produced as described in Section 5.3.2. Using Equation 
6.1 and the kinetic parameters from Table 6.1, it was predicted that the TK reaction 
would reach completion after 10 hr. At that time, a solution of IPA 500 mM was fed 
continuously to the bioreactor with a flow rate of 0.42 mL hr-1 during 48 hr, so that a 
total amount of 10 mmol of IPA would be added to the vessel, which was equivalent 
to the total amount of mmol of PKD that were predicted to be produced by the TK 
reaction.  
Figure 6.6 shows the experimental progress curves of the amount of each compound 
(mmol), as well as the predicted data of the TK step of the preparative scale one-pot 
synthesis of APD using fed-batch addition of IPA. Perfect agreement was found 
between the TK experimental and predicted data by Equation 6.1, which validated 
the TK model for concentrations as high as 200 mM in a preparative scale synthesis.  
The TAm bioconversion did not seem to be inhibited by any accumulation of IPA 
during the 3000 min that the amino donor was fed, suggesting that any excess of IPA 
was successfully evaporated.  
 
A total volume of IPA solution of 20 mL was added to the bioreactor, leading to a 
final APD yield of 70% mol/mol. This yield was 3.5 folds higher than the yield 
obtained under similar batch reaction conditions for a single TAm step bioconversion 
(Appendix XI). This suggested that IPA could be causing strong inhibition or be 
toxic to TAm in high concentrations.  
 
Using the selected reaction conditions and reactor configuration, the one-pot 
synthesis allowed a  6 fold greater yield (% mol/mol) using concentrations 1 order of 
magnitude higher than a previous 2 step preparative scale batch synthesis of APD  
(Smith et al., 2010).  
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Figure 6.6. Typical progress curves and modelling of the TK-TAm sequential one-pot 
synthesis of APD with continuous fed-batch addition of IPA following the equivalent 
concentration (reference volume of 50 ml) of: (■) HPA, (●) PKD and (▲) APD. The 
bioconversion was performed using preparative scale experimentation described in Section 
2.8.2. Initial reaction conditions: 50 mL working volume, 200 mM [HPA] and [PA], 0.2 mM 
[PLP], 2.4 mM [TTP], 9 mM [Mg2+], 30 oC, pH 7.5, 25 mM HEPES. After 600 min, a solution of 
500 mM [IPA] was added with a constant flow rate of 0.42 mL hr-1. [TK] and [TAm] were 0.75 
and 0.14 mg mL-1 respectively using a whole cell biocatalyst produced in the 7.5 L fermentor 
(Section 5.3.2). The modelling of the TK step was performed using Equation 6.1 with the 
corresponding kinetic parameters from Table 6.1 and was represented by a dashed line.  
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6.4. SUMMARY 
 
In summary, an overall scale-up of 167-fold for the one-pot syntheses of both APD 
and ABT was performed. The results obtained showed excellent agreement between 
those obtained at the micro and preparative scales (Figure 6.3 and 6.4).  
 
In order to simulate the multi-step synthesis, the kinetic models for the TK D469E 
and CV2025 TAm mediated synthesis of PKD and APD were established (Figure 6.1 
and 6.2 and Equations 6.1 and 6.2) building on the methodology developed in 
Chapter 4. 
 
Generation of the relevant kinetic constants enabled modelling for the one-pot 
bioconversion of both APD and ABT, showing that the methodology could be 
applied to different bioconversion of substrates and products. In both cases there was 
excellent agreement between the predicted and experimental data, validating the 
microscale kinetic models to simulate preparative scale syntheses (Figure 6.3 and 
6.4).  
 
Finally, the best bioconversion conditions and reactor configurations have been 
identified based on the mathematical models generated using microscale 
experimental data. These led to identification of a reactor with fed-batch addition of 
the amino donor to be the optimum operating strategy in each case. Under optimal 
conditions, the one-pot syntheses allowed up to a 6-fold increase in product yield (% 
mol/mol) (Figure 6.5 and 6.6), using concentrations 1 order of magnitude higher than 
published preparative scale data (Smith et al., 2010). 
 
The final chapter of this thesis will attempt to put this work in the wider context of 
industrial bioconversion process design and identify areas where further work is 
required or improvements can be made. 
7. CONCLUSIONS AND FUTURE WORK 
 
 
7.1.   OVERALL CONCLUSIONS 
 
In this study, the design and characterization of de novo engineered pathways in a whole 
cell E. coli biocatalyst for multi-step enzymatic syntheses of chiral amino alcohols was 
achieved. This was facilitated by developing a microscale high-throughput “toolbox”, 
which enabled the efficient evaluation and “mix and match” of the best enzyme 
candidates, as well as the simulation of the one-pot synthesis to speed-up process 
development. The toolbox approach was demonstrated for the synthesis of amino 
alcohols APD (Figure 3.11) and ABT (Figure 3.12), where the best enzyme pairs were 
found to be the E. coli TK mutant D469E and wild type TK combined with the CV2025 
TAm respectively using a whole cell biocatalyst.  
For this approach to work best the need for early characterization of the kinetics of the 
individual enzymes in the de novo engineered pathway is highlighted. This is necessary 
in order to rapidly identify the overall bioconversion bottleneck (Figures 3.7 and 3.8). 
This kinetic data is crucial for early establishment of optimum reaction conditions for the 
one-pot synthesis which in general needs to favour the rate limiting step of the overall 
bioconversion.  
It was also found that special attention must be taken for the early detection of side 
reactions that could occur between the different bioconversion steps. A sequential 
feeding of substrates may be needed to avoid side reactions, as was demonstrated for the 
case of the amino donor MBA in the one-pot synthesis of ABT (Figure 3.10). Expanding 
the size of the TK and TAm libraries, by further engineering the enzymes to limit its 
selectivity towards inappropriate substrates or intermediates, would increase the 
productivities of the one-pot synthesis strategy. 
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In principle the microscale toolbox approach could be used to rapidly evaluate any set of 
enzyme pairs and substrates, which could conceptually be integrated in a multi-step 
synthesis. It enables the early generation of crucial bioprocess and kinetic data for the 
effective design of complex bioconversion processes. 
For the particular de novo engineered pathways studied here, of particular relevance was 
the early identification and optimization of the critical step of the multi-enzymatic 
synthesis, which was found to be that catalyzed by TAm (Section 3.3.4).  To help 
optimize this step, a methodology to rapidly establish the full kinetic model and its 
parameters was developed and integrated in the microscale toolbox. 
 
The creation of a standardized methodology allowed the establishment of the kinetic 
parameters as a rapid routine procedure, easily applied to all the different enzymes of the 
de novo pathway, requiring less time and resources. It also contributed to a higher 
transparency of the kinetic parameters identification, facilitating the comparison of the 
different models. 
 
The key limiting TAm kinetic parameters were found to be the high Michaelis- Menten 
constant and the low catalytic constant for ABT and APD synthesis respectively (Table 
4.2 and 6.2). Also, the high toxicity of the amino donor towards the enzyme was found to 
limit the final yields of the bioconversion (Section 4.2.4 and 4.3). While saving time and 
resources through the use of simulations, the early discovery of those bottlenecks was 
crucial to determine the best reaction conditions and reactor configurations (Section 
6.3.4). This kinetic information will also be useful to inform protein engineering 
strategies to further unlock the potential of the TAm bioconversion.  
The modelling results were decisive in the rational design of the whole cell E. coli 
biocatalyst; informing the desired level of expression of each enzyme to match the 
sequential reaction kinetics. The effect of temperature and induction time was found to 
be crucial for the relative level of expression of both enzymes. This allowed the scale-up 
of the production of the E. coli biocatalyst to pilot scale obtaining maximum 
concentrations of TK and TAm, while maintaining a desired TAm/TK ratio of 5 (Figure 
Chapter 7: Conclusions and Future Work 
 
 
 
       207 
 
  
5.4 and 5.6a). The capacity to control the relative expression of each enzyme will be 
critical to harvest the full synthetic potential of de novo pathways at industrial scale, 
increasing productivities and allowing them to be flexible in order to adapt for new 
substrates and products. 
Excellent agreement was found between the kinetic performance of the biocatalysts 
produced at laboratory and small pilot scale (Figure 5.7 and 5.8), confirming that the 
integrity of the cells and the stability of the enzymes were maintained during the scale-up 
process. Further scale-up studies to identify the key issues related with the biocatalyst 
production will be essential for the efficient bioprocess development to manufacturing 
scale. 
Finally the microscale one-pot syntheses of amino alcohols were modelled and scaled-up 
167-fold to a preparative scale. Again, excellent agreement was found between the 
experimental data at both scales and the predicted data for the one-pot synthesis of ABT 
(Figure 6.3) and APD (Figure 6.4). Appropriate mixing in the preparative scale 
synthesis, combined with constant pH and solvent evaporation control in the microscale 
bioreactors were found to be critical to guarantee successful process scale-up (Section 
6.3.2). The main deviations of the experimental data and the model were attributed to 
TAm instability in the presence of the amino donor (Section 4.3.3.7 and Figure 6.5). In 
order to predict accurately longer multi-step bioconversions with high concentration of 
amino donor, the toxic effect of the substrate towards TAm should be taken into account 
in the mathematical models. 
Overall the best reaction conditions and reactor configurations were determined using the 
microscale models, which resulted in using an excess of the amino acceptor ERY due to 
its low Michaelis constant (Section 6.3.3), as well as applying a controlled fed batch 
addition of the amino donor to avoid its toxicity toward the enzyme (Section 6.3.4). 
Under these optimized conditions, the one-pot syntheses allowed up to a 6-fold increase 
in yield (% mol/mol) (Figure 6.5 and 6.6), using concentrations 1 order of magnitude 
higher than previously published preparative scale data (Smith et al., 2010).   
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We estimate that by applying this microscale systematic approach to design and 
characterize de novo engineered pathways, the industry could make savings of 100 to 
1000 times in resources and duration required compared to traditional laboratory scale 
non systematic methods.  
In order to further optimize a multi-step synthesis, the modelling should be combined 
with an economical analysis. This would allow establishing priorities, and help deciding 
between increasing the reaction rate at the expense of using an excess of one substrate as 
was done in this work (Figure 6.4).   
The interest of industry towards biocatalysis has been growing not only in the 
pharmaceutical sector, but also in the production of chemicals and bulk products. The 
majority of the biocatalytic industrial scale processes nowadays are performed with 
single enzyme bioconversions due to its simplicity and high productivities. However, it 
is expected that the biocatalysis of the future will integrate new complexities and 
configurations such as in vivo de novo multi-step enzymatic systems. The methodologies 
described in this thesis go some way toward helping better characterize and speed up the 
development of such systems which are generally considered to be difficult to assemble, 
characterize, and to operate productively at scale.  
 
7.2.   FUTURE WORK 
 
The work in this thesis has demonstrated the applicability of microscale tools to design, 
characterize and optimize in vivo multi-step enzymatic syntheses. Future work is 
required to expand the microscale tools towards downstream and upstream processes. 
Also further studies need to be done to enable better integration of these microscale 
approaches with advances in protein engineering, data driven modelling, high-throughput 
analytical technique and synthetic biology among others. A detailed list of future work 
recommendations is shown below: 
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• Future studies are required in the integration of the results of the microscale 
kinetics models, with the expansion of the TK and TAm libraries by protein engineering. 
This would result in the development of enzymes variants, with superior catalytic 
characteristics and improved selectivity, avoiding side reactions between the different 
bioconversion steps. 
 
• Taking advantage of the expansion of the TK and TAm library, further studies 
with new substrates, especially with aromatic TK products, which have been shown to be 
good substrates for ω-TAm, should be performed to produce a new set of  high value 
amino alcohols  (Hailes et al., 2009). 
 
• Future studies to expand the microscale toolbox towards the fermentation and 
biocatalyst manipulation prior to bioconversion, as well as the analytical analysis and 
downstream processing of the chiral compounds are necessary. In addition modelling of 
those new operation units would enable the complete simulation of the bioprocess, 
making the microscale toolbox a very powerful agent for the efficient process 
development. 
 
• Future automation studies of the microscale toolbox, including the previously 
mentioned expanded areas, would allow taking advantage of the full potential of the 
high-throughput nature of the tools. 
 
• In order to take the full advantage of the determined kinetic parameters in 
Chapter 4, future work is required to apply a systematic statistical methodology to 
determine the optimum reaction conditions through simulations of the kinetic model . 
 
• As was discussed in Section 4.3.7 and 6.3.4.1, the toxicity of the amino donor, as 
well as consumption of the substrates and products by whole cell side reactions were 
found to affect the quality of the modelling. Therefore new studies should be performed 
to include those effects in the mathematical equations to increase the accuracy of the 
predictions to a broader range of conditions. 
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• IPA showed a great potential as an amino donor for the synthesis of amino 
alcohols (Figure 3.11, 3.12 and 6.6). Further studies to establish its kinetic parameters 
are necessary. This would allow having more information to optimize the one-pot 
synthesis of amino alcohols, like designing gradient fed-batch additions of IPA, which 
would match the consumption of the amino donor by the enzyme as described in Section 
6.3.3. 
 
• As discussed in Section 4.4.3.6 the kinetic methodology to obtain the kinetic 
parameters could be further simplified, eliminating the experimentally difficult step of 
gathering reverse reaction data, which was shown to have a low impact in the modelling. 
Genetic algorithms could be a robust tool to assist the establishment of the data driven 
models. 
 
• The level of TK and TAm expression could be controlled by manipulating the 
fermentation temperature and induction time of the TAm (Figure 5.3). In order to have a 
more accurate control of the co-expression, the TK could also be induced instead of 
being constitutively expressed (Section 2.3.1). Therefore future studies using different 
compatible methods of induction between the different enzymes are required. 
 
• The final biomass concentration of whole cells containing the de novo pathway in 
this work was 8.5 gDCW L-1 (Figure 5.4). Further studies need to be performed in order to 
increase the final biomass concentration using fed-batch fermentation methods and 
various feeding strategies.  
 
 
• The key parameters affecting the scale up of the multi-step bioconversion to 
preparative scale were established in Section 6.3.2 and 6.3.3. Future studies are 
necessary to identify the crucial parameters that may affect the performance of the one-
pot syntheses at larger pilot plant scale.  
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• As was found in Section 3.3.6, the whole cell biocatalyst was selected because it 
improved the stability of TAm. Further studies should be performed in immobilization 
techniques, which can also improve the stability of the enzyme, while adding the benefit 
of allowing the enzyme to be recycled and used in a continuous flow bioprocess.  
 
• Studies including economical and environmental factors and constraints should 
be included in the modelling of the process. This would allow the determination of real 
optimum conditions that would be required in the manufacturing scale. 
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APPENDIX I 
CALIBRATION PLOT OF BIOMASS IN 
FUNCTION OF OD600 
 
 
 
Figure A.I. 1. Calibration graph of biomass in gDCW L-1 as a function of OD600 (Section 2.9.2). 
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APPENDIX II 
BRADFORD ASSAY: CALIBRATION 
PLOT OF BSA CONCENTRATION IN 
FUNCTION OF OD595 
 
 
 
Figure A.II. 1. Standard graph for Bradford assay of BSA concentration as a function of 
OD595 (Section 2.9.3). 
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APPENDIX III 
HPLC STANDARD CALIBRATIONS  
 
 
 
Figure A.III. 1. Calibration graph of ERY and HPA concentration as a function of HPLC 
area (Section 2.9.6). 
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Figure A.III. 2.  Calibration graph of derivatized ABT concentration as a function of HPLC 
area (Section 2.96). 
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APPENDIX IV 
TK KINETIC COMPARISON IN WHOLE 
CELL AND LYSATE FORM 
 
 
 
Figure A.IV. 1. ERY production by TK wild type lysate and whole cell at 25oC. Reaction has 
been performed at 25oC with 0.1 mg ml-1 of TK in lysate and whole cell form.  [HPA] and [GA] 
were 50 mM in 50 mM TRIS buffer pH 7. Results show the mean of 2 duplicates.  
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Figure A.IV. 2. Progress curves of the synthesis of ERY at 25oC with TK in lysate and whole 
cell form.  [GA] and [HPA] were 50 mM.  Enzyme concentration was 0.1 mg/ml ,  pH 7.0 with 50 
mM TRIS  
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APPENDIX V 
MATLAB PROGRAM FOR KINETIC 
PARAMETER ESTIMATION 
 
 
 
function ParaEst 
  
close all 
clear all 
  
format bank; 
  
% Intial setup 
NumDataSet = 15;                      % Number of progress curves   
NumSample(1:NumDataSet) = [12 12 12 12 12 12 12 12 12 12 12 12 12 12 
12]; 
%NumSample(1:NumDataSet) = [6 6 6 8 8 8 8 11 11 11 11 11 11 11 11 11 
11 11]; 
  
                   % Number of sampling points for each progress 
curve 
  
Data_Filename1 = 'InhibitionCurve';  % Data file for Inhibition data 
Data_Filename2 = 'P3';   % Data file for progress curves 
  
Result_File = 'Result';          % Result file 
  
  
  
  
% Call the programmes in the software 
Result_Filename = strcat(Result_File,'.xls'); 
  
  
  
[Theta0, Theta] = 
PE3(NumDataSet,NumSample,Data_Filename1,Data_Filename2,Result_Filena
me) 
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'Kf(1/min),     KERY(mM),     KMBA(mM),    Kr(mM),    KAP(mM),    
KEAT(mM),    KdeMBA(mM),    KiMBA(mM),   KiAP(mM)' 
  
StringTitle = 
{'Kf(1/min)','KERY(mM)','KMBA(mM)','Kr(mM)','KAP(mM)','KEAT(mM)','Kd
eMBA(mM)','KiMBA(mM)','KiAP(mM)'; ...  
    Theta(1) Theta(2) Theta(3) Theta(4) Theta(5) 
Theta(6),Theta(7),Theta(8), Theta(9)}; 
  
  
  
String1 = {'Initial'}; 
String2 = {'Final'}; 
     
xlswrite(Result_Filename, StringTitle,'Parameters','D4'); 
xlswrite(Result_Filename, String1,'Parameters','C5'); 
xlswrite(Result_Filename, String2,'Parameters','C6'); 
xlswrite(Result_Filename, Theta0,'Parameters','D5'); 
xlswrite(Result_Filename, Theta, 'Parameters','D6'); 
 
 
 
function Theta = PE1(Data_Filename) 
  
% Finding preliminary Kcat ka Kb in TK kinetics with initial rate 
data 
  
% Intial setup 
% Parameter Estimation 
    Theta0 = [1 1 1];     % Initial values for Kcat, Ka and Kb 
    LB = [0.01 0.001 0.001];            % Lower bound  
    UB = [80000 50000 50000];      % upper bound 
  
   
% Read experimental data 
Data = xlsread(Data_Filename); 
  
    CHPA = Data(:,1); %IN our Cases HPA is ERY 
    CGA  = Data(:,2); %IN our Cases GA is MBA 
    Rate = Data(:,3); 
    Ei   = Data(1,4); 
  
    [NumSample,n11] = size(CHPA); 
     
  
     
% options group for different optimisers 
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    foptions = optimset('MaxIter',200000,'TolFun',1e-9); 
  
    [Theta,Func]= ... 
       fmincon(@(x) ObjFunc(x,CHPA,CGA,Rate,Ei,NumSample), ... 
                 Theta0,[],[],[],[],LB,UB,[],foptions)  
  
% ======== Objective Function ========     
function Func = ObjFunc(C,CHPA,CGA,RateE,Ei,NumSample) 
% Objective function called by the main  
% DON'T change it 
  
A = 0.0; 
   
for I = 1:NumSample 
    y = [CHPA(I) CGA(I)]; 
    RateC(I)= Kinetics(y,C,Ei); 
  
    A = A + (RateC(I)-RateE(I))^2;  
     
end % for I 
  
Func = A; 
  
% ========  Kinetics Model ======== 
function R = Kinetics(y,Para,Ei) 
% Simplified (no inhibition terms) kinetic model 
  
  
  
    Kcat = Para(1);       % Rate constant   [1/min] 
    Ka  = Para(2);        % Michaelis constant of ERY  [mM] 
    Kb  = Para(3);        % Michaelis constant of MBA   [mM] 
  
     
     
     
% y(1) -- ERY concentration 
% y(2) -- MBA  concentration 
  
    Vmax = Kcat*Ei;               
    V = Kb*y(1)+Ka*y(2)+y(1)*y(2); 
    R = Vmax*y(1)*y(2)/V; 
  
 
 
function [Theta,tspa] = 
PE2(NumDataSet,NumSample,NumPara,RatePara,Data_Filename) 
format short eng 
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counter =1 
% Read experimental data 
Data = xlsread(Data_Filename); 
  
for I = 1:NumDataSet 
    for J = 1:NumSample(I) 
        Ei(I,J) = Data(counter,5); 
        Time(I,J) = Data(counter,1); 
        CHPA(I,J) = Data(counter,2); 
        CGA(I,J)  = Data(counter,3); 
        CERY(I,J) = Data(counter,4); 
        CEAT (I,J)= Data(counter,6); 
        counter = counter+1; 
    end 
end 
  
Lstep = 1; 
  
for I = 1:NumDataSet  
    tspa(I) = Time(I,NumSample(I)); 
end 
  
  
% Initial values for parameters 
    Theta0(1:2) = [0.1 0.1] 
     
    LB(1:2) = [0.00001 0.0001]; 
    UB(1:2) = [800 800] ; 
     
% Finding optimum parameters 
             
    options = 
optimset('Display','iter','MaxFunEvals',1000000,'MaxIter', 
1000,'tolx',10E-19,'tolfun', 10E-19,'TolCon',10E-19); 
     
    
    [Theta,Func]= ... 
       fmincon(@(x) 
ObjFunc(x,Time,CHPA,CGA,CERY,Ei,CEAT,tspa,NumDataSet,NumSample,RateP
ara), ... 
                 Theta0,[],[],[],[],LB,UB,[],options)  
  
% ================== Objective Function ================== 
  
function Func = 
ObjFunc(C,Time,CHPA,CGA,CERY,Ei,CEAT,tspa,NumDataSet,NumSample,RateP
ara) 
% Objective function called by the main  
% DON'T change it 
format short eng 
  
Lstep = 1; 
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F = 0.0; 
A(NumDataSet) = 0.0; 
  
  
for I = 1:(NumDataSet) 
   
    tspan = [0:Lstep:tspa(I)]; 
    B=CHPA (I,1); 
    D=CGA (I,1) ; 
     E=CERY(I,1); 
    G=CEAT(I,1); 
    Y0 = [CHPA(I,1),CGA(I,1),CERY(I,1),CEAT(I,1)]; 
  
    sol =ode45(@(t,y) TKKine2(t,y,C,Ei(I),RatePara),tspan,Y0); 
    
  
   Y = deval(sol,Time(I,:)); 
 % for J = 1:NumSample(I) 
         
%        EHPA(J) = ((B-Y(1,J))/B-((B-CHPA(I,J))/B))^2; 
%        EGA(J)  = ((D-Y(2,J))/D-((D-CGA(I,J))/D))^2; 
%        if B>D 
%     EERY(J) = ((Y(3,J)-CERY(I,J))/(D))^2; 
%        EEAT(J) = ((Y(4,J)-CEAT(I,J))/(D))^2;  
%        else 
%        EERY(J) = ((Y(3,J)-CERY(I,J))/(B))^2; 
%        EEAT(J) = ((Y(4,J)-CEAT(I,J))/(B))^2;  
        
%       end 
%      A(I) = A(I) + EHPA(J) + EGA(J) + EERY(J)+ EEAT(J) ; 
         
  
  
  
 for J = 2:NumSample(I) 
     EHPA(J) = (((Y(1,J))-CHPA(I,J))/Y(1,J))^2; 
 EGA(J) = (((Y(2,J))-CGA(I,J))/Y(2,J))^2; 
 EERY(J) = (((Y(3,J))-CERY(I,J))/Y(3,J))^2; 
 EEAT(J) = (((Y(4,J))-CEAT(I,J))/Y(4,J))^2; 
 A(I) = A(I) + EHPA(J) + EGA(J) + EERY(J)+ EEAT(J) ; 
   
 end  
  
  F = F + A(I) ;% for J; 
end 
  
Func = F; 
return 
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% ========  Kinetics Model ======== 
function dy = TKKine2(t,y,RC,Ei,RatePara) 
% PingPong Bi-Bi mechanism for reaction: 
kf = RatePara(1);    % Rate constant   [1/min] 
KmA = RatePara(2);     % Michaelis constant of ERY  [mM] 
KmB = RatePara(3);     % Michaelis constant of MBA   [mM] 
kr=RatePara(4); 
KmP=RatePara(5); 
KmQ = RatePara(6); 
KiBs = RatePara (7); 
KiB = RC(1); 
KiQ= RC(2); 
%KiQ = (kf/kr)*(kf/kr)*KmQ*KmP*KiB*KiA/(KmB*KmA*KiP); 
  
  
  
[M,N]=size(y); 
RealZero = 1.0e-18; 
for I = 1:M 
    if (y(I) <= RealZero) 
        y(I) = RealZero; 
    end 
end 
  
  
dy = zeros(M,1);                   
  
KEQ = (kf/kr)*(kf/kr)*KmP*KmQ/(KmA*KmB); 
  
  
d3=(kf*Ei*kr*Ei*(y(1)*y(2)-
(y(3)*y(4))/(KEQ)))/(kr*Ei*KmB*y(1)+kr*Ei*KmA*y(2)+kr*Ei*y(1)*y(2)+k
f*Ei*KmP*y(4)/(KEQ)+kf*Ei*KmQ*y(3)/(KEQ)+... 
  kf*Ei*y(3)*y(4)/(KEQ)+kr*Ei*KmB*y(1)*y(4)/KiQ 
+kf*Ei*KmQ*y(2)*y(3)/(KEQ*KiB)... 
+kr*Ei*KmA*y(2)*y(2)/(KiBs*KEQ)+kf*Ei*KmP*y(2)*y(4)/(KiBs)); 
%last line contains the extra terms for the model with substrate 
inhibition 
  
  
dy(1) =- d3; 
dy(2) = -d3; 
dy(3) = d3; 
dy(4) = d3; 
     
  
  
  
return 
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function [Theta0, Theta] = PE3(NumDataSet,NumSample, ... 
    Data_Filename1,Data_Filename2,Result_Filename) 
  
format short eng 
  
% Intial setup 
NumPara2 = 2;         % Number of parameter to be estimated (for Ki) 
NumPara3 = 9;         % Number of parameter to be estimated (for 
complete model) 
NumComponent = 4;     % Number of Reaction component, here is HPA, 
GA, ERY 
%n=0 
%for P = 0.1:0.5:10 
%n=n+1     
Theta1 = PE1(Data_Filename1); 
  
RatePara = Theta1; 
  
[Theta2,tspa] = 
PE2(NumDataSet,NumSample,NumPara2,RatePara,Data_Filename2) 
  
  
  
Theta0 = double(([Theta1 Theta2])) 
KEQ= 
Theta0(1)/Theta0(4)*Theta0(1)/Theta0(4)*Theta0(5)*Theta0(6)/(Theta0(
2)*Theta0(3)) 
KiERY= Theta0(1)*Theta0(5)*Theta0(9)/(KEQ*Theta0(4)*Theta0(3)) 
KiAP=KEQ*Theta0(4)*Theta0(2)*Theta0(8)/(Theta0(1)*Theta0(6)) 
K1=Theta0(8)/KiAP 
K2=Theta0(9)/KiERY 
Lstep = 1 
  
% Read experimental data 
Data = xlsread(Data_Filename2); 
counter =1; 
for I = 1:NumDataSet 
    for J = 1:NumSample(I) 
        Time(I,J) = Data(counter,1); 
        CHPA(I,J) = Data(counter,2); 
        CGA(I,J)  = Data(counter,3); 
        CERY(I,J) = Data(counter,4); 
        Ei(I)     = Data(counter,5); 
        CEAT(I,J)     = Data(counter,6); 
        counter =counter+1; 
    end 
end 
  
for I = 1:NumDataSet 
    Conc(I,1,:) = CHPA(I,:); 
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    Conc(I,2,:) = CGA(I,:); 
    Conc(I,3,:) = CERY(I,:); 
    Conc(I,4,:) = CEAT(I,:); 
     
    % Finding optimum parameters 
  %  psoptions = 
psoptimset('Display','iter','MaxFunEvals',2000000,'MaxIter',2000000,
'TolFun',1e-12);  
  % [Theta,Func]= ... 
   %   patternsearch(@(x) ObjFunc(x,Ei,Time,Conc,NumDataSet,... 
    %         
NumComponent,NumSample,tspa),Theta0,[],[],[],[],LB,UB,[],psoptions); 
end 
  
% Initial values for parameters 
  
 
LB(1:NumPara3) = [0.1 0.1  0.01 0.1 0.1  0.1  0.1 0.00001  0.001 ]; 
 UB(1:NumPara3) = [8000 8000 8000 8000 8000 8000 8000 80000  800  ] 
; 
  
  
            
options = 
optimset('Display','iter','MaxFunEvals',10000,'MaxIter',400,'tolx',1
0E-12,'tolfun', 10E-12,'TolCon',10E-12); 
%'UseParallel','always','algorithm', 'interior-
point')%'AlwaysHonorConstraints','bounds','DerivativeCheck','on','Fu
nValCheck','on'); % ,'MaxIter', 10); 
      
  
  
[Theta,Func]= ... 
       fmincon(@(x) ObjFunc(x,Ei,Time,CHPA,CGA,CERY,CEAT,NumDataSet, 
... 
             
NumComponent,NumSample,tspa),Theta0,[],[],[],[],LB,UB,[],options) 
          
       
  
KEQ= 
Theta(1)/Theta(4)*Theta(1)/Theta(4)*Theta(5)*Theta(6)/(Theta(2)*Thet
a(3)) 
KiERY= Theta(1)*Theta(5)*Theta(9)/(KEQ*Theta(4)*Theta(3)) 
KiAP=KEQ*Theta(4)*Theta(2)*Theta(8)/(Theta(1)*Theta(6)) 
%Parameter(1:20) =1 
%result(1:20)=1 
%Parameter(n) = (P) 
%result (n)=(Func) 
%end 
%Sensitivity_File = 'Sensitivity';          % Result file 
  
%Sensitivity_Filename = strcat(Sensitivity_File,'.xls'); 
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%String1 = {'Parameter'}; 
%String2 = {'Residual'}; 
     
%xlswrite(Sensitivity_Filename,Parameter ,'Parameters','D5'); 
%xlswrite(Sensitivity_Filename, String1,'Parameters','C5'); 
%xlswrite(Sensitivity_Filename, String2,'Parameters','C6'); 
%xlswrite(Sensitivity_Filename,result,'Parameters','D6'); 
  
% ======== Plotting the result comparison ======== 
NC = Theta;  
Lstep = 1; 
  
  
for I = 1:NumDataSet 
   tspan = [0:Lstep:tspa(I)]; 
    Y0 = [CHPA(I,1),CGA(I,1),CERY(I,1),CEAT(I,1)]; 
  
   W=I; 
     
     
    [t,y] =ode45(@(t,y) TKKine3(t,y,NC,Ei(I)),tspan,Y0); 
  
 figure(I) 
  
    plot(Time(I,:),CHPA(I,:),'ro','LineWidth',2) 
    hold on 
    plot(Time(I,:),CGA(I,:),'md','LineWidth',2) 
    plot(Time(I,:),CERY(I,:),'bs','LineWidth',2) 
    plot(t,y(:,1),'r-','LineWidth',2) 
    plot(t,y(:,2),'m-','LineWidth',2) 
    plot(t,y(:,3),'b-','LineWidth',2) 
    hold off 
   
    xlabel('Time (min)','fontsize',14, 'fontweight','bold') 
   ylabel('Concentration (mM)','fontsize',14, 'fontweight','bold') 
    set(gca, 'fontsize',14, 'fontweight','bold', 'LineWidth',2); 
    legend('ERY)','MBA','ABT','Location','best'); 
  
%    for J = 1:NumSample 
%        fprintf(fid, '%6.2f %12.8f %12.8f %12.8f %12.8f\n', ... 
%            Time(I,J),YY(1,J),YY(2,J),YY(3,J),YY(4,J)); 
%    end 
end 
  
  
% Write experiment data, model prediction and residuals into data 
file 
for I = 1:NumDataSet 
    tspan = [0:Lstep:tspa(I)]; 
    Y0 = [CHPA(I,1),CGA(I,1),CERY(I,1),CEAT(I,1)]; 
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    [t,y] =ode45(@(t,y) TKKine3(t,y,NC,Ei(I)),tspan,Y0); 
   
  
    sol =ode113(@(t,y) TKKine3(t,y,NC,Ei(I)),tspan,Y0); 
  
  
    Y = deval(sol,Time(I,:)); 
    
    Residual1(I,:) = CHPA(I,:) - Y(1,:); 
    Residual2(I,:) = CGA(I,:)  - Y(2,:); 
    Residual3(I,:) = CERY(I,:) - Y(3,:); 
    Residual4(I,:) = CEAT(I,:) - Y(4,:); 
     
    for J = 1:NumSample(I) 
        T1(J+(I-1)*NumSample(I)) = Time(I,J); 
        C1(J+(I-1)*NumSample(I)) = CHPA(I,J); 
        Y1(J+(I-1)*NumSample(I)) = Y(1,J); 
        R1(J+(I-1)*NumSample(I)) = Residual1(I,J); 
         
        C2(J+(I-1)*NumSample(I)) = CGA(I,J); 
        Y2(J+(I-1)*NumSample(I)) = Y(2,J); 
        R2(J+(I-1)*NumSample(I)) = Residual2(I,J); 
         
        C3(J+(I-1)*NumSample(I)) = CERY(I,J); 
        Y3(J+(I-1)*NumSample(I)) = Y(3,J); 
        R3(J+(I-1)*NumSample(I)) = Residual3(I,J); 
         
        C4(J+(I-1)*NumSample(I)) = CEAT(I,J); 
        Y4(J+(I-1)*NumSample(I)) = Y(4,J); 
        R4(J+(I-1)*NumSample(I)) = Residual4(I,J); 
    end 
end% I 
  
StringMatrix = {'Time', 'HPA-E', 'HPA-P', 'Residual-1', 'GA-E', ... 
    'GA-P', 'Residual-2', 'ERY-E',  'ERY-P', 'Residual-3'}; 
   
xlswrite(Result_Filename,StringMatrix,'Comparison','A1'); 
  
DataMatrix = [T1;C1;Y1;R1;C2;Y2;R2;C3;Y3;R3;C4;Y4;R4];  
  
xlswrite(Result_Filename, DataMatrix,'Comparison','A2'); 
  
% ================== Objective Function ================== 
function Func = ObjFunc(CC,Ei,Time,CHPA,CGA,CERY,CEAT, ... 
                       NumDataSet,NumResp,NumSample,tspa) 
format short eng 
Lstep = 1; 
F = 0.0; 
MaxNum = max(NumSample(1:NumDtaSet)); 
A(NumDataSet) = 0.0; 
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for I = 1:NumDataSet 
    tspan = [0:Lstep:tspa(I)]; 
      Y0 = [CHPA(I,1),CGA(I,1),CERY(I,1),CEAT(I,1)]; 
 B=CHPA (I,1); 
    D=CGA (I,1);  
    E=CERY(I,1); 
    G=CEAT(I,1); 
W=I; 
  
  
    sol =ode45(@(t,y) TKKine3(t,y,CC,Ei(I)),tspan,Y0); 
  
  
    Y = deval(sol,Time(I,:)) ; 
% 
%  for J = 1:NumSample(I) 
        
%        EHPA(J) = ((B-Y(1,J))/B-((B-CHPA(I,J))/B))^2; 
%        EGA(J)  = ((D-Y(2,J))/D-((D-CGA(I,J))/D))^2; 
%        if B>D 
%        EERY(J) = ((Y(3,J)-CERY(I,J))/(D))^2; 
%        EEAT(J) = ((Y(4,J)-CEAT(I,J))/(D))^2;  
%        else 
%       EERY(J) = ((Y(3,J)-CERY(I,J))/(B))^2; 
%        EEAT(J) = ((Y(4,J)-CEAT(I,J))/(B))^2;  
         
%        end 
%        A(I) = A(I) + EHPA(J) + EGA(J) + EERY(J)+ EEAT(J) ; 
        
  
 for J = 1:NumSample(I) 
     EHPA(J) = (((Y(1,J))-CHPA(I,J))/Y(1,J))^2; 
 EGA(J) = (((Y(2,J))-CGA(I,J))/Y(2,J))^2; 
 EERY(J) = (((Y(3,J))-CERY(I,J))/Y(3,J))^2; 
 EEAT(J) = (((Y(4,J))-CEAT(I,J))/Y(4,J))^2; 
 A(I) = A(I) + EHPA(J) + EGA(J) + EERY(J)+ EEAT(J) ; 
   
 end  
  
 F = F + A(I); 
end 
Func = F; 
  
return 
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% ========  Kinetics Model ======== 
function dy = TKKine3(t,y,RC,Ei) 
  
% PingPong Bi-Bi mechanism for reaction: 
  
% PingPong Bi-Bi mechanism for reaction: 
kf = RC(1);    % Rate constant   [1/min] 
KmA = RC(2);     % Michaelis constant of HAP  [mM] 
KmB = RC(3);     % Michaelis constant of GA   [mM] 
kr=RC(4); 
KmP = RC(5); 
KmQ = RC(6); 
KiBs= RC(7); 
KiB =RC(8); 
KiQ = RC(9); 
  
[M,N]=size(y); 
RealZero = 1.0e-18; 
for I = 1:M 
    if (y(I) <= RealZero) 
        y(I) = RealZero; 
    end 
end 
  
  
  
dy = zeros(M,1);                   
  
KEQ = (kf/kr)*(kf/kr)*KmP*KmQ/(KmA*KmB); 
  
  
d3=(kf*Ei*kr*Ei*(y(1)*y(2)-
(y(3)*y(4))/(KEQ)))/(kr*Ei*KmB*y(1)+kr*Ei*KmA*y(2)+kr*Ei*y(1)*y(2)+k
f*Ei*KmP*y(4)/(KEQ)+kf*Ei*KmQ*y(3)/(KEQ)+... 
  kf*Ei*y(3)*y(4)/(KEQ)+kr*Ei*KmB*y(1)*y(4)/KiQ 
+kf*Ei*KmQ*y(2)*y(3)/(KEQ*KiB)... 
+kr*Ei*KmA*y(2)*y(2)/(KiBs*KEQ)+kf*Ei*KmP*y(2)*y(4)/(KiBs)); 
%last line contains the extra terms for the model with substrate 
inhibition 
  
  
dy(1) =- d3; 
dy(2) = -d3; 
dy(3) = d3; 
dy(4) = d3; 
     
  
return 
APPENDIX VI 
PROGRESS CURVES WITH MODEL 
PREDICTIONS FOR THE TAM 
SYNTHESIS OF ABT USING MBA AS 
AMINO DONOR 
 
Table A.VI.1 Initial experimental substrate concentrations for the 12 progress curves used to 
obtain the kinetic parameters in Steps 4 and 5 of the methodology described in Figure 4.1 for the 
synthesis of ABT using TAm whole cells. The first 9 progress curves represent forward reaction 
bioconversions, while the last 3 represent reverse reaction bioconversions. The concentration of 
PLP was 0.2 mM at 30oC and pH 7.5 in 200 mM HEPES for all the progress curves. 
 
 
 Progress 
curve No 
1 2 3 4 5 6 7 8 9 10 11 12 
[ERY] 
(mM) 
50 70 150 250 300 150 200 10 20 0 0 0 
[MBA] 
(mM) 
100 250 250 40 30 15 50 120 200 0 0 0 
[AP] 
(mM) 
0 0 0 0 0 0 0 0 0 10 20 40 
[ABT] 
(mM) 
0 0 0 0 0 0 0 0 0 120 200 100 
Ei 
mg mL-1 
0.3 0.44 0.3 0.15 0.15 0.15 0.15 0.3 0.45 0.15 0.44 0.3 
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Figure A.VI. 1. Progress curves of whole cell TAm mediated synthesis of ABT from substrates 
ERY and MBA. The number of each graph relates with the initial concentrations of substrates 
and enzyme described in Table A.VI.1. Modelling was performed with Equation 4.1 and the 
parameters from Table 4.2 and is shown in solid lines. 
Appendix VI 
 
 
247 
  
Figure A.VI. 2. Progress curves of whole cell TAm mediated synthesis of ABT from 
substrates MBA and ERY (continuation from Figure A.VI.1). The number of each graph relates 
with the initial concentrations of substrates and enzyme described in Table A.X.1. Modelling was 
performed with Equation 4.1 and the parameters from Table 4.2 and is shown in solid lines. 
APPENDIX VII 
SENSITIVITY ANALYSIS OF THE 
KINETIC PARAMETERS OF THE TAM 
MEDIATED SYNTHESIS OF ABT 
 
 
Figure A.VII.1. Effect of the parameter value of (a) kf, (b) kr, (c) KERY and (d) KMBA in the 
simulated yield of  ABT (% mol/mol) considering a 24 hr reaction using 100 mM equimolar of 
[MBA] and [ERY] and 0.3 mg ml-1 of TAM. Equation 4.1 was used with the parameters from 
Table 4.2, and the parameters were varied increasing and decreasing 10-fold their values. The 
sensitivity results are discussed in Section 4.4.3.    
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Figure A.VII. 2. Effect of the parameter value of (a) kAP, (b) kABT, (c) KiMBA, (d) KiABT and (e) 
KiMBAc in the simulated yield of  ABT (% mol/mol) considering a 24 hr reaction using 100 mM 
equimolar of [MBA] and [ERY] and 0.3 mg ml-1 of TAM. Equation 4.1 was used with the 
parameters from Table 4.2 (original values indicated with a dashed line), and the parameters 
were varied increasing and decreasing 10-fold their values.   The sensitivity results are discussed 
in Section 4.4.3.    
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APPENDIX VIII 
PILOT PLANT FERMENTATION OF E. 
COLI CELLS OVEREXPRESSING TAM 
 
 
VIII. TRANSAMINASE PILOT SCALE FERMENTATIONS 
VIII.I Fermentation with one single pulse addition of glycerol 
The shake flask fermentation of E. coli single induced with plasmid pQR801 to 
express TAm shown in Figure 3.1 reached a final biomass of 1.8 gDCW L-1 and 
a final TAm concentration of 0.36 g L-1. In order to increase the total volume 
of the reaction and the final yield of TAm, the fermentation was scaled up to a 
7.5L New Brunswick fermentor (BioFlo 110, New Brunswick, Hertfordshire, 
UK) with a working volume of 5L. (For more details about the characteristics 
of the fermentor see Section 2.5.2 of the Materials and Methods). The 
temperature and pH were the same as for the shake flask fermentations of 
Figure 3.1, which were 37oC, pH 7.0 and the DOT was set to be maintained to 
a minimum of 80% through a cascade control of the impeller speed. The 
selected media was LB-glycerol which initially only contained 3g L-1 of 
glycerol. One single shot addition of pre-sterilized 25 grams of glycerol was 
made to the fermentor after 5.0 hours. Figure VIII.1 shows the cell growth 
curve of the fermentation while figure VIII.2 shows the profiles of DOT, rpm 
of the impeller, pH and temperature. 
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Figure VIII.1. Growth profile of E. coli cells overexpressing TAm for the fermentation 
with single shot addition of glycerol as described in Section VIII.1. 
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 Figure VIII.2. Logged pH, DO2, temperature and agitation speed for the E. coli 
fermentation of Figure VIII.1 
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The fermentation presented a first exponential phase with a specific growth 
rate of 0.36 hr-1 which ended after 4 hours of fermentation when the cells 
reached the first stationary phase, which correlated with a sharp decrease in the 
speed impeller after 4 hours (Figure VIII.2), due to decrease in metabolic 
activity of the cells. Therefore after 5 hours, 25 g of glycerol were added, 
which correlated with an immediate increase in the impeller speed and a steady 
decrease in DOT, leading to second exponential growth phase with a specific 
growth rate of 0.24 hr-1 which ended after 9 hours of fermentation when the 
cell reached the second stationary phase with a final biomass 6.4 gDCW L-1. 
Figure VIII.3 shows the SDS PAGE gels for cellular extracts taken at different 
time intervals.  
 
 
Figure VIII.3. SDS PAGE gel of the cellular extracts at different intervals of time of the 
fermentation shown in Figure VIII.1  
 
 
Appendix VIII 
 
 
254 
 
The cells were induced after 6.5 hours, which correlated with a sharp increase 
in enzyme synthesis as can be seen in Figure VIII.3 The final TAm expression 
represented 40% of the total protein, which was similar to the level of 
expression obtained in shake flasks, however due to the higher biomass 
concentration achieved in the 7.5L fermentor, the final TAm concentration was 
found to be 1.3 g L-1, which represented a 3.5 improvement compared to the 
shake flask fermentations of Chapter 3.  
VIII.II.  Fermentation with continuous fed batch feeding of glycerol 
In order to increase the biomass and enzyme yield obtained in the fermentation 
described in Appendix Section VIII.I, a continuous fed-batch fermentation of 
TAm was performed in a 2L fermenter (Adaptive Biosystems, London, 
England) as described in Sections 2.5.1 and 2.5.3. The temperature and pH 
were controlled at 37oC and pH 7.0, the media was LB with 5 g L-1 of glycerol, 
and the speed impeller was fixed at 1100 rpm. Figure VIII.4 shows the growth 
curve over time while Figure VIII.5 illustrates the DOT, pH, temperature and 
impeller speed profiles of the fermentation. 
After 8 hrs of growth, when the carbon source was depleted which correlated 
with the DOT reaching 100%, glycerol was added in a continuous fed batch 
mode with increasing rates as described by Equation 2.1 in Section 2.5.3, 
maintaining a specific growth rate of 0.3. The fermentation reached a final 
biomass of 24 g L-1 after 43 hrs, and figure VII.6 shows the SDS PAGE gels 
for cellular extracts taken at different time intervals.  
Induction was performed after 15 hr, where a sharp increase in enzyme 
synthesis could be observed in Figures 5.7 and 5.8 reaching a final TAm yield 
of 4.8 g L-1, which represented a 4X and 13X improvement compared to the 
fermentation with a single shot addition of glycerol and the shake flask 
fermentation respectively of Chapter 3.   
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Figure VII.4. Growth curve as a function of time for the fed batch fermentation of E. 
coli cells with plasmid pQR801 as described in Section 2.8.3. 
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Figure VII.5.  Logged pH, temperature, DOT and RPM for the fed batch fermentation 
of Figure VII.4 
 
Figure VIII.6. SDS PAGE gel for different interval samples of the fermentation shown 
in Figure VIII.5. (Note that time increases from right to left). 
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APPENDIX IX 
PROGRESS CURVES WITH MODEL 
PREDICTIONS FOR THE TK D469E 
SYNTHESIS OF PKD  
 
 
 
Table A.IX.1. Initial experimental substrate and enzyme concentrations for the 9 progress 
curves used to obtain the kinetic parameters in Steps 4 and 5 of the methodology described in 
Figure 4.1 for the synthesis of PKD using TK D469E whole cells. The concentration of TPP and 
Mg2+ was 2.4 and 9 mM respectively at 30oC in 50 mM TRIS buffer pH 7.5. 
 
 
 
 
 
 
 
 
 
 
No Progress 
curve 1 2 3 4 5 6 7 8 9 
[HPA] 
(mM) 100 130 150 230 100 150 200 300 300 
[GA] (mM) 130 170 200 300 50 110 140 200 270 
Ei 
mg ml-1 0.3 0.3 0.3 0.4 0.5 0.5 0.6 0.6 0.6 
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Figure A.IX.1. Progress curves of whole cell TK D469E mediated synthesis of PKD from 
substrates PA and HPA. The number of each graph relates with the initial concentrations of 
substrates and enzyme described in Table A.IX.1. Modelling was performed with Equation 6.1 
and the parameters from Table 6.1 and is shown in solid lines. 
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Figure A.IX. 2. Progress curves of whole cell TK D469E mediated synthesis of PKD from substrates 
PA and HPA (continuation from Figure A.IX.1). The number of each graph relates with the initial 
concentrations of substrates and enzyme described in Table A.IX.1. Modelling was performed with 
Equation 6.1 and the parameters from Table 6.1 and is shown in solid lines. 
 
 
 
 
 
 
APPENDIX X 
PROGRESS CURVES WITH MODEL 
PREDICTIONS FOR THE TAM 
SYNTHESIS OF APD  
 
 
Table A.X. 1. Initial experimental substrate and enzyme concentrations for the 9 progress 
curves used to obtain the kinetic parameters in Steps 4 and 5 of the methodology described in 
Figure 4.1 for the synthesis of APD using CV2025 TAm whole cells.  The concentration of PLP 
was 0.2 mM at 30oC and pH 7.5 in 200 mM HEPES for all the progress curves. 
 
 
 
 
 
 
 
  
 
 
 
 
No progress  
curve 
1 2 3 4 5 6 7 8 9 
[PKD] (mM) 50 70 100 250 300 150 200 300 10 
[MBA] (mM) 100 250 250 40 30 15 50 200 120 
Ei 
mg ml-1 
0.3 0.4 0.3 0.15 0.15 0.15 0.15 0.6 0.3 
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Figure A.X.1. Progress curves of whole cell TK mediated synthesis of APD from substrates 
PKD and MBA. The number of each graph relates with the initial concentrations of substrates 
and enzyme described in Table A.X.1. Modelling was performed with Equation 6.2 and the 
parameters from Table 6.2 and is shown in solid lines. 
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Figure A.X.2. Progress curves of whole cell TK mediated synthesis of PKD from substrates 
PKD and MBA (Continuation from Figure A.X.1). The number of each graph relates with the 
initial concentrations of substrates and enzyme described in Table A.X.1. Modelling was 
performed with Equation 6.2 and the parameters from Table 6.2 and is shown in solid lines. 
 
 
 
 
APPENDIX XI 
PROGRESS CURVES OF THE TAM 
MEDIATED SYNTHESIS OF ABT AND 
APD USING IPA AS AMINO DONOR 
 
 
 
A.XI. 1. TAm mediated synthesis of ABT with IPA as amino donor. ERY and IPA were 100 
mM, 0.3 mg ml-1 of TAm in whole cell form, pH 7.5 in 200 mM HEPES buffer at 30oC. 
Bioconversions performed as described in Section 2.8.1.  
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A.XI. 2. TAm mediated synthesis of APD with IPA as amino donor. PKD and IPA were 200 
mM, 0.3 mg ml-1 of TAm in whole cell form, pH 7.5 in 200 mM HEPES buffer at 30oC. 
Bioconversion performed as described in Section 2.8.1. 
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APPENDIX XII 
LC−ECI−MS CHROMATOGRAMS 
 
LC-ECI-MS analysis was carried out on reaction mixture with ABT produced from a 
single TAm bioconversion using MBA and ERY as subtrates (Figure A.XI.1), and 
from dual TK-TAm reaction (Scheme 3.1). Results were compared with previous 
ABT MS-MS standards (Matosevic, 2009). 
 
 
 
Appendix A.XII. 1. LC-ECI-MS analysis for reaction mixture with ABT produced from 
individual TAm bioconversion using ERY and MBA as substrates (Section 2.9.7). 
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Appendix A.XII. 2. LC-ECI-MS analysis for reaction mixture with ABT produced from 
dual-TK-TAm multi-step bioconversion (Scheme 3.1) (Section 2.9.7). 
 
